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ABSTRACT 
 
Whole exome sequencing (WES) is a powerful tool to identify new molecules involved 
in skeletal homeostasis. In particular we used WES to establish the molecular diagnosis 
of two particular skeletal diseases: osteopetrosis and the acrofrontofacionasal dysostosis 
1 (AFFND1). 
The osteopetroses are a group of rare bone diseases characterized by increased bone 
density due to the failure in bone resorption. Due to their genetic heterogeneity, WES 
represents a valuable strategy to identify the genetic defect. We analyzed osteopetrotic 
patients with autosomal dominant osteopetrosis (ADO) and autosomal recessive 
osteopetrosis (ARO), which is the most severe form. In our cohort we performed 
molecular diagnosis of 4 ADOI or ADOII patients that carried mutations in the LRP5 
and CLCN7 genes, respectively. The analysis of ARO patients confirmed TCIRG1 as 
the most frequently mutated gene, identified mutations in the other known ARO genes 
and in genes very rarely associated with osteopetrosis, namely FERMT3 and USB1. Of 
note, we demonstrated the causative role of four deep intronic mutations in TCIRG1 
gene and two different synonymous changes in the TCIRG1 and CLCN7 genes in the 
pathogenesis of the disease. In addition, WES helped in the differential diagnosis in a 
patient who was found to bear a mutation in the FAM20C gene, known to cause Raine 
syndrome.  
Regarding AFFND1, this is an extremely rare syndrome, comprising facial and skeletal 
abnormalities, short stature and intellectual disability. WES found a novel truncating 
mutation in the neuroblastoma-amplified sequence (NBAS) gene in two Indian patients 
(c.6237-3C>G). This mutation impaired NBAS functions in HEK293T cells 
overexpressing the truncated NBAS protein. Furthermore, we demonstrated that NBAS 
expression in mouse embryos was compatible with a role in bone and brain 
development and that the depletion of endogenous z-nbas in fish embryos resulted in 
defective morphogenesis of chondrogenic cranial skeletal elements. Overall, we 
provided evidence supporting the hypothesis of a causative role of the mutated NBAS 
gene in the pathogenesis of AFFND1. 
In conclusion, we effectively exploited WES in the genetic diagnosis of rare skeletal 
diseases. We also highlighted potential limitations of this approach, specifically with 
respect to deep intronic mutations and synonymous changes, and underlined the 
importance to complement WES with analysis at the transcript level and functional 
validation, when possible. 
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1,25(OH)2D3: 1,25 dihydroxy vitamin D3  
ADO: autosomal dominant osteopetrosis  
AFFND1: acrofrontofacionasal dysostosis 1  
AKT: protein kinase B  
ALP: alkaline phosphatase  
AP1: activator protein 1  
APC: adenomatous polyposis coli  
ARL8: ADP-ribosylation factor-like protein 8  
ARO: autosomal recessive osteopetrosis  
ATF4: activating transcription factor 4 
Atp6v0d2: d2 isoform of vacuolar ATPase V0 domain  
Bcl6: B-cell lymphoma 6 
BD: basolateral domain  
BGLAP: bone gamma-carboxyglutamate protein  
BLCs: bone lining cells  
BLIMP1: B lymphocyte-induced maturation protein 1  
BMP: bone morphogenetic protein  
BMU: basic multicellular unit  
BSP: bone sialoprotein  
CA2: carbonic anhydrase type II  
CBS: cystathionine-beta-synthase  
cDNA: complementary DNA  
CE: capillary electrophoresis  
Ch: ceratohyale  
CHIP: chromatin immunoprecipitation   
CHKA: choline kinase alpha  
CLCN7: chloride voltage-gated channel 7  
COLIA1: collagen type I alpha 1  
COMMAD: coloboma, osteopetrosis, microphthalmia, macrocephaly, albinism, and 
deafness 
CT: computed tomography  
CTLA4: cytotoxic T-lymphocyte protein 4  
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CTSK: cathepsin K  
DAB: 3,3'-diaminobenzidine  
DAP12: DNAX-activating protein 12  
DC-STAMP: dendritic cell-specific transmembrane protein  
DKK1: dickkopf-related protein 1  
DLX3: distal-less homeobox 3  
DMP1: dentin matrix protein 1  
dNTPs: deoxyribonucleotide triphosphates  
Dpf: days post fertilization  
DSH: disheveled  
DSS: dysosteosclerosis  
E: embryonic day  
ERK: extracellular signal-regulated kinase 
ERRa: estrogen-related receptor a 
ESID: european society for immunodeficiences  
FcRg: Fc receptor common g subunit  
FERMT3: fermitin family member 3  
FGF23: fibroblast growth factor 23  
FSD: functional secretory domain  
FZD: frizzled  
GAGs: glycosaminoglycans  
GATK: genome analysis toolkit  
GH: growth hormone  
GRB2: growth-factor-receptor-bound protein 2  
GSK3: glycogen synthase kinase 3  
GTP: guanosine triphosphate  
HLA: human leukocyte antigen  
Hpf: hours post fertilization  
HSCs: hematopoietic stem cells  
HSCT: hematopoietic stem cell transplantation  
IEWP-EBMT: inborn errors working party of the EBMT  
IFNγ:  interferon γ  
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IGF I: insulin-like growth factor I  
IHH: indian hedgehog 
IKBKG: inhibitor of nuclear factor kappa B kinase subunit gamma 
IKK: IκB kinase  
IL-17: interleukin 17 
InDel: insertion/deletion  
IQ: intelligence quotient  
IRF8: interferon regulatory factor 8  
ITAM: immunoglobulin tyrosine-based activation motif 
JNK: c-Jun N-terminal kinase  
LAD-III: leukocyte adhesion deficiency  
LEF: lymphoid enhancing factor 
LGR4/5/6: leucine-rich repeat containing G-protein-coupled receptors  
LIR: LC3-interacting region  
LRP5/6: low-density lipoprotein co-receptors  
MAFB: v-Maf musculoaponeurotic fibrosarcoma oncogene family homolog B  
MAPK: mitogen activated protein kinase  
Mck: meckel’s cartilage  
M-CSF: macrophage-colony stimulating factor  
MGP: matrix gla protein  
MITF: microphthalmia-associated transcription factor 
MMP9: matrix metalloprotease 9 
MOs: morpholino oligonucleotides  
MRI: magnetic resonance imaging 
mRNA: messenger RNA  
MSCs: mesenchymal stem cells  
MSX1: msh homeobox 1  
MVs: matrix vesicles  
NBAS/NAG: neuroblastoma amplified sequence/neuroblastoma amplified gene  
NCC: neural crest cells  
NEMO: NF-kB essential modulator  
NFATc1: nuclear factor of activated T cell c1 
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NF-kB : nuclear factor kappa B 
NGS: next generation sequencing  
NIK: NF-kB-inducing kinase  
NMD: nonsense-mediated decay  
OCN: osteocalcin  
OC-STAMP: osteoclast stimulatory transmembrane protein  
OFC: orbitofrontal cortex  
OI: osteogenesis imperfecta  
OL-HED-ID: osteopetrosis, lymphoedema, hypohidrotic ectodermal dysplasia and 
immunodeficiency  
OPG: osteoprotegerin  
OPN: osteopontin  
OSCAR: osteoclast-associated receptor  
OSTM1: osteopetrosis associated transmembrane protein 1 
OSX: osterix  
PBMCs: peripheral blood mononuclear cells  
PBS: dulbecco’s phosphate buffer saline  
PBST: PBS 0,05% Tween 20  
PCR: polymerase chain reaction  
PFA: paraformaldehyde  
PGs: proteoglycans  
PH: pleckstrin homology  
PI3K: phosphatidylinositol 3-kinase 
PLEKHM1: pleckstrin homology domain-containing family M (with RUN domain) 
member 1  
PN: poikiloderma with neutropenia  
PN2: post-natal day 2  
PPARg: peroxisome proliferator-activated receptor gamma  
Pq: palatoquadrate  
PTH: parathyroid hormone  
PTHrP: parathyroid hormone-related protein  
RAB7: ras-related protein Rab 7  
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RAG1: recombination activating gene 1  
RALF: recurrent acute liver failure  
RANK: receptor activator of nuclear kappa B  
RANKL: receptor activator of nuclear kappa B ligand 
RB: ruffled border  
RH: rubicon homology  
RHOA: ras homolog family member A  
RNA-seq: RNA-sequencing  
RNF43: ring finger 43  
RSK2: ribosomal S6 kinase 2 
RSPO: roof plate-specific spondin  
RT-PCR: reverse transcriptase-polymerase chain reaction  
RUNX2: runt-related transcription factor 2  
S1P: sphingosine 1 phosphate  
SCID: severe combined immunodeficiency  
Scr: scrambled  
SDF1 or CXCL12: stromal-derived factor 1  
sFRP: frizzled related proteins  
SIBLING: small integrin-binding ligand N-linked glycoprotein  
SLC19A1: solute carrier family 19 (folate transporter) member 1  
SLC29A3: solute carrier family 29 (nucleoside transporter), member 3  
SNAREs: N-ethylmaleimide-sensitive factor attachment protein (SNAP) receptors  
SNPs: single-nucleotide polymorphisms  
SNX10: sorting nexin 10  
SOPH: syndrome, presenting with short stature, facial dysmorphisms, optic nerve 
atrophy and Pelger-Huet anomaly of the neutrophils  
SPARC: secreted protein acidic and rich in cysteine  
SPP1: secreted phosphoprotein 1 
SS: splice site  
SYK: tyrosine-protein kinase  
SZ: sealing zone  
T3: thyroid hormones  
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TB: translation block  
TBST: tris-buffered saline, 0.1% Tween 20 
TCF: T-cell factor 
TCIRG1: T cell immune regulator 1  
TGFβ: transforming growth factor beta 
TNFa: tumor necrosis factor a  
TNFRSF11A: TNF receptor superfamily member 11a 
TNFSF11: TNF superfamily member 11 
TNMD: tenomodulin  
TRAF6: TNF receptor-associated factor 6  
TRAIL: TNF-related apoptosis inducing ligand  
TRAP: tartrate resistant acid phosphatase  
TREM 2: triggering receptor expressed in myeloid cells 2  
TWISTNB: TWIST Neighbor  
UPF2: regulator of nonsense transcripts 2  
UTR: untranslated regions  
VCAM1: vascular cell adhesion molecule 1  
VEGF: vascular endothelial growth factor  
VLA4: very late antigen 4  
WES: whole exome sequencing  
WGS: whole genome sequencing  
WIF1: Wnt inhibitor factor 1  
ZNRF3: transmembrane E3 ubiquitin ligase zinc and ring finger 3  
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3.1 General aspects of bone biology 
 
The skeleton is a dynamic tissue exerting different functions: it provides support and 
protection to soft tissues, aids locomotion serving as lever for muscular action, stores 
calcium and phosphate contributing to their homeostasis, and harbors the bone marrow 
[1-3].  
The dynamic nature of the skeleton is achieved through a process of modeling and 
remodeling in response to mechanical and metabolic influences [4]. Bone modeling is a 
hallmark of skeletal development and growth, but it can occur also in adult life as an 
adaptation to permanent changes in mechanical strain or in response to hormonal or 
genetic factors, ultimately resulting in changes in bone size and shape [5]. During the 
modeling process, osteoblast and osteoclast activities (bone deposition and resorption, 
respectively) are not necessarily coupled; on the contrary, by definition, in bone 
remodeling osteoclasts and osteoblasts sequentially work in the same basic multicellular 
unit (BMU) [6]. 
Bone remodeling is a highly complex cyclic process, which can be divided in three 
phases: 
1) Initiation phase (duration: about 2 weeks): osteoclast precursors are recruited to 
the bone surface, differentiate and start resorbing bone. 
2) Transition or reversal phase (duration: about 1 month): osteoclasts undergo 
apoptosis, while osteoblast precursors are recruited and differentiate into mature 
osteoblasts. 
3) Termination or formation phase (duration: several months): it ensures that the 
resorbed lacuna is refilled with new bone produced by the osteoblasts. When this 
phase is completed, flattened lining cells cover the surface, which enters a 
resting period [7]. 
The balance between bone formation and resorption is crucial to maintain bone 
homeostasis; indeed an imbalance may result in bone diseases. For example, 
unrestrained resorption leads to bone loss and osteoporosis [8], on the contrary the lack 
of osteoclast activity may result in osteopetrosis [9]. 
The bone tissue is a composite environment: in addition to bone-specific cells, several 
other cell types are present, such as mesenchymal stem cells (MSCs) and hematopoietic 
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stem cells (HSCs), their derivatives at different stage of differentiation and, moreover, 
blood vessels and peripheral nerve fibers that all together contribute to generate a 
dynamic compartment. As an additional layer of complexity, several local and systemic 
factors (hormones, cytokines, biomechanical stimulation) contribute to modify cell 
behavior [10, 11].  
 
3.1.1 Bone composition 
The bone tissue is a mineralized connective tissue formed by a dense extracellular 
matrix and a cellular component, which comprises “skeletal-specific” cell types 
(osteoblasts, osteocytes, osteoclasts, bone lining cells and chondrocytes) and also other 
cells, such as immune cells, hematopoietic stem and progenitor cells at different stages 
of lineage commitment, endothelial cells and adipocytes. 
 
3.1.1.1 Osteoblasts 
Osteoblasts (4-6% of total resident bone cells) are cuboidal-shaped cells covering the 
bone surface as a single cells row. They are polarized, rich in alkaline phosphatase 
(ALP, the enzyme responsible for pyrophosphate hydrolysis) on the basolateral 
membrane, while no or little expression on the membrane facing the osteoid (non-
mineralized bone matrix). In addition, osteoblasts possess abundant rough endoplasmic 
reticulum, large Golgi apparatus and numerous vesicles, which are typical features of 
secretory cells; in particular, the Golgi complex is filled with fibrillar structures, 
containing procollagen and proteoglycans [12]. Osteoblasts establish different types of 
interactions with other cells: they form focal, non-continuous tight junctions and gap 
junctions, mainly composed of connexin 43 and involved in ion and micromolecules 
exchange. Adherens junction, based on cadherins and important to transduce 
differentiation, activation and survival signals are also present. Moreover, osteoblasts 
bind type I collagen through b1 integrins; this interaction activates mitogen activated 
protein kinase (MAPK) and is crucial for osteoblast differentiation and function. These 
cells are responsible for the deposition of bone matrix, and contribute to the regulation 
of osteoclasts functionality and to the development and maintenance of the 
hematopoietic stem cell niche [2, 13, 14].  
3. INTRODUCTION 
19 
 
 
Osteoblast differentiation 
Osteoblasts derive from MSCs, which are multipotent stem cells that can differentiate 
towards osteogenic, adipogenic and chondrogenic lineages under different stimuli 
(Figure 1) [10]. Specific transcription factors drive the differentiation towards one or the 
other lineage: SOX5, 6 and 9 guide chondrogenic differentiation, peroxisome 
proliferator-activated receptor gamma (PPARg) the adipocytic one, runt-related 
transcription factor 2 (RUNX2) and osterix (OSX) regulate the osteogenic 
differentiation and in fact their absence completely block skeletal mineralization [15, 
16]. Besides RUNX2 and OSX, a plethora of transcription factors have been involved in 
the regulation of osteoblast differentiation and function [17]; among them, TWIST 
proteins provide a transient block during early skeletogenesis through interaction of 
their Twist box with RUNX2 DNA binding domain [18]. Homeobox factors, such as 
msh homeobox 1 ad 2 (MSX1, MSX2), distal-less homeobox 3 and 5 (DLX3, DLX5), 
orchestrate skeletal patterning via intricate regulatory loops [19]. Activating 
transcription factor 4 (ATF4) mediates some aspects of RUNX2-driven transcriptional 
program and intervenes in the control of mature osteoblast function after 
phosphorylation by the growth factor-regulated kinase ribosomal S6 kinase 2 (RSK2) 
[20]. 
Overall, these transcriptional regulatory systems result in increased expression of cell 
lineage markers, such as collagen type I alpha 1 (COLIA1), ALP, bone sialoprotein 
(BSP) and bone gamma-carboxyglutamate protein (BGLAP), morphological changes 
(cells become large and cuboidal) and high secretion of bone matrix proteins [13, 21]. 
The activation of bone morphogenetic protein (BMP) and Wnt pathways is a crucial 
event in promoting MSCs commitment towards osteoprogenitors [22, 23]. Other factors 
regulating osteogenic differentiation are hormones, such as 1,25 dihydroxy vitamin D3 
(1,25(OH)2D3), parathyroid hormone (PTH) and estrogens, and cytokines. 
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Figure 1: Schematic representation of MSCs commitment towards different cell fates. Adapted 
from Pinzone et al., 2009. 
 
 
Main pathways in osteoblast differentiation: Wnt and BMP signaling 
There are two main pathways involved in osteoblast differentiation: the Wnt and the 
BMP signaling pathways. 
Wnt ligands constitute a family of secreted glycoproteins that bind a co-receptor 
complex, including the seven-pass transmembrane G-protein coupled receptor frizzled 
(FZD) and the low-density lipoprotein co-receptors LRP5/6. The elicited intracellular 
signaling may occur either via β-catenin activation (canonical) or via a calcium-
dependent or planar-cell polarity pathway (non-canonical); however, the former has 
been better characterized. The hallmark of Wnt pathway activation is the inhibition of 
glycogen synthase kinase 3 (GSK3) activity and the resulting increase of β-catenin, an 
integral E-cadherin cell-cell adhesion adaptor protein and transcriptional coregulator 
[24]. More in detail, in the absence of Wnt ligands, the inhibitory complex composed of 
adenomatous polyposis coli (APC), axin and GSK3 binds and phosphorylates β-catenin, 
thus targeting it to degradation by the proteasome [25]. Instead, when Wnt ligands bind 
FZD and LRP5/6, the destruction complex is disrupted: axin is recruited by the 
cytoplasmic tail of LRP5/6 and de-phosphorylated, disheveled (DSH) is activated by 
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sequential phosphorylation, poly-ubiquitination and polymerization and inhibits GSK3. 
Therefore β-catenin is stabilized and translocates into the nucleus, where it drives the 
expression of Wnt target genes in collaboration with TCF/LEF (T-cell factor/lymphoid 
enhancing factor) transcription factors. For example, Wnt5a and Wnt10b not only 
promote osteoblast differentiation, but also prevent the expression of transcription 
factors responsible for MSCs commitment towards adipogenesis [26].  
A number of molecules negatively regulate the Wnt pathway. The dickkopf-related 
protein 1 (DKK1) binds LRP5/6 receptor and kremen, inducing internalization of the 
receptor and reduced availability for Wnt ligands [27-29]. Sclerostin acts similarly to 
DKK1, i.e. it binds LRP5 and inhibits the Wnt pathway activation.  
On the other hand, secreted frizzled related proteins (sFRP) and Wnt inhibitor factor 1 
(WIF1) act by directly binding Wnt ligands, thus reducing their availability for the 
functional receptors (Figure 2) [30].  
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Schematic representation of Wnt signaling pathway and regulatory mechanisms. (A) 
The association between Wnt ligands, FZD and LRP5/6 receptors results in the stabilization 
and nuclear translocation of β-catenin, and activation of transcription. (B) DKK1 binds LRP5/6 
and Kremen (KRM), and triggers endocytosis of the receptor. (C) Similarly sclerostin binds the 
LRP5/6 receptors, thereby favoring β-catenin degradation. (D) sFRP binds Wnt ligands and 
prevents the activation of the functional receptors. Adapted from Evenepoel et al., 2015. 
 
Moreover, the transmembrane E3 ubiquitin ligase zinc and ring finger 3 (ZNRF3) 
associates with the Wnt ligand/receptors complex and promotes turnover of the 
receptors. 
 
sFRP binds to 
Wnt 
sFRP 
C D A B 
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On the contrary, leucine-rich repeat containing G-protein-coupled receptors (LGR4/5/6) 
and R-spondins (roof plate-specific spondin, RSPO) potentiate Wnt pathway [31]. R-
spondins are potent stem cell growth factors, whose role in bone metabolism has been 
only recently highlighted. They form a complex with their LGR receptors, ZNRF3 and 
its homologue ring finger 43 (RNF43), and lead to β-catenin stabilization, ultimately 
promoting osteoblast differentiation and bone formation. In particular, LGR4 signals 
through the cAMP-PKA-ATF4 pathway and is important for BMP induced osteoblastic 
differentiation [32].  
BMPs comprise at least 20 molecules that belong to the transforming growth factor beta 
(TGFβ) family and act in several biological processes such as embryogenesis, skeletal 
formation, hematopoiesis and neurogenesis. Among different BMPs, BMP-2, 4, 5, 6 and 
7 are clearly implicated in osteogenesis: for example, BMP-2 increases osteocalcin 
(OCN) expression and induces bone formation; BMP-7 stimulates the expression of 
ALP and other osteoblastic differentiation markers and increases calcium 
mineralization. BMPs are implicated in many steps during endochondral bone 
development; indeed, BMP signaling promotes chondrocyte proliferation and 
differentiation by sustaining SOX9 expression, fundamental for chondrogenic 
commitment and differentiation. In particular, BMP-2 and BMP-4 are essential for 
osteoblastogenesis as well as chondrocyte proliferation, differentiation and apoptosis 
during skeletal development [33]. 
BMPs bind their receptors on MSCs surface and form a heterotetrameric complex 
composed of type I and type II serine/threonine kinase receptors. The activated type II 
receptor transphosphorylates the type I receptor which, in turn, phosphorylates the 
SMAD1/5/8 complex. This associates to SMAD4 and translocates to the nucleus, 
stimulating the expression of the transcription factors RUNX2 and OSX [13]. 
BMP signaling pathway is regulated by various BMP antagonists, such as noggin, 
chordin, follistatin, twisted gastrulation and DAN family members (Dan, Cerberus, 
Sclerostin), that prevent specific binding of BMPs to their cell surface receptors [34].  
 
Osteoblast functions 
Osteoblasts are specialized cells primarily responsible for bone matrix synthesis. This 
process is characterized by deposition of organic matrix and subsequent mineralization. 
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In the first step, osteoblasts secrete collagen, non-collagen proteins and proteoglycans 
(PGs), which form the osteoid. In the second step, osteoblasts secrete matrix vesicles 
(MVs) by budding and shedding of specific regions of the outer plasma membrane. The 
MVs contain hydroxyapatite crystals preformed in the osteoblasts; in the extracellular 
environment mineral crystals are released from the MVs, further grow thanks to the 
presence of Ca
2+
 and PO4
(3-)
 in the extracellular fluids and serve as template for the 
formation of new crystals [35]. At the end of the bone formation phase, osteoblasts can 
become embedded in the bone as osteocytes, or become bone-lining cells or undergo 
apoptosis. 
In addition, osteoblasts carry out an intense crosstalk with osteoclasts through different 
molecular mechanisms. The best known is represented by the macrophage-colony 
stimulating factor (M-CSF)/C-FMS and receptor activator of nuclear kappa B ligand 
(RANKL)/RANK/OPG signaling axis. M-CSF and RANKL interact with their 
receptors (C-FMS and RANK respectively) on osteoclast precursors surface to promote 
their proliferation and differentiation [10, 36]. On the contrary, osteoprotegerin (OPG) 
is a soluble factor acting as a decoy receptor for RANKL preventing its interaction with 
the functional receptor RANK. OPG itself is controlled by many ligands, such as TNF-
related apoptosis inducing ligand (TRAIL), von Willebrand factor and 
glycosaminoglycans (GAGs), which impacts on the overall inhibitory effect of OPG on 
RANKL [37-39].  
Other molecules for osteoblasts-osteoclasts communication are semaphorins, a large 
family of secreted and membrane-bound glycoproteins characterized by the presence of 
the “sema” domain. In particular, SEMA3A, mainly produced by cells of the osteoblast 
lineage, reduces the differentiation and migration of osteoclast precursors by 
suppressing immunoglobulin tyrosine-based activation motif (ITAM) signaling and ras 
homolog family member A (RHOA) activation; on the contrary, it increases osteoblast 
differentiation by activating Wnt/b-catenin signaling [40]. 
Moreover, osteoblasts are important for the development and maintenance of the HSC 
niche [14]. They favor HSC homing in the marrow and self-renewal. Different ligand-
receptor pairs are exploited for this function; the best characterized are the stromal-
derived factor 1 (SDF1 or CXCL12)/CXCR4 and the vascular cell adhesion molecule 
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1/very late antigen 4 (VCAM1/VLA4) systems. Homotypic interactions between N-
cadherins on osteoblasts and HSC plasma membrane are also involved. 
 
3.1.1.2 Osteocytes 
Osteocytes are the most abundant cells in bone (90-95% of the total cells). They derive 
from terminal differentiation of osteoblasts which remain embedded in the bone matrix 
during bone formation, undergo morphological and ultrastructural changes (i.e. rough 
endoplasmic reticulum and Golgi apparatus decrease in volume and the 
nucleus/cytoplasm ratio increases), modify their gene expression profile (e.g. the 
expression of osteoblast markers such as OCN, BSPII, collagen type I and ALP 
decreases, while the expression of osteocyte markers such as dentine matrix protein 1 
and sclerostin increases) and reduce their synthetic and secretory functions [41]. 
Osteocytes have up to 50 long and branched processes, which elongate through tiny 
tunnels originating from the lacuna space (canaliculi). Thanks to these cytoplasmic 
processes, osteocytes are connected to other osteocytes, osteoblasts and bone lining 
cells, which facilitates the exchange of signaling molecules (Figure 3). The cell-cell 
communication is also achieved by means of the interstitial fluid flowing in the 
canaliculi [2]. 
 
                 
 
 
 
 
 
 
 
                  
 
 
 
Figure 3: Osteocytes differentiate from osteoblasts that become trapped in the bone matrix 
during bone deposition. They develop dendritic-like cell processes that connect them to other 
osteocytes and to cells on the bone surface. Adapted from Capulli et al., 2014. 
Bone Marrow 
Bone 
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The canalicular structure allows osteocytes to respond to mechanical and biological 
signals [2, 13]. Even though the underlying mechanism is not completely clear, the 
involvement of protein complexes composed of a cilium and cilia-associated proteins, 
and of cytoskeletal elements activated by changes in the fluid flow deriving from 
mechanical load, has been proposed to mediate the conversion of the mechanical signal 
into a chemical one. As a result, different factors such as nitric oxide, prostaglandins, 
and sclerostin are produced by osteocytes and modulate bone resorption and formation 
[42].  
Osteocytes are an essential source of RANKL which is required to stimulate osteoclasts 
during bone remodeling in cancellous bone [43], under the control of PTH [42]. 
Changes in the RANKL/OPG ratio, together with increased vascular endothelial growth 
factor (VEGF) production from cells neighboring apoptotic osteocytes and release of 
pro-inflammatory chemotactic signal for osteoclasts from dying osteocytes, are 
probably some of the mechanisms linking osteocyte apoptosis and increased bone 
resorption [44].  
Another essential osteocytic factor is fibroblast growth factor 23 (FGF23), which is a 
hormone regulating mineralization and phosphate homeostasis. In fact, FGF23 reduces 
the expression of the sodium-phosphate transporters (type IIa and IIc) in the kidney 
proximal tubule and increases phosphate excretion; in addition, it inhibits the expression 
of 1-α-hydroxylase and promotes 24-hydroxylase in the kidney, thus diminishing 
1,25(OH)2D levels and phosphate absorption from the gut and bone [45].    
Finally, osteocytes can remodel the lacuna where they are located, thus changing its 
shape. This process is called osteocytic osteolysis and, even though debated, is probably 
limited to situations requiring increased release of mineral from the skeleton, such as 
pregnancy or lactation [46].  
 
3.1.1.3 Bone Lining Cells 
Bone lining cells (BLCs) are quiescent osteoblasts on bone surfaces where neither bone 
resorption nor bone formation occurs [2, 47]. BLCs are flat-shaped with thin and flat 
nuclear profile; their cytoplasm extends on bone surface and is characterized by few 
cytoplasmic organelles. Thanks to gap junctions and processes that extend into 
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canaliculi, BLCs interact with each other and with osteocytes into bone matrix, 
respectively.   
Depending on bone physiological status, BLCs can display a secretory activity and 
change their size, adopting a cuboidal appearance [48]. Their function is not completely 
understood, but they have been demonstrated to produce OPG and RANKL, thus 
participating in osteoclast differentiation, and to prevent the direct interaction between 
osteoclasts and bone matrix when bone resorption should not occur [49, 50]. 
 
3.1.1.4 Osteoclasts 
Osteoclasts are large multinucleated cells originating from hematopoietic progenitors of 
the monocyte/macrophage lineage, responsible for bone resorption. To perform this 
activity, they contain many mitochondria and lysosomes and display a unique 
morphology, organelle distribution and plasma membrane domain organization [51]. 
They move by extending membrane protrusions called lamellipodia at their leading 
edge and retracting the plasma membrane at the opposite side; during this phase they 
are flattened cells. At the site of resorption, the osteoclasts are dome-shaped and their 
plasma membrane is polarized. Four specialized domains can be distinguished: the 
sealing zone, which is a large F-actin ring structure anchoring the osteoclast to the bone 
surface by peculiar adhesions called podosomes; the ruffled border, which is a highly 
convoluted membrane region delimited by the sealing zone and facing the resorption 
lacuna; the functional secretory domain, located at the opposite side of the cell with 
respect to the ruffled border; and the basolateral membrane (Figure 4) [52]. This 
polarization allows vesicular trafficking from the basolateral membrane to the ruffled 
border and from this latter to the functional secretory domain.  
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Figure 4: Electron microscopy image of an osteoclast showing the four functional domains: the. 
ruffled border (RB), the sealing zone (SZ), the basolateral domain (BD) and the functional 
secretory domain (FSD). N: nucleus. Adapted from Crockett et al., 2011. 
 
 
Through bone resorption, osteoclasts participate in the regulation of calcemia and 
phosphatemia under the control of PTH. In addition, they are involved in the formation 
and maintenance of the HSC niche in the bone (even though this is debated) and in HSC 
mobilization from the bone marrow. This is achieved by cleaving factors present in the 
matrix and important for the HSC niche and by producing TGFb and bFGF that direct 
HSC fate [53, 54]. Osteoclasts influence osteoblast differentiation by releasing potent 
anabolic agents, such as BMPs, insulin-like growth factor I (IGF I) and TGFb, from the 
bone matrix and secreting so-called clastokines, such as a sphingosine 1 phosphate 
(S1P), BMP6 and Wnt10b, with a similar anabolic effect. Through the production of 
VEGF and other angiogenic factors, osteoclasts play a role in the regulation of blood 
supply to bone. Finally, they are extremely sensitive and responsive to stimuli coming 
from the immune system such as RANKL, tumor necrosis factor a (TNFa) and 
interferon γ (IFNγ); the recognition of the complex interactions between osteoclasts and 
immune cells fuelled a specific research field, named osteoimmunology [55]. 
Osteoclasts themselves have been suggested to act as innate immune cells, based on 
several evidence, such as the production of a variety of cytokines, the expression of 
immune receptors and the capacity to process and present antigens [56, 57]. 
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Molecular control of osteoclast differentiation 
Osteoclast differentiation takes place through the activation of different pathways 
comprising an ever-growing number of molecules either directly or indirectly involved. 
In the early stage of the process, the commitment of hematopoietic cells towards the 
osteoclast lineage is regulated by the transcription factors PU.1 and microphthalmia-
associated transcription factor (MITF)/Tfe3, which induce the expression of the M-CSF 
receptor C-FMS [58]. Then, M-CSF promotes RANK expression by myeloid 
precursors, thus priming them to respond to RANKL, and enhances proliferation, 
differentiation and survival of osteoclast precursors via the signaling complexes 
DNAX-activating protein 12/tyrosine-protein kinase (DAP12/SYK), extracellular 
signal-regulated kinase/growth-factor-receptor-bound protein 2 (ERK/GRB2) and 
protein kinase B/phosphatidylinositol 3-kinase (AKT/PI3K) [55].   
RANKL binding to its receptor RANK induces trimerization of the receptor and 
recruitment of different adaptor molecules; among them, TNF receptor-associated factor 
6 (TRAF6) appears to be the most important. TRAF6 recruitment leads to the activation 
of several signaling pathways such as c-Jun N-terminal kinase/activator protein 1 
(JNK/AP1), nuclear factor kappa B (NF-kB) and nuclear factor of activated T cell c1 
(NFATc1) during osteoclast formation; SRC and p38/MITF in the resorption phase; 
SRC and ERK to promote osteoclast survival [59, 60].  
More in detail, the most important regulator is NF-kB that comprises a family of 
transcription factors, such as p65, p50 and p52, which during basal/unstimulated 
conditions are inhibited by proteins called IκBs. After the initiation of osteoclast 
differentiation, TRAF6 activates NF-kB-inducing kinase (NIK) and then a complex 
consisting of IκB kinase (IKK) α, IKKβ and IKKγ (IKBKG, hereafter called NF-kB 
essential modulator, NEMO). IKK phosphorylates and degrades IκBα, thus releasing 
the p65/p50 heterodimer, which translocates into the nucleus and mediates a key event, 
which is the up-regulation of NFATc1 [61]. NFATc1 is the master regulator of 
osteoclast differentiation; its promoter contains NFAT binding sites that allow transient 
autoamplification during osteoclastogenesis, resulting in a robust induction of NFATc1. 
After NFATc1 activation, the expression of genes essential for osteoclast fusion (such 
as dendritic cell-specific transmembrane protein, DC-STAMP; osteoclast stimulatory 
transmembrane protein, OC-STAMP; and the d2 isoform of vacuolar ATPase V0 
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domain, Atp6v0d2) and for osteoclast function (tartrate resistant acid phosphatase, 
TRAP and cathepsin K, CTSK) is induced (Figure 5) [62].  
In parallel to RANKL/RANK axis, co-stimulatory signaling contributes to induce 
osteoclast formation and activation. Basically, Immunoglobulin-like receptors, such as 
triggering receptor expressed in myeloid cells-2 (TREM 2) and osteoclast-associated 
receptor (OSCAR), after binding to as yet poorly defined ligands, recruit adaptor 
molecules, including Fc receptor common g subunit (FcRg) and DAP12. The 
phosphorylation of ITAMs in these adaptors stimulates downstream pathways, 
comprising also phospholipase Cg and calcium-calmodulin signaling, resulting in 
potentiation of NFATc1 signal via a calcium-dependent mechanism [55]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Principal molecules involved in osteoclast differentiation and function. PU.1 and M-
CSF with its receptor C-FMS act in the early stage regulating HSC differentiation into 
osteoclast precursors, which form multinucleated cells by cell-cell fusion. RANKL-RANK 
binding stimulates the activation of downstream molecules that lead to the formation of mature 
and functional osteoclast. Adapted from Boyce, 2013.  
 
In this framework, the transcription factor c-MYC has been proposed as the key 
upstream regulator of the metabolic reprogramming occurring upon RANKL/RANK 
signal activation. c-MYC expression would be activated downstream of 
RANKL/RANK binding through an as yet undefined mechanism, and this would 
directly enhance the expression of the estrogen-related receptor a (ERRa), ultimately 
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resulting in increased osteoclastogenesis via enhanced mitochondrial respiration. Of 
note, c-MYC would also act upstream NFATc1 [63]. 
Another important transcription factor downstream activation of the RANKL/RANK 
signaling axis is the B lymphocyte-induced maturation protein 1 (BLIMP1), which 
mediates the transcriptional repression of anti-osteoclastogenic genes, such as B-cell 
lymphoma 6 (Bcl6), interferon regulatory factor 8 (IRF8), and v-Maf 
musculoaponeurotic fibrosarcoma oncogene family homolog B (MAFB) [64]. 
In addition, LGR4 has recently been demonstrated to prevent RANKL binding to its 
functional receptor RANK. LGR4 binding to RANKL activates the GSK3 pathway 
suppressing the expression of NFATc1 during osteoclastogenesis, thus reducing 
osteoclast differentiation [65].   
 
Osteoclast physiology 
Osteoclasts’ main function is the degradation of the bone matrix; to this end, they form 
the sealing zone, through which they firmly attach to bone thanks to integrin expression 
(in particular ανβ3 integrin). The binding process results in actin ring formation and 
deployment of adhesive proteins into a ring-shaped structure, so that a seal is formed 
[66, 67]. 
The adherent osteoclasts are polarized and form the ruffled border, a series of fingerlike 
processes that increase the surface area of the plasma membrane facing the resorption 
lacuna. The ruffled border is enriched in vacuolar H
+
-ATPase proton pumps, 
multisubunit complexes which allow establishing the low pH required for the 
dissolution of bone mineral matrix and degradation of the organic matrix by a number 
of secreted lysosomal enzymes. Several acid hydrolases are present in the osteoclast 
lysosomes and in the resorption lacuna, for example the cysteine protease cathepsin K, 
matrix metalloprotease 9 (MMP9) and TRAP [68]. 
The protons extruded by the V-ATPase originate in the cytoplasm by the activity of the 
enzyme carbonic anhydrase type 2 (CA2), which accelerates the hydration of CO2 in 
H2CO3, soon dissociated into HCO3
-
 and H
+
. The generated HCO3
-
 is taken up by a Cl
-
/HCO3
-
 anion exchanger located in the basolateral membrane, which prevents 
cytoplasmic alkalinization and provides the Cl
- 
ions required by the chloride voltage-
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gated channel 7/osteopetrosis associated transmembrane protein 1 (CLCN7/OSTM1) 
2Cl
-
/H
+
 antiporter complex in order to electrically shunt the resorption lacuna [69]. 
Two distinct subdomains of the ruffled border, the fusion zone and the uptake zone, 
have been implicated in vesicular fusion and uptake of bone degradation products, 
respectively; both subdomains would take part also in vesicular trafficking, membrane 
recycling and re-uptake of lysosomal enzymes. Intricate mechanisms involving also 
small guanosine triphosphate (GTP)-binding proteins and microtubule-based protein 
complexes, allow efficient delivery of osteolytic cargos and transport of products of 
bone matrix degradation through the cell and their release at the functional secretory 
domain into the extracellular space [51].  
 
3.1.1.5 Other cells in bone 
In the bone tissue, several other cells are present besides those above described. Here 
we will provide just few examples in order to give a flavor of the complexity of bone 
tissue composition and of the cellular interactions taking place therein.  
MSCs can be found in the bone marrow, periosteum, endosteum and in the mineralized 
tissue itself. In addition to osteoblasts, they give rise to other cell types, in particular 
adipocytes and chondrocytes. Adipogenic differentiation is specifically important for 
bone homeostasis, because in many physiopathological conditions (such as aging, 
estrogen loss) differentiation occurs towards either lineage as mutually exclusive cell 
fate decision [70]. Moreover, bone marrow adipocytes secrete a spectrum of 
biologically active signaling molecules, such as resistin, leptin and adiponectin, that 
have been reported to influence the development and function of osteoblasts and 
osteoclasts [71].  
HSC residing in the bone marrow establish complex interactions with their 
microenvironment, which can direct their fate. On one hand, osteoblasts and osteoclasts 
produce molecules able to affect HSC localization and function, whereas the activation 
of osteoclasts leads to HSC egress from the bone marrow [72]. On the other, HSCs 
themselves express factors, such as angiopoietin1, able to modulate the properties of 
their niche [73] and, more in general, of the bone tissue, particularly in pathological 
conditions [74]. 
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Immune cells are important components of the bone microenvironment playing a role in 
health and disease. For example, in physiological bone turnover B and T lymphocytes 
have been shown to participate in the maintenance of tissue homeostasis by regulating 
the RANKL/OPG ratio (of note, B cells are a key source of OPG in the bone marrow) 
and by directly modulating osteoclastogenesis via cytotoxic T-lymphocyte protein 4 
(CTLA4) [75]. In pathological conditions, activated immune cells drive systemic bone 
loss by producing TNFa and RANKL. Moreover, Th17 cells produce interleukin 17 
(IL-17) that induces RANK expression on osteoclast precursors as well as RANKL 
production, further supporting osteoclasts formation [76].  
 
3.1.1.6 Bone matrix 
Bone matrix is composed of an organic phase (20%), an inorganic one (70%) and water 
(10%); the relative amount of each component varies depending on age, gender, site, 
and in general physiopathological conditions [77].  
The organic component is also called osteoid; the most abundant protein in this part is 
type I collagen (90%), which is a heterotrimer of two type I alpha 1 chains [a1(I)] and 
one type I alpha 2 chain [a2(I)]. Other types of collagen are also present in bone in a 
lower amount, such as type II, IX and XI. Collagen is synthetized as a procollagen 
molecule, in which an N-terminal and a C-terminal globular domain flank the helical 
domain. These propeptides are required for folding, which starts at the C-terminal and 
proceeds towards the N-terminal, and are cleaved by specific proteases after secretion. 
The basic feature of the helical domain is the presence of an uninterrupted series of 
triplets Gly-X-Y, in which the glycine residue in the first position is mandatory, while 
in the second and third position a proline and hydroxyproline, respectively, are often 
found. The small side chain of the glycine residue in the triplet can be easily 
accommodated in the inner part of the helix, thus is essential for collagen structural 
integrity [78]. The helical structure undergoes posttranslational modifications, mainly 
hydroxylation at proline and lysine residues in specific positions, glycosylation of 
hydroxylysine and isomerization of peptidyl prolyl bonds. These modifications, 
occuring mainly in the rough endoplasmic reticulum, require the activity of several 
enzymes and are essential for proper folding. The folded collagen is then transferred to 
the Golgi and released in the extracellular space, where it undergoes a maturation 
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process consisting in the removal of the propeptides and in the spontaneous assembly in 
microfibrils. These latter grow in longitudinal and axial directions by forming crosslinks 
between each other and generating long, thin and elastic mature fibers (Figure 6) [79]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Schematic representation of collagen synthesis. The process starts in the 
rough endoplasmic reticulum with the translation of pro-collagen α chains. These 
chains form a triple helix and are secreted from the cell, where they undergo further 
processing and aggregation into fibrils and fibers. Adapted from McKleroy et al., 2013.  
 
The organic matrix of the bone tissue contains also non-collagenous proteins, such as 
PGs, osteonectin, osteocalcin and proteins of the small integrin-binding ligand N-linked 
glycoprotein (SIBLING) family, such as BSP, osteopontin (OPN) and dentin matrix 
protein 1 (DMP1).  
Proteoglycans are molecules composed of a proteic core covalently bound by one or 
more sulfated GAG chains, i.e. linear polymers formed by repeated disaccharidic units 
produced in the Golgi. Based on the disaccharide, GAGs can be divided in 
glucosaminoglycans (comprising heparin/heparan sulfate and keratan sulfate) and 
galactosaminoglycans (comprising chondroitin sulfate and dermatan sulfate); a peculiar 
GAG is hyaluronic acid, which is not sulfated and not bound to a protein. In general, 
PGs are involved in the organization of the bone matrix structure; in addition, they bind 
several growth factors, such as TGFb, FGFs and VEGF, thus modulating their 
availability in the bone microenvironment. Recent evidence suggests that PGs may also 
interfere with the RANKL/RANK signaling axis by binding osteoprotegerin [see below 
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for detailed description of this pathway] and modulate cathepsin K activity, thus 
indirectly influencing osteoclast function [80]; in parallel, PGs may inhibit osteoblast 
proliferation [81]. 
Osteonectin (also named secreted protein acidic and rich in cysteine, SPARC) is a 
calcium-binding protein; it contains two distinct domains for the interaction with 
collagen and hydroxyapatite, respectively. Osteonectin is highly expressed during bone 
formation, while its production decreases in mature bone. It has been proposed to 
facilitate procollagen processing by limiting its interaction with the cell surface collagen 
receptors discoidin domain receptors 1 and 2 [82].  
Osteocalcin is abundantly deposited in the extracellular matrix thanks to the high 
affinity for the mineral component conferred by three carboxylated glutamate residues. 
Osteocalcin is also present in the general circulation, where its levels are measured as a 
bone turnover marker. Of note, recent advances have identified osteocalcin as a bone-
derived hormone able to influence energy metabolism and reproductive functions [83]. 
The SIBLING proteins have been implicated in cell attachment/signaling processes due 
to the presence of an Arg-Gly-Asp (RGD) motif mediating their interaction with 
integrins; moreover, they have been implicated in matrix mineralization. In particular, 
BSP is expressed at the early stage of bone formation during embryogenesis, suggesting 
that it might have a role in mineral nucleation. On the contrary, OPN (also termed 
secreted phosphoprotein 1, SPP1), originally described as a bridge between cells and 
mineral, has been shown to inhibit hydroxyapatite formation and growth. Finally, 
DMP1 seems to perform opposite functions: it inhibits the mineralization process as a 
native protein, while it initiates this process when cleaved or dephosphorylated, through 
the activation of an intracellular signaling cascade downstream avb3 integrin resulting in 
the release of Ca
2+
 stored in the osteoblasts. Interestingly, BSP has been also implicated 
in bone remodeling and in particular in osteoclast adhesion to bone [84, 85]. 
Of note, the bone organic matrix contains also many growth factors, like TGFβ, BMPs, 
IGF I and II [33], which are produced by osteoblasts, stored in the matrix and made 
available by osteoclast resorbing activity promoting the osteoclast-osteoblast crosstalk.     
The inorganic component of the bone matrix is the mineral phase. It contributes to the 
mechanical properties of the matrix, such as strength in compression and stiffness in 
tension, while it reduces toughness. Bone crystals are small (20-50 nm long, 15 nm 
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wide and 2-5 nm thick), plate-shaped and often quite closely packed, with their long 
axes almost parallel to the axes of the collagen fibrils [86]. The primary constituent of 
the mineral phase is hydroxyapatite (Ca10(PO4)6(OH)2), since calcium and phosphate are 
the most abundant ions; amorphous calcium phosphate is present, too. The mineral 
phase is also rich in carbonate ions, which form carbonate hydroxyapatite; other ions, 
such as citrate, magnesium, sodium, potassium and fluoride, are present in a lower 
amount. Mineralization is a biphasic process; in the initial phase, crystal number and 
size rapidly increase within the gaps inside collagen fibrils, then a slower phase lasting 
months to years allows mineral interaction with local ions, crystal growth towards the 
overlapping zones and matrix maturation [86]. 
 
Finally, another important component of the bone matrix is water, which binds collagen 
and mineral particles and allows their relative movement and deformation during 
loading. Therefore, the amount of water in the bone tissue can importantly impact on 
bone mechanical properties. In particular, the mineralization process allows mineral 
crystals to replace water within collagen fibers and to lose their diffusion capacity; this 
results in reduced collagen fiber diameter and loss of toughness and elasticity [87]. 
 
3.1.2 Bone material pattern 
At microscopic level, two types of bone can be distinguished based on its composition: 
woven bone and lamellar bone. 
Woven bone is characterized by irregular disposition of collagen fibers and mineral 
crystals. This type of bone is a transient tissue, typical of young fetal bones, but is 
present also in adults during very rapid bone remodeling and fractures repair. It is 
quickly laid down and displays similar mechanical properties in all directions.  
On the other hand, almost all adult bones have a lamellar structure, which means they 
are composed of a series of 3-7 mm thick lamellae forming circumferential layers at the 
outer (periosteal) and inner (endosteal) surfaces. The greatest portion of lamellae forms 
osteons, which represent the basic units of cortical bone; the estimated number of 
osteons in the adult skeleton is 21 million [88]. The osteons are characterized by the 
presence of neurovascular channels (termed Haversian canals) surrounded by concentric 
cylinders of lamellae with a final diameter ranging from 100 to 400 µm (Figure 7). They 
3. INTRODUCTION 
36 
 
contain osteocytes in confined spaces called lacunae, and are crossed by canaliculi, 
which are crossed by the cytoplasmic processes connecting the cells one to another and 
allow the diffusion of nutrients, gases and other diverse molecules. The central 
Haversian canals communicate with each other and with the bone marrow cavity via 
channels called Volkmann’s canals, which run obliquely to the long axes of the osteons. 
This three dimensional structure and the main direction of the collagen fibers within 
osteons of long bone shafts can vary: the fibers are predominantly longitudinal at sites 
mostly subjected to tension, and more oblique at sites subjected to compression. 
The trabecular bone (also called cancellous or spongy bone) does not contain osteons 
and is less dense as compared to cortical bone, which makes it more flexible and 
suitable for metabolic activities [89]. It is typically found at the ends of long bones, is 
highly vascularized and hosts bone marrow cells. The trabeculae, thin plates of bone, 
are its primary anatomical and functional unit and are aligned towards the mechanical 
load distribution (Figure 2).  
 
             
 
Figure 7: Schematic section of a long bone showing cortical and trabecular bone tissue. 
Adapted from Cowin et al., 2015. 
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3.2 Bone development 
 
Bone development takes place through two different processes: endochondral and 
intramembranous ossification. During the former, ossification is preceded by the 
formation of a cartilaginous template; this mechanism gives rise to all the axial 
(vertebral column and ribs) and appendicular (limb) bones of the body.  
On the other hand, the majority of the face and skull bones (called dermal or membrane 
bones) directly originate by intramembranous ossification of the mesenchyme, from 
neural crest cells or unsegmented paraxial mesoderm [90].   
Fine temporal and spatial regulation of the commitment to the chondrogenic and 
osteogenic lineages is essential for both embryonic and adult bone development and is 
determined, at a molecular level, by distinct transcription factors. In particular, SOX9 is 
a key regulator of the differentiation towards the chondrogenic lineage acting on 
collagen type II expression, whose protein product is the main constituent of the early 
cartilaginous matrix. On the other hand, commitment to the osteoblastic lineage requires 
the transcription factor RUNX2 (as already described in 3.1.1.1 chapter) [91]. 
Accordingly, loss of SOX9 in mice affects the early development of all cartilaginous 
bones, whereas gene inactivation of Runx2 in mice results in ossification defects due to 
lack of osteoblasts [92, 93]. 
 
3.2.1 Endochondral ossification 
Endochondral ossification begins as mesenchymal cells condense. In response to growth 
factors, chondrocytes differentiate within the mesenchyme, become hypertrophic and 
start to secrete molecules of the cartilaginous extracellular matrix mainly composed of 
collagen type II and PGs (Figure 8A). Afterwards, osteoblasts differentiate from the 
cells of the perichondrium, that is the layer surrounding the cartilaginous area, and form 
a primary bone collar around the circumference of the bone in the diaphysis, whereas 
hypertrophic chondrocytes attract blood vessels and then undergo apoptosis (Figure 8B) 
[94, 95]. The ossification process starts in the primary ossification center in the middle 
of the long bone, when the developing bone is invaded by multiple blood vessels and 
proceeds towards the epiphyses (i.e. each of the two extremities of a long bone). The 
establishment of the vasculature recruits preosteoblastic cells that differentiate into 
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osteoblasts and replace hypertrophic chondrocytes. Osteoblasts of the primary 
spongiosa produce the trabecular bone, while those of the bone collar produce the 
cortical bone; in the meantime, chondrocyte proliferation results in bone elongation 
(Figure 8C). Osteoclast precursors migrated in the spongiosa through blood vessels, 
which differentiate and remove cartilage matrix, while osteoblasts use the remaining of 
this matrix as a scaffold for the deposition of bone; overall, these processes achieve 
modeling of the growing bone.  
At birth, the diaphyses are completely ossified, whereas the epiphyses are still 
cartilaginous and ossify after birth during the secondary ossification. However, a layer 
of cartilage (epiphyseal growth plate) persists between the epiphysis and the growing 
end of the diaphysis (metaphysis) (Figure 8D) [95]. Finally, when the growth of the 
body is complete (around 20 years of age), the epiphyseal growth plate completely 
ossifies. 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 8: Schematic representation of long bone development. h = hypertrophic chondrocytes. 
bc = bone collar. soc = secondary ossification center. col = columns of proliferating 
chondrocytes. hm = hematopoietic marrow. gp = growth plate. Adapted from Kronenberg, 
2003.    
 
In all these processes chondrocytes play a pivotal role. In order to accomplish their 
functions, they undergo morphological and functional changes (from resting to 
proliferating, then hypertrophic and lastly apoptotic) under the control of systemic 
factors such as growth hormone (GH) and thyroid hormones (T3), and of locally 
A B C D
gp 
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secreted factors, such IGFs, Indian hedgehog (IHH), parathyroid hormone-related 
protein (PTHrP), BMPs, Wnts and FGFs [96, 97]. These extracellular factors control a 
number of transcription factors and signaling pathways, including the already 
mentioned SOX9 and RUNX2 transcription factors and the BMP and Wnt (canonical 
and non-canonical) signaling pathways (Figure 9) [97]. 
 
 
                                 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Schematic representation of the roles of systemic, secreted and transcriptional factors 
in the regulation of chondrocytes proliferation and hypertrophy during endochondral 
ossification. Arrows and crossed lines indicate stimulatory and inhibitory pathways, 
respectively. Adapted from Mackie et al., 2008.   
 
3.3 Genetic skeletal disorders 
 
Congenital alterations of bone homeostasis can cause several skeletal pathologies: 
namely, dysplasias are generalized disorders of cartilage and bone, whereas dysostoses 
are defects of an individual bone or group of bones. These disorders are mostly rare and 
can have different levels of severity. Even if the bone compartment is primarily 
affected, a variety of neurologic, visual, cardiac, renal and psychological complications 
can be present, too.  
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The total number of different skeletal disorders is higher than 400 and the total number 
of affected genes higher than 350. Hence the need to provide a classification, such as 
the one periodically provided and revised/updated by the Nosology and classification of 
genetic skeletal disorders [98], aimed at facilitating clinical and genetic diagnosis of 
patients and correct management of their disease, when specific therapies are available; 
at delineating genotype-phenotype correlations and helping interpretation of results 
from next generation sequencing technologies. To this end, the Nosology divides 
skeletal disorders into 42 groups defined either by a single gene or a group of related 
genes, by a particular phenotypic feature or by specific radiological findings [98].  
In this context, group 23 comprises the large family of osteopetroses and related 
disorders, while group 34 comprises dysostoses with predominant craniofacial 
involvement. 
 
3.4 Osteopetrosis 
 
The term osteopetrosis derives from the Greek “osteo” that means bone and “petros”, 
stone; indeed, osteopetrosis describes a group of rare, heritable disorders that share the 
hallmark of increased bone density on radiographs due to a failure in bone resorption [9, 
99, 100]. The osteopetroses can be divided in two main groups based on the mode of 
inheritance: autosomal dominant osteopetrosis (ADO, also called Albers-Schӧnberg 
disease, after the name of the German radiologist who described the pathology for the 
first time in 1904) and autosomal recessive osteopetrosis (ARO). An X-linked form also 
exists, which is extremely rare (only 4 unrelated patients have been reported thus far in 
literature) and specifically associated with mutations in the NEMO gene [101-103]. 
ADO has an incidence of 1 in 20,000 births and is generally considered benign, since 
clinical manifestation most often occurs in adolescence or adulthood and life 
expectancy is usually normal. However, this form displays a wide range of severity, 
from asymptomatic cases to severely affected individuals, where the disease is evident 
already in childhood.  
ARO has an incidence of 1 in 250,000 births in the general population, but in specific 
geographic regions (such as Costa Rica, the Middle East, the Chuvash Republic of 
Russia) is more frequent due to a founder effect, geographic isolation or high parental 
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consanguinity [104, 105]. ARO is also called malignant infantile osteopetrosis, because 
it presents soon after birth and is associated with diminished life expectancy; in fact, 
untreated patients often die in the first decade of life due to bone marrow suppression 
and consequent infections.  
 
3.4.1 Clinical presentation 
ADO can be recognized based on the typical radiographic sign of “sandwich vertebrae” 
determined by endplate thickening. Increased bone density is particularly evident at the 
spine, pelvis and skull base in the so called ADO type II, while in ADO type I, which 
would be more properly classified as a form of high bone mass, generalized 
osteosclerosis is more pronounced in the cranial vault. 
Complications are mainly confined to the skeleton; they include frequent fragility 
fractures (ADO I differs also for this aspect: in fact, it’s the only form of osteopetrosis 
not associated with increased fracture rate), bone pain, scoliosis and osteomyelitis, 
affecting in particular the mandible with dental abscess or caries [106]. The outcome of 
orthopedic surgery interventions often is limited by nonunion events (i.e. permanent 
healing failure), infections, prosthesis loosening and intraoperative fractures. Cranial 
nerve compression leading to hearing and/or visual loss and/or facial palsy affects only 
a minority of patients. Similarly, secondary hematological defects are not common. 
ARO is clinically heterogeneous. It presents at birth or during the neonatal period. The 
defect in bone resorption causes extremely high bone mineral density and a typical 
facies, with macrocephaly despite general growth retardation, frontal bossing, 
exophthalmos (eye protrusion), micrognathia (abnormally small jaw) and hypertelorism 
(increased distance between the eyes) (Figure 10A).  
Typical findings at radiological investigation are “bone-in-bone” appearance, “sign du 
masque” of the skull and Erlenmeyer flask deformity of the distal femoral and humeral 
metaphyses (Figure 10B). Pathological fragility fractures after minor trauma may occur 
and the healing process may be delayed. 
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Figure 10: (A) Clinical picture showing the typical facies of an osteopetrotic patient with 
macrocephaly, frontal bossing and exophthalmos. (B) Representative radiographies showing 
diffuse increase in bone density, “sign du masque” of the skull, bone-in-bone appearance, 
absence of bone marrow cavity in the long bones and Erlenmeyer flask deformity (arrows). 
Adapted from Pangrazio et al., 2013. 
 
Skull abnormalities, such as calvarial thickening and stenosis of the cranial foramina 
that are crossed by nerves, lead to increased intracranial pressure and neurological 
defects, such as progressive blindness and/or deafness, cerebellar tonsillar herniation 
and hydrocephalus [107]. Choanal stenosis can result in respiratory difficulties. In some 
cases, craniosynostosis (i.e. premature fusion of cranial sutures) is present and is 
responsible for abnormal skull shape and intracranial hypertension. 
The reduction of bone marrow space causes bone marrow failure, anemia, 
thrombocytopenia, variable leucocyte counts, compensatory extramedullary 
hematopoiesis, hepatosplenomegaly and recurrent infections. Hypogammaglobulinemia 
has been reported in some patients [108-110]. 
Dental defects include absence of teeth, delayed tooth eruption, higher risk of severe 
caries; moreover, osteomyelitis of the jaw is a common complication after tooth 
extraction. 
Patients frequently show low serum Ca
2+
 levels causing secondary hyperparathyroidism 
and occasionally hypocalcaemic seizures; on the other hand, serum levels of alkaline 
phosphatase, 1,25(OH)2D3 and lactate dehydrogenase vary from patient to patient, so 
they are not reliable biomarkers for ARO [109]. 
Other clinical features are found in specific ARO subtypes (Table 1): in the neuropathic 
form (displayed by all patients bearing mutations in the OSTM1, and in some patients 
with mutations in the CLCN7 gene), primary progressive neurodegeneration with severe 
developmental delay, hypotonia and primary retinal atrophy, is present. In these patients 
A B 
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pathological changes can be detected by electroencephalography even before the onset 
of clinical signs [111, 112]. Patients with mutations in the TCIRG1 or SNX10 gene can 
present rickets together with osteopetrosis (hence, the term osteopetrorickets) because 
of defective Ca
2+
 uptake in the gut and consequent inability to fully mineralize newly 
formed osteoid [113, 114]. 
Other clinical features reported in sporadic cases are structural brain malformations, in 
particular agenesis of the corpus callosum, possibly due to a defect during early 
embryonic development; coagulation defects, such as Glanzmann thrombasthaenia and 
severe bleeding, and haemophilia A; glucose-6-phosphate dehydrogenase deficiency; 
congenital hypothyroidism [9]. 
 
Table 1: Classification, genetics and clinical manifestations in ARO patients. Adapted 
from Sobacchi et al., 2013. 
 
 
3.4.2 The genetic bases of ARO 
The first gene identified in the pathogenesis of osteopetrosis was the CA2. Actually, 
CA2 deficiency presents as an autosomal recessive syndrome in which osteopetrosis is 
accompanied by renal tubular acidosis, cerebral calcification and mental retardation. 
The defect responsible for the disease was firstly identified through biochemical studies; 
then, some years later, the first mutation was identified by direct sequencing of the gene 
[115, 116]. However, CA2 deficiency is frequently not considered a classic form of 
osteopetrosis, because the renal defect is preponderant as compared to the mild skeletal 
pathology. 
3. INTRODUCTION 
44 
 
The first gene found to be responsible for “pure” human ARO was the TCIRG1 gene 
[117]. After that, six additional genes have been involved in ARO pathogenesis, thus 
providing a genetic classification for about 90% of ARO cases. 
Five of these disease-genes (TCIRG1, CLCN7, OSTM1, SNX10 and PLEKHM1) encode 
proteins involved in the acidification of the resorption lacunae and/or in vesicular 
transport. Loss-of-function mutations in these genes lead to osteoclast-rich 
osteopetrosis, in which osteoclasts are abundant but not functional.  
Mutations in two other genes are associated with osteoclast-poor ARO, in which 
osteoclastogenesis is blocked: TNFSF11 (also called RANKL) and TNFRSF11A (its 
receptor RANK). 
 
3.4.2.1 Genes mutated in osteoclast-rich osteopetrosis 
  
TCIRG1 
The T cell immune regulator 1 (TCIRG1) gene is located on human chromosome 11q13 
and comprises 20 exons. By alternative splicing, a shorter isoform can be produced 
(TIRC7); this transcript lacks the first 4 exons and codes for a transmembrane molecule 
expressed on activated T cells as an inhibitory receptor, regulating the immune 
response.  
The longer isoform is a component of the vacuolar proton pump V-ATPase, a 
multimeric protein complex involved in the acidification of extra- and intra-cellular 
compartments including lysosomes, endosomes, the Golgi apparatus and clathrin-coated 
vesicles. Its function is essential for several cellular functions, such as pH and ion 
homeostasis, and protein and vesicle trafficking. In the osteoclasts, the V-ATPase 
localizes on the membrane of the ruffled border, lysosomes and also on the basolateral 
membrane.  
The V-ATPase is composed of two reversibly assembled domains: the membrane-
embedded V0 and V1. V0 is formed by subunits a, c, c’’, d and e, and is responsible for 
proton translocation across the lipid bilayer; the cytosolic V1, formed by subunits A to 
H, is responsible for ATP hydrolysis. In addition, two accessory subunits (Ac45 and 
M8_9) are associated with the V0 domain. Both V1 and V0 domain work through a 
rotary mechanism [118].  
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The TCIRG1 gene encodes the a3 subunit of the V0 domain, the largest among the V0 
subunits (molecular weight: 116 kDa, hence the name “oc116”). Four different “a” 
subunits can be present in the V0 domain, however the a3 is more specifically expressed 
in osteoclasts and in gastric parietal cells. In bone, the activity of the V-ATPase is 
required to achieve the low pH needed for the dissolution of the inorganic matrix and 
the degradation of the organic matrix by acid proteases; in the stomach, it determines 
the low pH, which allows dietary Ca
2+
 absorption. Overall, this explains the peculiar 
phenotype (i.e. osteopetrorickets) deriving from TCIRG1 mutations.  
In addition to its proton-pump activity, the V0 complex is involved in vesicle 
trafficking; in fact, it interacts with microtubules and actin cytoskeleton, probably by 
means of the a3 subunit itself, and this is crucial for ruffled border formation [113, 118] 
[119]. Accordingly, mutations in TCIRG1, which account for more than 50% of ARO 
cases and are distributed along the entire gene, cause defects in the proton-pumping 
function of the V-ATPase and in vesicle trafficking/fusion in osteoclasts.  
 
 CLCN7  
The chloride voltage-gated channel 7 (CLCN7) gene is located on human chromosome 
16p13.3 and comprises 25 exons. Its protein product belongs to a large family of CLC 
proteins sharing the common feature of electrical neutralization of the protons actively 
pumped into the lumen of intracellular vesicles. The CLCN7 protein is ubiquitously 
expressed and found on the membrane of late endosomes and lysosomes. It has 12 
transmembrane domains, a cytosolic short amino-terminus and a long carboxy-terminus, 
containing two cystathionine-beta-synthase (CBS) domains, which may modulate 
transport activity, and a (putative) ATP binding site. It acts as a slowly voltage-gated 
2Cl
-
/1H
+
 antiporter channel [120]: it mediates the exchange of chloride ions against 
protons, thus cooperating with the V-ATPase in the acidification of the resorption 
lacuna and of lysosomal vesicles. CLCN7 forms a dimer and each monomer contains an 
ion translocation pathway, with conserved gating glutamate residues; simultaneous 
gating of the two pores through conformational rearrangements outside the ion pathway 
has been demonstrated [121].    
Gene inactivation in mouse causes osteopetrosis, optic atrophy and neurodegeneration 
with severe lysosomal storage disease, accumulation of electron-dense material in 
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neurons, autofluorescent structures, microglial activation and astrogliosis; in addition, 
fur color changes are evident [122, 123]. In agreement with the mouse phenotype, some 
patients carrying biallelic mutations in the CLCN7 gene have primary neurological 
defects besides osteopetrosis [111, 124, 125]. Recessive mutations in the CLCN7 gene 
are responsible for about 15% of ARO cases, while dominant ones cause ADO II. Key 
questions about CLCN7-deficient osteopetrosis still have to be answered: for example, 
is there a genotype-phenotype correlation? In particular, are there mutations specifically 
associated with the neuropathic presentation? If this is the case, what is the underlying 
mechanism responsible for it? With respect to dominant osteopetrosis: why can the 
same mutation lead to variable disease severity in different individuals, even in the 
same family? The answers to these questions are relevant for genetic counseling, 
prognosis and treatment; moreover, by allowing understanding a peculiar aspect of bone 
biology, may have implications well beyond osteopetrosis. 
 
OSTM1 
The osteopetrosis-associate transmembrane protein 1 (OSTM1) gene is located on 
human chromosome 6q21 and is composed of 6 exons. Its protein product is post-
translationally processed and specifically N-glycosylated. 
OSTM1 encodes a type I transmembrane protein which localizes to intracellular vesicles 
(mainly endosomes and lysosomes) and primarily acts as the β subunit of ClC-7 (Figure 
11). Its highly glycosylated N-terminus stabilizes ClC-7 and protects it from lysosomal 
degradation; OSTM1 aminoterminus and transmembrane domain are required for ClC-7 
2Cl
-
/1H
+
 exchange, whereas the transmembrane domain is important for ClC-7-
dependent trafficking to the lysosomes [120, 126]. OSTM1 has also been suggested to 
function as an E3 ubiquitin ligase for the heterotrimeric G-protein Gαi3 and to potentiate 
Wnt canonical signaling by modulating β-catenin/LEF1 interaction [127, 128]. 
More recently, additional cytosolic OSTM1 binding partners have been identified, 
suggesting that OSTM1 might behave as an adaptor molecule within a cytosolic 
scaffolding multiprotein complex. In particular, a direct interaction of OSTM1 with the 
kinesin 5B heavy chains has been demonstrated, playing a role in intracellular 
trafficking and dispersion of cargos from the endoplasmic reticulum to late 
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endosomal/lysosomal subcellular compartments, which is relevant in 
physiopathological conditions [129]. 
Mutations in the OSTM1 gene account for about 6% of ARO cases and invariably cause 
an extreme severe phenotype with rapidly progressing primary neurodegeneration. 
Almost all the identified mutations are truncating defects. In line, in vitro studies have 
recently demonstrated that a secreted form of truncated OSTM1 inhibits osteoclast 
formation through down-regulation of the BLIMP1-NFATc1 axis, thus providing a 
putative additional pathogenetic mechanism for OSTM1-deficient ARO [64]. 
 
 PLEKHM1 
The pleckstrin homology domain-containing family M (with RUN domain) member 1 
(PLEKHM1) gene is located on human chromosome 17q21.31 and is composed of 11 
exons [9]. 
It encodes a cytosolic protein implicated in endosomal trafficking pathways and 
containing a RUN domain, two pleckstrin homology (PH) domains separated from one 
another by an LC3-interacting region (LIR), a rubicon homology (RH) domain and a C1 
zinc finger.  
PLEKHM1 interacts with the small GTPases Ras-related protein Rab 7 (RAB7) and the 
ADP-ribosylation factor-like protein 8 (ARL8) and essentially acts as an effector, 
establishing multiple protein-protein interactions which ultimately permit trafficking, 
positioning and fusion of endosomes and lysosomes (Figure 11) [130]. [131]. In 
addition, PLEKHM1 participates in the fusion of autophagosomes and lysosomes, 
required for clearance of diverse protein aggregates. Disruption of the RUN or the PH 
domains, or loss of PLEKHM1 abrogates proper vesicle distribution and impairs 
secretion and ruffled border formation, leading to a detrimental effect on bone 
resorption in osteoclasts [132-135].  
Recessive mutations in this gene have been identified only in two affected siblings, 
while in two unrelated patients two different putatively dominant mutations have been 
reported [9, 136].  
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SNX10 
The sorting nexin 10 (SNX10) gene is located on human chromosome 7p15.2 and is 
composed of 7 exons. 
The SNX family comprises a number of cytoplasmic and membrane-bound proteins 
sharing as common feature the presence of a phosphoinositide-binding domain, called 
PX domain. In general, SNX proteins take part in protein sorting and membrane 
trafficking by establishing protein-protein and protein-lipid interactions. In particular, 
SNX10 interacts with the V1 D subunit of V-ATPase (Figure 11) and regulates its 
subcellular trafficking. Recent studies in human cells and mouse bone tissue have 
definitely established that SNX10-deficient ARO is osteoclast-rich and is caused by 
defective osteoclast function due to disrupted V-ATPase trafficking to the ruffled border 
[114, 137]. Accordingly, the osteopetrosis associated with SNX10 mutations closely 
resembles TCIRG1-dependent ARO and, since SNX10 is expressed in the gastric 
epithelium too, it presents as osteopetrorickets.  
Of note, mutations in SNX10, which overall account for about 6% of ARO cases, are 
responsible for "Västerbottenian osteopetrosis", so called from the name of the Swedish 
Province where a higher incidence of the disease has been reported. 
 
3.4.2.2 Genes mutated in osteoclast-poor osteopetrosis 
The vast majority of ARO cases in humans are osteoclasts-rich forms, in which a 
normal to high number of non-functional osteoclasts is present. On the contrary, 
osteoclast-poor cases are only a minority [138, 139]. Thus far, loss of function 
mutations in two genes have been involved in the pathogenesis of osteoclast-poor ARO: 
the TNFSF11 (alias RANKL) and TNFRSF11A (alias RANK) genes [108, 140].  
We have already extensively described the RANKL/RANK signaling axis (see chapter 
3.1.1.4). Here we would just underline that the key difference between these two 
subgroups of patients is the fact that in RANKL-deficient ARO osteoclast precursors 
have a non-cell autonomous defect; indeed, they are able to correctly differentiate into 
functional osteoclasts in vitro and in vivo (in the Rankl knock-out mouse), once 
recombinant RANKL is exogenously provided [140, 141]. On the other hand, in 
RANK-mutated ARO a cell autonomous defect in the osteoclast lineage is present, so 
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osteoclast precursors in vitro and in vivo fail to differentiate and generate osteoclasts 
[108, 110]. 
Inactivation of either gene in mouse models causes also defects of the immune system, 
because of the critical involvement of the RANKL/RANK signaling axis in many 
immunological functions [142]. In patients, as far as it was investigated, a partial defect 
in cytokine production from T-cell in RANKL-deficient ARO [143] and a partial defect 
in B-cell immunoglobulin production in RANK-mutated ARO have been described 
[110].  
 
3.4.2.3 Atypical forms of osteopetrosis  
Osteopetrosis is sometimes associated with other pathologies, which results in 
extremely rare, atypical and more complex phenotypes.  
An example is represented by dysosteosclerosis (DSS), a form of osteopetrosis 
characterized by red-violet macular atrophy of skin, platyspondyly and metaphyseal 
osteosclerosis, and caused by mutations in the solute carrier family 29 (nucleoside 
transporter), member 3 (SLC29A3) gene [144]. SLC29A3 encodes a lysosomal 
nucleoside transporter present in different cell types, including osteoclasts. Its 
involvement in the pathogenesis of a skeletal disease underlines the importance of 
endosomal and lysosomal function in bone physiology (Figure 11). 
X-linked osteopetrosis caused by mutation in the NEMO gene is peculiar in that the 
skeletal defect is accompanied by lymphedema, hypohidrotic ectodermal dysplasia (a 
congenital disorder of teeth, hair and eccrine sweat glands) and immunodeficiency (OL-
HED-ID) affecting both T and B cells and responsible for multiple life-threatening 
infections [102, 145, 146]. NEMO (also called IKKγ) is a subunit of the IkB kinase 
complex that activates NF-κB (Figure 11). In the osteoclasts, NEMO deficiency blocks 
the activation of the IKK complex in the osteoclast precursors, thus impeding the 
osteoclastogenic process [147]. 
Additionally, in few patients osteopetrosis is associated with severe bleeding despite 
normal platelet counts, hemoglobin levels, and peripheral blood cell morphology; 
recurrent bacterial infections are present, too. These patients carry mutations in the 
fermitin family member 3 (FERMT3) gene, which encodes for kindlin-3, one of the 
three members of kindlin family. Kindlin-3 is an intracellular protein linked to the actin 
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cytoskeleton and expressed in hematopoietic cells (Figure 11). Mutations in the 
FERMT3 gene are responsible for the rare autosomal recessive disease called leukocyte 
adhesion deficiency (LAD-III); interestingly, some LAD-III patients also suffer from 
severe osteopetrosis [148, 149]. Kindlin-3 interacts with multiple integrin classes and 
mediates their adhesive function and inside-out signaling, which in bone is essential for 
osteoclast resorptive activity. Indeed, kindlin-3 deficiency causes a severe 
morphological alteration of osteoclasts and impairs their ability to adhere to bone 
surfaces [150].  
 
 
Figure 11: Schematic representation of genes important for osteoclast resorption that cause 
osteopetrosis when mutated.  
 
 
Furthermore, a complex syndrome has been recently described in two unrelated patients 
and named COMMAD, because of the coexistence of coloboma, osteopetrosis, 
microphtalmia, macrocephaly, albinism and deafness. All these defects are explained by 
the presence of compound heterozygous mutations in the MITF gene in the two 
probands, altering nuclear migration and DNA binding properties of the encoded 
transcription factor [145].  
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Finally, two affected siblings have been very recently reported to display osteopetrosis 
and severe combined immunodeficiency (SCID) due to a homozygous genomic deletion 
encompassing the 5' region of TRAF6, recombination activating gene 1 and 2 (RAG1, 
RAG2) genes (the RAG proteins are essential for recombination of B and T cell 
receptors, and for the survival and differentiation of these cells) [146]. 
 
3.4.3 Diagnosis of osteopetrosis 
Osteopetrosis can be recognized due to the presence of the typical clinical 
manifestations and radiographic appearance of the skeleton above described. 
For the benign form of osteopetrosis, creatine kinase BB isoenzyme and TRAP can be 
informative [151]. For the recessive form, the presence of peculiar features like 
neurodegeneration, mental retardation, skin and immune system involvement or renal 
tubular acidosis, can point to a particular subtype of osteopetrosis. Bone biopsy can 
distinguish between osteoclast-poor and osteoclast-rich subtypes of ARO, but it is rarely 
performed because it is invasive and risky in these severely affected children. 
Genetic testing confirms the clinical diagnosis and allows classifying each case in a 
specific ARO subtype, to provide additional information on prognosis and response to 
treatment, and for genetic counseling of family members and prenatal diagnosis. 
 
3.4.4 Therapeutic treatment 
In the majority of ARO patients, the functional defect is intrinsic to osteoclasts, cells of 
hematopoietic origin. Therefore, repopulation of the bone marrow with “healthy” donor 
cells via hematopoietic stem cell transplantation (HSCT) can cure the disease. The 
exception is TNFSF11-dependent ARO in which the osteoclast differentiation defect 
caused by absence of RANKL is non-cell autonomous, therefore cannot be corrected by 
HSCT. 
The first bone marrow transplantation with a favorable outcome in an osteopetrotic 
patient was reported in 1980 [152]; so far, HSCT is the only curative treatment for 
ARO. According to the registry of the european society for immunodeficiences (ESID) 
and the inborn errors working party of the EBMT (IEWP-EBMT), nowadays ARO 
patients receiving an human leukocyte antigen (HLA)-identical HSCT have 88% of 5-
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year disease-free survival, 80% in the case of HLA-matched unrelated donor and about 
66% in the case of HLA-haplotype-mismatched related donor. Actually, percentages 
may vary (actually, may be lower) in different cohorts of patients [153]. 
In order to achieve the higher benefit for the patient, HSCT should be performed as 
soon as possible after diagnosis in order to prevent the establishment of irreversible 
secondary deficits. On the other hand, HSCT cannot cure neurological symptoms in 
patients, such as the OSTM1-defective subgroup, with early development of primary 
progressive neurodegeneration, which invariably leads them to death. Therefore, careful 
neurological assessment and monitoring of these patients is essential to define the 
treatment strategy. 
Supportive care based on gamma-interferon, vitamin D/calcium supplementation or 
PTH is offered when HSCT is not performed because of a variety of hindrances, such as 
poor clinical condition of the patient. For the dominant form of osteopetrosis a 
standardized treatment protocol is not available: supportive care is usually offered and 
life-style strategies are suggested in order to reduce the risk of fracture. In very few, 
early onset ADO patients HSCT has been performed, but this is not a standard care, of 
course.  
 
3.5 Acrofrontofacionasal dysostosis 1 
 
The dysostoses are caused by defects in embryonic development. They may have high 
heterogeneity of clinical presentation; different skeletal compartments like cranium, 
face, axial or appendicular skeleton can be affected and symptoms at other organ can be 
present. In many cases, the molecular defect that causes the pathology is known, but 
some forms lack a molecular classification. 
One of these cases is acrofrontofacionasal dysostosis 1 (AFFND1, OMIM: 201180) in 
which the mutated gene that leads to the disease is unknown. 
AFFDN1 is a very rare syndrome (estimated prevalence less than 1:1,000,000 
individuals) with predominant craniofacial and limb involvement. Principal features of 
the patients are short stature, facial and skeletal abnormalities such as cleft lip/palate, 
campo-brachy-poly-syndactyly and marked anomalies of foot structures, and 
intellectual disability (Figure 12). 
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AFFND1 is distinct from the form 2 (AFFND2), in which genitourinary anomalies are 
also present [154-157]. 
Until now, only four families, three of Brazilian and one of Indian origin, have been 
described as affected by AFFND1 [158-161]. The segregation of the disease in the 
families suggested an autosomal recessive pattern of inheritance, but the underlying 
genetic defect has not been identified, yet. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Representative pictures of the hallmarks of AFFND1. (A-B) A Brazilian 
patient showing wide forehead, broad-notched nasal tip, bilateral cleft lip and palate, 
camptodactyly. (C-D) Computed tomography (CT scan of one Brazilian patient showing 
normal cerebral parenchyma, microphthalmia with dense calcification of eye structures 
at left. Adapted from Richieri-Costa et al., 1992 and Guion-Almeida et al., 2003.  
 
3.6 Next Generation Sequencing technology 
 
The first human genome sequence was published in parallel in Science and Nature in 
2001 and it took 15 years to sequence it [162, 163]. Since 2003, when the human 
genome project ended, the importance of genomics (the study of genomes) in 
biomedical research has become evident [164]. Therefore, more powerful tools have 
been designed, in order to achieve automation, dramatic shortening of the time required 
for the analysis (e.g. nowadays, a complete human genome can be read in a single day), 
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adaptation to different needs, substantial reduction of costs and wide exploitation. This 
modern high-throughput sequencing, also known as next generation sequencing (NGS), 
is based on capillary electrophoresis (CE) sequencing: it exploits fluorescently labeled 
deoxyribonucleotide triphosphates (dNTPs) that are identified by fluorophore excitation 
after the incorporation into a DNA template strand during each cycle. The essential step 
forward of NGS is the possibility to perform the same procedure as CE sequencing 
across millions of fragments at the same time (the so called massive parallel 
sequencing). Briefly, NGS workflow can be divided in 4 steps (Figure 13): 
1. Library preparation. The DNA or complementary DNA (cDNA) sample is 
randomly fragmented by mechanical or enzymatic breakage, then adapters are added 
at the 5’ and 3’ ends.  
2. Cluster generation. The library is loaded onto a flow cell where surface-bound 
oligonucleotides bind the complementary adapters linked to the DNA fragments. 
Each fragment is amplified into distinct clonal clusters through bridge amplification. 
3. Sequencing. Fluorescent dNTPs are added; each time a base is incorporated, the 
corresponding emission of each cluster is recorded. The emission wavelength and its 
intensity identify the inserted base; this cycle is repeated “n” times to create an “n”-
bases-long read.  
4. Data Analysis. The reads are aligned to a reference genome and possible variations 
are identified [165].  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Next Generation Sequencing workflow. Adapted from Bahassi et al., 2014.   
 
 
A. Library preparation B. Cluster amplification C. Sequencing D. Alignment and Data Analysis 
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3.6.1 NGS applications 
The study of the human genome using NGS technology is extremely useful for the 
understanding of the pathogenesis of human diseases and the improvement of clinical 
practice in terms of time to precise diagnosis and therapy. NGS clinical applications are 
divided according to the targeted sequences [166].  
 Briefly, whole genome sequencing (WGS) covers the entire genome of an 
individual. It is mainly exploited in genome-wide association studies, in which a high 
number of patients are sequenced to gain information about the connection between a 
certain disease or trait and genetic variants, including also those located in non-coding 
regions. This increases the knowledge of the pathophysiological mechanisms and can 
have implications for patient treatment, when the genetic component of a disease is 
searched.  
 Whole exome sequencing (WES) or sequencing of a panel of genes related to a 
specific disease or a category of disorders may find novel mutations in patients and is a 
useful tool in clinical diagnostics. The need to use targeted sequencing is due to the 
complexity of human diseases: on one hand, mutations in genes involved in the same 
pathway sometimes lead to similar clinical phenotypes; on the other, different mutations 
in the same gene can cause different disease manifestations. 
 NGS can be applied also to the study of the epigenome; in this case, platforms 
such as CHIP (chromatin immunoprecipitation)-seq-protein-DNA binding and histone 
modification allowing the mapping of the methylome of a genome, are used. Results 
achieved through these strategies are uncovering the importance of epigenetic 
alterations in physiopathology. 
 RNA-sequencing (RNA-seq) is a combination of hybridization capture of cDNA 
and NGS to analyze the full transcriptome of a cell and identify mutations, structural 
alterations and alternative splicing variants, and to quantify expression levels. 
 Finally, NGS can be applied to the analysis of microbial populations, which 
generated the new and rapidly expanding research field called metagenomics [167, 
168]. 
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3.6.2 Whole exome sequencing to diagnose Mendelian diseases 
The human genome contains 3 billion base pairs comprising coding and noncoding 
sequences; only about 1-2% of the entire genome is translated into proteins, however it 
is estimated that almost 85% of the mutations causing Mendelian diseases are in gene 
coding and functional regions [169]. Hence, the rationale for applying WES to the 
diagnosis of Mendelian disorders stems. 
The sequencing of an exome produces a list of hundreds of thousands of variants, which 
can be filtered using several parameters and prioritized on the basis of different 
strategies [170] such as: 
1. Overlap-based strategy: in the absence of genetic heterogeneity for a given 
disease, sequencing unrelated patients with the same phenotype allows 
substantially decreasing the number of putative causative variants to further 
investigate. 
2. Linkage-based strategy: in large families with known mode of inheritance, by 
sequencing individuals from different (preferably distant) generations presenting 
the phenotype and non-affected individuals, the causative variant(s) may be 
easily found in the small fraction of the genome shared by the affected subjects. 
3. De novo-based strategy. For sporadic patients with a rare Mendelian disease, 
after sequencing of a trio (unaffected parents and affected child) a variant that is 
not present in the parents and appears for the first time in the patient is searched. 
4. Allele frequency. More than 95% of the identified variants in exomes are 
polymorphisms present in the general population. Extremely large databases are 
available; the most comprehensive is the GnomAD browser, which collects 
genetic data from many large sequencing projects. Dealing with rare diseases, it 
is reasonable to exclude variants with allele frequencies > 0.01.  
5. Predicted effect. Many in silico tools are available to predict the effect of a 
genetic change; some examples are SIFT, PolyPhen, Provean. The best strategy 
is to use more than one, since they are based on different algorithms. Loss-of-
function variants such as insertions/deletions, stop codon gain or loss, and 
splicing defects are usually considered strong candidates, based on their obvious 
impact on the protein product. However, genome-sequencing studies have 
recently indicated the presence of a non-negligible number of loss-of-function 
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changes in the general population, suggesting a really unexpected tolerance for 
gene inactivation [171].  
6. Presence in genes or molecular pathways already associated or with plausible 
association with the disease, based on data from literature. 
At the end, the remaining variants have to be validated by Sanger sequencing and 
functionally tested in order to draw a definitive conclusion regarding their pathogenicity 
[171].  
 
Whole Exome Sequencing limitation 
Some limitations inherent in WES may hamper its final result in terms of disease-gene 
identification: first, also variants outside coding exons (i.e. in introns, untranslated 
regions, microRNAs, promoters, regulatory regions) can be responsible for the disease, 
but for their location are very likely missed by WES. Moreover, the databases used for 
variant filtering, in which a high number of exomes is reported, cannot effectively 
exclude non-pathogenic variants; this happen if these variants are specific of a 
populations not sufficiently represented in those sequencing projects leading to 
misinterpretation of results. On the same line, synonymous variants are most often 
filtered out in the early steps of a standard analysis workflow, based on the assumption 
that they are silent; actually, this may be an error: in fact, several recent reports in 
literature show that some of them can cause diseases through different mechanisms. In 
addition, the presence of GC-rich sequences can lead to uneven coverage and 
incomplete capture, while variable base quality and errors introduced during library 
preparation may affect variant calling [170].  
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The general objective of my project was to contribute to the understanding of bone 
pathophysiology by identifying new molecules involved in skeletal homeostasis. To this 
end, I initially focused on human osteopetrosis, in whom a precise molecular diagnosis 
has already been demonstrated to be relevant with respect to the prognosis of the 
disease and the response to therapy. 
 
In detail, the specific aims of my project were: 
 
1. To characterize the molecular defect in human osteopetrosis through: 
 1A. Molecular analysis of the known osteopetrotic genes by Sanger sequencing. 
 1B. Identification of a group of patients with atypical phenotype and unknown 
genetic defect; for this group I performed exome sequencing to obtain a list of variants 
possibly associated with the disease. 
 
2. To evaluate the possible pathogenetic consequences of the putative mutations by in 
silico, in vitro and in vivo studies. 
 
3. To apply the same technology and experimental approach to a different skeletal 
disorder. In particular, we collected patients from 3 different families affected by 
Acrofrontofacionasal dysostosis type 1 that is a neglected pathology in which the 
causative genetic defect is unknown.  
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5.1 Osteopetrosis project 
 
During my PhD, in order to characterize the molecular defect in ARO patients I 
performed the analysis of the known osteopetrotic genes in 41 unrelated patients 
through PCR amplification and direct Sanger sequencing, according to protocols well 
established in our lab. Patients with atypical phenotype and unknown genetic defect 
were further investigated by exome sequencing to obtain a list of variants possibly 
associated with the disease (Figure 14).  
 
 
 
 
 
 
 
 
Figure 14: Scheme of the group of ARO patients classified by Sanger sequencing, NGS or 
without identification of causative mutations. 
 
 
In detail, for 25 of these patients we identified the causative mutation (Table 2), 
whereas 6 patients remained unclassified.  
The clinical diagnosis was ARO in most of the analyzed patients , ADO II in 2 patients 
and also ADO I in two patients. S23 was reclassified as Raine syndrome and will be 
specifically addressed below. Most of the analyzed patients were of Turkish (about 
30%) and Caucasian origin (about 15%), the others included Iranians, Brazilians, 
Caribbeans, Ecuadorians and Kurdish. In this relatively small cohort of patients we 
confirmed that in ARO patients the most frequently mutated gene was TCIRG1 (more 
than 40%); other mutations were located CLCN7, SNX10, RANK, OSTM1, CA2. The 
mutations that we found were missense mutations (51%), insertion/deletion (InDel) and 
nonsense mutations (32%) and mutations that impact in the splicing process (around 
17%). Most of them were known mutations; in addition, we found 12 novel mutations 
that have been verified with in silico prediction. For 2 of them we confirmed the 
41 patients analyzed by 
Sanger sequencing 
25 patients classified by 
Sanger sequencing 
10 patients classified 
by NGS 
6 patients 
unclassified  
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negative effect of the splice site mutations analyzing the cDNA obtained from 
Peripheral blood mononuclear cells (PBMCs) of the patients. 
 
Table 2: Mutations found in subjects with clinical diagnosis of osteopetrosis  
Subject Origin of 
subject 
Diagnosis Mutated 
gene 
State Specific mutation
§ 
S1 Caribbean ARO TCIRG1 Homozygous c.793C>T 
S2 Turkish ARO TCIRG1 Homozygous c.1384_86delAAC 
S3 Brazilian ARO TCIRG1 Homozygous c.346C>T 
S4 Ecuadorian ARO TCIRG1 Homozygous c.979C>T 
S5 Turkish ARO TCIRG1 Homozygous c.862delCinsAA 
S6 Caucasian ARO TCIRG1 Homozygous c.1559G>A 
S7 Turkish ARO TCIRG1 Homozygous c.196+5G>A 
S8 Turkish ARO TCIRG1 Homozygous c.1384_86delAAC 
S9 Turkish ARO TCIRG1 Homozygous c.1384_86delAAC 
S10 Turkish ARO TCIRG1 Homozygous del ex11_13 
S11 Turkish ARO TCIRG1 Homozygous c.702delG 
S12 Turkish ARO TCIRG1 Homozygous c.1165+5G>A 
S13 Caucasian ARO TCIRG1 Homozygous c.2236+1G>A 
S14 Iranian ARO CLCN7 Homozygous c.1727A>T 
S15 Turkish ARO SNX10 Homozygous c.152G>C 
S16 Kurdish ARO RANK Homozygous c.443A>T 
S17 Turkish ARO RANK Homozygous c.385C>T 
S18 Turkish ARO RANK Homozygous c.443A>T 
S19 Turkish ARO FAM20C Homozygous c.708C>A 
S20 Iranian ARO OSTM1 Homozygous c.811C>T 
S21 Pakistan ARO CA2 Homozygous c.291G>A 
S22 Indian ADO I LRP5 Heterozygous c.713C>T 
S23 Caucasian ADO I LRP5 Heterozygous c.200C>A 
S24 Caucasian ADO II CLCN7 Heterozygous c.2071A>G 
S25 Caucasian ADO II CLCN7 Heterozygous c.643G>A 
§Accession number of the TCIRG1 variant cDNA: NM_006019; CLCN7: NM_001114331; LRP5: NM_001291902; 
SNX10: NM_013322; RANK: NM_003839; FAM20C: NM_020223; OSTM1: NM_014028; CA2: NM_000067. The 
numbering used starts with nucleotide +1 for the A of the ATG-translation initiation codon.  
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We also analyzed a patient born from consanguineous parents of Turkish origin and 
presenting at birth with respiratory distress, general osteosclerosis, craniosynostosis and 
visual problems, overall raising the suspect of ARO. However, the facies of the patient 
was reminiscent of a different pathology called Raine syndrome, which is included in 
the differential diagnosis of osteopetrosis; in fact, it presents as a neonatal osteosclerotic 
bone dysplasia, but periosteal bone formation differentiates it from osteopetrosis. 
Accordingly, we found a novel mutation (c.708C>A; p.Tyr236X) that causes the 
formation a stop codon in the FAM20C gene, which is known to cause Raine syndrome. 
FAM20C encodes a Golgi serine/threonine protein kinase that phosphorylates serine 
residues of proteins involved in bone mineralization including FGF23 and OPN. 
Furthermore, we analyzed 2 ADO I patients of Indian and Caucasian origin that, as 
expected, demonstrated mutations in the LRP5 gene and 2 ADO II patients both of 
Caucasian origin that showed the typical clinical features of a mild/benign 
osteopetrosis. Both patients presented visual impairment and were not diagnosed in 
infancy with a general clinical picture of benign osteopetrosis, only one of them 
reported several fractures. The molecular analysis, as expected, demonstrated mutations 
in the CLCN7 gene.  
 
In addition to patients analyzed by direct Sanger sequencing, I also performed exome 
sequencing analysis on 10 patients from 7 unrelated families (Table 3). Results are 
reported in the next paragraph. 
 
Table 3: List of the families analyzed by exome sequencing and corresponding mutations  
   
Family ID # samples Gene State Mutation
§ 
1 2 CLCN7 Compound 
heterozygous 
c.269T>C 
c.982-1G>T 
2 3 CLCN7 Heterozygous c.746C>T 
3 1 OSTM1 Homozygous c.25C>T 
4 3 FERMT3 Homozygous c.1802delA 
5 4 TCIRG1 Homozygous c. 1884+146G>A 
6 3 TCIRG1 Homozygous c.1371C>A 
7 4 C16orf57 Homozygous c.683del-
AGGAACTACAGG 
§Accession number of the CLCN7 cDNA variant: NM_001114331; OSTM1: NM_014028; FERMT3: NM_178443; 
C16orf57: NM_024598; TCIRG1: NM_006019. The numbering used starts with nucleotide +1 for the A of the ATG-
translation initiation codon.  
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5.1.1 WES results: mutations in known ARO genes 
Family 1 comprised the patient and his mother. The patient was diagnosed at 3 months 
of age as affected by severe ARO presenting also macrocephaly, frontal bossing and 
hepatosplenomegaly. The analysis of the exome showed that the patient was a 
compound heterozygous for two mutations in the CLCN7 gene. A missense mutation, 
found also in his mother, in the exon 3 (c.269T>C) causes an amino acid change 
(p.Leu90Pro); a nucleotide change in the canonical acceptor splice site (c.982-1G>T), 
absent in his mother so presumably of paternal origin (the paternal DNA was not 
available), causes an alteration in the splicing process. 
Family 2 was composed of 3 affected siblings with a typical ADO II presentation 
(Figure 15). The analysis revealed the presence of the known mutation c.746C>T in the 
exon 9 of the CLCN7 gene that causes a change at the protein level (p.Pro249Leu), in 
all of them in the heterozygous state. 
 
 
 
 
 
 
 
 
 
 
Figure 15: X-ray images of the patients of Family 2 showing the classical sandwich vertebrae 
and bone-in-bone appearance. (A), (B) and (C) show pictures of the three distinct patients, 
respectively. 
 
In Family 3 WES was performed on the patient only. She was born from 
consanguineous parents, diagnosed at 15 days of age due to severe osteopetrosis, 
anemia, hepatosplenomeglay and thrombocytopenia. WES revealed the presence of a 
known mutation in the OSTM1 gene (c.25C>T), causing a premature stop codon 
A B C 
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(p.Gln9X), in the homozygous state, confirmed in the heterozygous state in the parents 
by Sanger sequencing. 
Family 4 was composed of the proband and her parents. The patient was a female born 
from Pakistani consanguineous parents (first degree consanguinity) that presented at 
birth with widespread purpuric/petechial rash, hepatomegaly, limited bleeding of the 
scalp and severe anemia. The clinical picture included also very dense bones noted in 
radiographic analysis, and abnormal bone architecture, increased osteoclast number 
with limited signs of remodeling, and reduced residual hematopoiesis shown by bone 
biopsy examination (Figure 16A and 16B). Overall this suggested a diagnosis of 
osteoclast-rich ARO. At 2 months of age the patient underwent allogeneic HSCT from a 
match unrelated umbilical cord donor, which corrected the bone pathology (Figure 
16C). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Clinical presentation of the patient from Family 4. (A) X-ray before HSCT, 
demonstrating the osteopetrotic phenotype. (B) Hematoxylin-eosin staining of iliac crest bone 
marrow trephine biopsy shows abnormal bone architecture (light blue) with cartilage remnants 
(bright pink), numerous multinucleated osteoclasts (arrows), and limited residual 
hematopoiesis. Magnification 10X. (C) X-ray performed 2.5 years after HSCT clearly showing 
restoration of normal bone density. 
     
 
At the last follow-up, at 5.5 years of age, she was well, without visual, hearing or 
developmental problems, and attended school full time. The major complain was 
secondary dentition formation problems, that is common among osteopetrotic patients 
even after successful HSCT [9]. We performed the trio-based exome sequencing and 
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found a novel single nucleotide deletion (c.1802delA) in the FERMT3 gene. This 
mutation was confirmed by Sanger sequencing in the homozygous state in the patient 
and in the heterozygous state in her parents. At the protein level, this mutation was 
predicted to cause a frameshift (p.Asn603Thrfs*) affecting the F3 domain which is 
involved in integrin binding [172]. Unfortunately, in the absence of an adequate sample 
from the patient, the presence of a mutated protein or absence of the wild type could not 
be evaluated by Western Blot; however, based on its position, the mutation was 
predicted to severely impact on the protein function and considered responsible for the 
disease in the patient. 
 
5.1.2 Patients with particular mutations in known ARO genes 
 
Deep intronic mutation in the TCIRG1 gene 
Here we describe the study carried out on Family 5 (Table 3). Since this work has 
already been published, hereafter we will refer to these subjects and to all the patients 
reported in the manuscript according to the numbering adopted in the paper [173]. 
Family 1 was composed of two affected siblings (Pt 1A, female, and Pt 1B, male) born 
from Italian consanguineous parents (third-degree consanguinity). Pt 1A was evaluated 
for the first time when she was 6 years old, because of visual problems; she displayed a 
generalized increase in bone density (Figure 17A) and mild hepatosplenomegaly, thus a 
diagnosis of mild osteopetrosis was made. So, her younger brother (Pt 1B) was 
investigated too, and received a similar diagnosis at 2 years of age (Figure 17B). 
 
 
 
 
 
 
 
 
 
Figure 17: Radiographic analysis of the patients showing the typical signs of the disease. (A) Pt 
1A at 6 years of age. (B) Pt 1B at 2 years of age. (C) Pt 2 at 22 years of age.     
A C B 
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During the follow up, both patients suffered from recurrent fractures (8 in Pt 1A and 11 
in Pt 1B), dental problems, and progressive deterioration of the visual acuity in Pt 1A; 
laboratory investigations did not show significant alterations of the evaluated 
parameters. The histological analysis on a bone specimen from Pt 1A showed an 
incomplete osteopetrosis with some areas containing mineralized cartilage, normal 
lamellar bone in well-formed trabecular bone and osteoclasts (Figure 18). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: Representative histological sections of a formalin-fixed paraffin-embedded 
decalcified bone specimen of Pt 1A at 35 years of age. (A) Visualization in polarized light (left) 
and hematoxilin-eosin (right) staining: the mature cortical bone shows lamellae in polarized 
light; islands of retained mineralized cartilage are present. Scale bar: 200 µm. (B) 
Hematoxilin-eosin staining showing several multinucleated osteoclasts. Scale bar: 100 µm. (C) 
TRAP fluorescent antibody labeling (red) and phase contrast with the fluorescence image 
overlaid; nuclei are stained with Hoechst (blue). Scale bar: 100 µm. The inset shows a single 
osteoclast at twice the magnification. Scale bar: 10 µm. (D) TCIRG1 fluorescent antibody 
labeling (green) and phase contrast with the fluorescence overlaid (right). Scale bar: 100 µm; 
inset: 10 µm.  
 
When we performed this work, both patients (Pt 1A 37 years old, Pt 1B 33 years old) 
were not receiving any specific therapy and overall their clinical picture could be 
considered benign. The molecular analysis of the genes known to cause recessive 
osteopetrosis did not identify any mutation. Therefore, we performed WES on both 
patients and their parents and found 32 homozygous variants in coding regions not 
including obvious candidate genes, so we focused our attention on variants in 3’ 
A 
D C 
B 
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untranslated regions (UTR) based on the assumption that they could influence gene 
expression [174]. In particular, we noted a variant in the 3’UTR of the choline kinase 
alpha (CHKA) gene, which maps to chromosome 11q13.2 on the reverse strand as 
compared to the TCIRG1 gene. Because of the close proximity of the two genes, we 
asked if the variant in the CHKA could influence the expression of the TCIRG1 gene. 
Investigation at the cDNA level in the patients through reverse transcriptase-polymerase 
chain reaction (RT-PCR) spanning exons 14 to 17 did not show a reduction in the 
expression of TCIRG1, but the unexpected formation of at least two different transcripts 
in both affected siblings (Figure 19A), suggesting a splicing aberration. So we 
sequenced the entire genomic region between exons 14 and 17, including the intronic 
parts, and identified a single nucleotide change in the middle of intron 15 
(c.1884+146G>A) which was present in the homozygous state in both patients and in 
the heterozygous state in their parents (Figure 19B). Moreover, this variant was absent 
in dbSNP and in 100 control chromosomes from a matched population. In silico 
analysis suggested a potential alteration of the splicing process even though this change 
was far from both the canonical donor and acceptor splice site. In order to confirm this 
prediction, we cloned the cDNA PCR product spanning exons 14 to 17, sequenced 73 
independent clones, and found that the large majority carried aberrant transcripts 
(namely, we identified at least 8 different transcripts), while only 4 clones displayed the 
wild type sequence. The two most abundant molecular species showed either retention 
of 144 nucleotides of intron 15 (22/73 clones) or skipping of the first 183 nucleotides of 
exon 15 and retention of 144 of intron 15 (30/73 clones) (Figure 19C). Overall, these 
data supported the hypothesis of a pathogenic role of this intronic variant. 
This unexpected result prompted us to sequence TCIRG1 intron 15 in 26 osteopetrotic 
patients without molecular diagnosis and in 7 ARO patients in which we had previously 
identified a single mutated TCIRG1 allele [104, 109]. We did not find any mutation in 
the 26 unclassified patients, but in 3 out of 7 patients carrying a single mutated TCIRG1 
allele we found additional heterozygous single nucleotide changes in intron 15.  
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Figure 19: (A) Semi-quantitative RT-PCR spanning either exons 14 to 17 (upper panel), 
showing the presence of at least two abnormal bands in the patients (the normal band visible in 
Pt 2 is from the other mutated allele), or exons 7 to 10 (middle panel), showing only the 
presence of the expected band in all the samples. The amplification of the GAPDH gene is used 
as housekeeping (lower panel). (B) Schematic representation of the region of the TCIRG1 gene 
from exon 14 to 16, highlighting the position of the mutations identified in intron 15; the 
nucleotide change found in each patient is in bold in the lower line. (C) Structure of the most 
frequent aberrant transcripts found in Pt 1A, Pt 1B and Pt 2: clones in which only the last 31 
nucleotides of exon 15 are retained, followed by 143 nucleotides of intron 15 (upper panel), and 
clones retaining 143 nucleotides of intron 15 (lower panel). The nucleotide change found in 
each patient is in bold in the lower line, as in (B). 
 
Among these 3 patients, Patient 2 (Pt 2) was the third child of unrelated Italian parents 
and was diagnosed at 4 years of age with a generalized increase in bone density (Figure 
17C). He reported 7 non-traumatic fractures; he did not display neurological or sensorial 
deficits, and was alive and reasonably well at 24 years of age.  
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Patient 3 (Pt 3) was already described as Pt 6 in Mazzolari et al., 2009 [109]; she was 
diagnosed at 6.5 months of age as classical ARO with bone defect and secondary 
hematological and neurological deficits. She received HSCT from a matched unrelated 
donor at 20.5 months with a favorable outcome: she was alive and well 7.5 years after 
transplantation. 
Patient 4 (Pt 4) was born from unrelated parents from Southeastern Asia, presented with 
bone defects, blindness and hepatosplenomegaly in neonatal life. He received HSCT but 
unfortunately died 4 years after the treatment without engraftment.        
All the mutations found in these patients were in close proximity to that present in Pt 
1A and Pt 1B: c.1884+142T>A in Pt 2 (mutation confirmed in the heterozygous state in 
Pt 2’s healthy mother and in one unaffected brother), c.1884+132T>C in Pt 3 and 
c.1884+149C>T in Pt 4 (Figure 19B, Table 4).  
 
Table 4: Deep intronic mutations in intron 15 of the TCIRG1 gene 
Patient Genomic change
#
 Location cDNA change
§
 Effect 
1A and 1B g.10466G>A 
g.10466G>A 
Intron 15 
Intron 15 
c.1887+146G>A 
c.1887+146G>A 
Putative aberrant splicing 
Putative aberrant splicing 
2 g.9909G>A 
g.10462T>A 
Exon 14 
Intron 15 
c.1559G>A 
c.1887+142T>A 
p.Trp520X 
Putative aberrant splicing 
3 g.11622T>C 
g.10452T>C 
Exon 19 
Intron 15 
c.2345T>C 
c.1887+132T>C 
p.Met782Thr 
Putative aberrant splicing 
4 g.8600T>C 
g.10469C>T 
Intron 11 
Intron 15 
c.1305+2T>C 
c.1887+149C>T 
Putative aberrant splicing 
Putative aberrant splicing 
# _Accession number genomic sequence of the TCIRG1 gene: AF033033. 
§_Accession number of the TCIRG1variant1 cDNA: NM_006019; the numbering used starts with 
nucleotide +1 for the A of the ATG-translation initiation codon. 
 
Also for these novel variants, in silico analysis predicted a potential disruptive effect on 
splicing process. The confirmation was performed in Pt 2, because his cell sample was 
the only available, by RT-PCR, cloning and sequencing of the PCR product. We found 
the same pattern of aberrant transcripts already described for Pt 1A and Pt 1B; in detail, 
12/75 clones retained 143 nucleotides of intron 15, 20/75 clones skipped the first 183 
nucleotides of exon 15 and retained 143 nucleotides of intron 15, 20/75 clones skipped 
the first 183 nucleotides of exon 15 and retained 141 nucleotides of intron 15. In 
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addition, other less frequent species and a residual amount of wild type transcript (5/75 
clones) were also present. 
Based on sequence analysis of the aberrant transcripts, we hypothesized that the 
molecular pathogenetic mechanism elicited by all these mutations in intron 15 could be 
the usage of an internal, cryptic acceptor site in exon 15 and of an intronic, cryptic 
donor site in intron 15, causing loss of part of exon 15 and retention of 143 nucleotides 
of intron 15, respectively (Figure 20). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: Proposed mechanism of aberrant splicing; upper case indicates exonic regions, 
lower case intronic ones. In grey was reported the intronic and exonic part lost after the 
aberrant splicing and in black the part maintained in the aberrant transcript.  
 
Synonymous but not silent mutations 
Family 6 analyzed in my thesis (Table 3) has been described in our work Palagano et 
al., J Bone Miner Res 2017, therefore the subjects therein described will be hereafter 
numbered as in the paper [175]. Patient 1 was diagnosed at 2 months of age as severe 
osteopetrosis; in the absence of a matched donor, HSCT was not performed and she 
died at 18 months of age because of septic shock (patient described in Mazzolari et al., 
2009, as Pt 14) [109]. Since Sanger sequencing of the patient had not identified obvious 
mutations in the known ARO genes, the entire family (i.e. the proband and her parents) 
CACATGGCCTTTGGGGTGGTCCTCGGAGTCTTCAACCACGTgtgagggccaag
gctgcccgggggacgggaggctggcaggccagagtgggcccagtgagcacacc
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was analyzed by WES. Also WES did not detect variants possibly responsible for the 
disease, after application of common filters to exclude low quality, common and 
synonymous variants. However, a synonymous variant attracted our attention: it was 
located in exon 12 of the TCIRG1 gene (c.1371C>A, p.Thr457Thr), segregated as 
expected based on parental consanguinity (it was present in the homozygous state in the 
patient and in the heterozygous state in his parents) and was absent both in single-
nucleotide polymorphisms (SNPs) databases and in our in-house database. This specific 
threonine residue is highly conserved during evolution and in particular the adenosine 
nucleotide in the third position of the corresponding codon was never present (Figure 
21A). Moreover in silico studies with different software confirmed the possible 
formation of a new acceptor site that could alter the splicing process (Human Splicing 
Finder prediction of +49.30% of variation, Fruitfly software score of 0.85). 
Unfortunately we did not have an RNA sample from the patient or his parents, so we 
tested these predictions by means of the well-known minigene technology. The 
minigene vector is an hybrid construct that allows performing a functional splicing 
assay reproducing the splicing pattern of a specific genomic sequence inserted therein 
after transfection in eukaryotic cell lines [176]. In detail, we cloned the wild type or the 
mutated TCIRG1 genomic region spanning exons 11 to 13 into the pTB minigene vector 
(Figure 21B), transfected the constructs in HeLa cells and 48 hour later analyzed the 
pattern of transcripts obtained. We confirmed that the variant c.1371C>A caused 
aberrant splicing, with loss of 67 nucleotides (Δ67nt) of exons 12, due to the usage of 
the internal acceptor site created by the mutation (Figure 21C e 21D). The minigene 
vector is an artificial system, so it is expected that a variety of transcripts are also 
produced in HeLa cells transfected with the wild type construct. However, the key point 
is the complete absence of the splicing aberration Δ67nt in clones carrying the wild type 
TCIRG1 sequence (Figure 21C). At the protein level the Δ67nt transcript was predicted 
to result in frameshift and premature termination (p.Ile436AlafsX70). 
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Figure 21: (A) Sequence alignment of the TCIRG1 gene and protein in the region of interest in 
different species. The alignments show absence of the adenosine residue (A1371) in the last 
position of codon 457 (referring to number of the human sequence) in the gene, and 
evolutionary conservation of the Threonine residue in the protein. (B) Schematic representation 
of the insertion of TCIRG1 sequence in the minigene vector. (C) Analysis of the amplicons 
obtained from minigene constructs carrying the normal or the mutant TCIRG1 sequence; 
schematic representation of the sequence of the different transcripts. (D) Sequence of the most 
abundant aberrant transcript of TCIRG1 gene; upper case illustrates exonic regions, lower case 
intronic ones. The creation of a new acceptor site in exon 12 (circled), possibly used instead of 
the canonical one, causes the loss of part of the exon 12. 
 
Prompted by this finding, we checked other osteopetrotic patients in our series lacking a 
molecular diagnosis and we obtained a similar finding in another patient (Pt 2). He was 
born from an Italian mother and a Moroccan father. At 2 months of age he showed 
splenomegaly, thrombocytopenia and anemia. Total body radiography revealed a 
generalized increase in bone density (Figure 22A); all these findings led to the diagnosis 
of ARO. At 7 months of age he received HSCT from a fully matched unrelated donor, 3 
months later hemoglobin and platelet levels were in the normal range and 1 year after 
transplantation the bone defect was completely corrected (Figure 22B). At last follow 
up at 5.6 years, the patient was alive and well, despite impaired vision.  
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Figure 22: Representative radiographs of Pt 2 showing (A and B, upper panel) diffuse increase 
in bone density compatible with osteopetrosis diagnosis; (B, lower panel) complete restoration 
of bone phenotype and marrow cavity after transplantation.  
 
In this patient a synonymous mutation was found in the CLCN7 gene in a compound 
heterozygous state: the mutation, located on the paternally-inherited allele, was a single 
nucleotide change (c.1098G>A) in the last base of exon 12, that caused an amino acid 
synonymous substitution (p.Glu366Glu) never reported in any database to the best of 
our knowledge. On the maternally-inherited allele, a deletion of two nucleotides in 
intron 17 (c.1617+6_1617+7delTG), close to the canonical acceptor splice site, was 
detected. 
Both mutations were predicted to cause splicing aberration. To confirm this prediction, 
we analyzed the cDNA of the patient by amplifying separately the two relevant regions 
spanning exons 11 to 16 and exons 16 to 20, respectively, cloning the RT-PCR products 
and sequencing about 50 independent clones (Figure 23A). Sequence analysis revealed 
that the synonymous mutation c.1098G>A caused in-frame skipping of exon 12 thus 
demonstrating a non-neutral effect (Figure 23B, left panel); on the other hand, the 
c.1617+6_1617+7delTG mutation gave rise to at least 3 aberrant transcripts showing 
either retention of 230 nucleotides of intron 17 or complete skipping of exon 17, both 
predicted to cause frameshift, or deletion of 93 nucleotides of exon 17 that could cause 
in frame loss of 31 amino acids (Figure 23B, right panel). To understand if normal 
transcripts were present too, we amplified a larger CLCN7 cDNA region spanning 
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exons 11 to 18 containing both mutations. We cloned the RT-PCR product and 
sequenced independent clones, but we could never find the wild type transcript (Figure 
23C); even the band that migrated similarly to the normal transcript, once sequenced, 
turned out to lack 13 nucleotides as compared to the wild type. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23: (A) RT-PCR of the CLCN7 gene in Pt 2 separately amplifying the two mutations. (B) 
Schematic representation of the principal aberrant transcripts: the mutation of paternal origin 
caused skipping of exon 12 (on the left), whereas the maternal one led to at least three different 
transcripts (on the right). (C) RT-PCR spanning exons 11 to 18 of the CLCN7 gene in Pt 2 
cDNA (left panel) and PCR amplification of 6 independent clones (right panel). The asterisk 
indicates the apparently normal transcript lacking 13 bases respect the wild type. HD= healthy 
donor; CTRL–: negative control. 
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Overall, these results confirmed that both mutations affected the splicing process and 
did not allow any residual normal transcript. 
 
5.1.2 Atypical genes involved in the pathogenesis of osteopetrosis  
The patient of Family 7 was born from Italian consanguineous parents (second degree 
consanguinity). Osteopetrosis was diagnosed at 2 months of age; at presentation, he 
displayed anemia, thrombocytopenia, neutropenia, hepatosplenomegaly, 
hyperferritinemia and hyperbilirubinemia. The bone biopsy showed the presence of 
many osteoclasts with scarce signs of resorption, suggesting a diagnosis of osteoclast-
rich osteopetrosis, confirmed by radiological investigation (Figure 24). At 7 months of 
age growth and development were normal, neurological defects absent, hemoglobin 
levels normalized, spleen and liver were palpable, but in normal range of size. In this 
patient we performed Sanger sequencing of the known ARO genes but we didn’t find 
mutations. So, WES of the entire family, comprising the proband, his healthy sister and 
parents, was performed. While the analysis was ongoing, at 9 months of age the patient 
started displaying translucent papular skin lesions, which worsened over time and were 
classified as poikiloderma after histological examination. Moreover, neutropenia 
became more pronounced and was treated with G-CSF; on this basis, the diagnosis of 
poikiloderma with neutropenia (PN) was made. Interestingly, a single patient affected 
by PN and osteopetrosis (OP) has been described in literature [177]. 
In 2010, two different groups, analyzing unrelated patients, found C16orf57 (also 
known as USB1) as the gene responsible for PN [178, 179].  
Accordingly, in our patient, WES revealed a 12-nucleotide deletion in the USB1 gene 
(c.683_693+1del) in the homozygous state in the proband and heterozygous in the other 
family members (confirmed by Sanger sequencing). The same mutation had been 
already reported in a PN patient at the heterozygous state and caused skipping of exon 6 
at the cDNA level [178].  
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Figure 24: Representative radiological images of the patient of Family 7 at diagnosis (2 months 
of age; panel A) and at 1 year of age (panel B). Typical signs of osteopetrosis, such as 
thickening of the skull base, sign du masque, sandwich vertebrae, diaphiseal thickening of long 
bones and clubbing of metaphyses, were clearly visible. 
 
5.2 Acrofrontofacionasal dysostosis 1 project 
 
Acrofrontofacionasal dysostosis type 1 is a very rare syndrome: only four families, three 
of Brazilian and one of Indian origin, have been described so far and an autosomal 
recessive pattern of inheritance has been suggested. 
In order to define the molecular basis of AFFND1, we collected DNA samples from the 
Indian family (Family 8) and from two Brazilian families (Family 9 and 10) (Table 5). 
 
A 
B 
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Table 5: list of AFFND1 families analyzed by exome sequencing 
Family ID # samples gene mutation 
8 4 NBAS c.6237-3C>G 
9 2 ongoing  
10 3 ongoing  
§Accession number of the NBAS cDNA variant: NM_015909. The numbering used starts with nucleotide +1 for the A 
of the ATG-translation initiation codon.  
 
Family 8 was composed of two affected siblings (the elder one had already been 
described in Prontera et al.) and their parents [161]; the two Brazilian families included 
a single patient already reported in Richieri-Costa et al., and in Guion-Almeida and 
Richieri-Costa; in Family 9 only one parent was available for the analysis [159, 160]. 
Parental consanguinity is reported in two out of these three patients (the Indian and 
Brazilian families) and suspected in the other one. 
 
5.2.1 Clinical presentation of patients 
All the patients (Figure 25) shared a common presentation of the disease, with 
craniofacial abnormalities including brachycephaly, wide forehead and nasal bridge, 
hypertelorism, abnormal hairline, cleft lip and palate, ear anomalies, malar hypoplasia; 
limb defects, including campto-brachy-poly-syndactyly, broad thumbs, mesomelic 
shortness of the legs, hypoplastic nails and phalanges of toes; and severe intellectual 
disability. The Indian patient also showed oligodontia, hypoplastic gums, wide and 
protruding upper central incisors. 
Her younger sibling presented at birth with several dysmorphic features, including 
hypertelorism, epicanthus, long and dystrophic eyelashes, palatoschisis, brevity of arms 
with cutaneous folds, clinodactyly, flexed and adducted thumbs, sacral dimple with 
abundant fuzz and microcephaly with diastasis of anterior and posterior cranial suture. 
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Figure 25: Clinical aspects of AFFND1 patients. (A) Clinical pictures of the elder patient of 
Family 8 at 3 months of age (first panel on the left) and at 12 years, showing wide nasal bridge, 
wide and protruding upper central incisors, downturned ears with wide conchae, thin helices 
and absent lobules and camptodactyly and clinodactyly of the 5th digit. (B) Clinical pictures of 
the patient of Family 9 at 26 years of age. (C) Clinical picture of the patient of Family 10 
showing macrobrachycephaly, a wide forehead, a widow's peak, macrostomia with open mouth, 
mild S-shaped palpebral fissures, palpebral ptosis and convergent strabismus.  
 
At 8 months of age, microcephaly (orbitofrontal cortex, OFC 38.8 cm) with open 
anterior and posterior fontanel, dysmorphisms (hypertelorism, exotropia, posterior 
palatoschisis and short lingual frenulum) and marked growth defects with diffuse 
muscular hypotrophy were observed. Neurological examination clearly documented 
severe neuropsychomotor delay: the patient displayed drastic truncal hypotonia with 
very limited control of the head, and distal hypertonus with increased tendon reflexes. 
Eye examination confirmed bilateral optic atrophy and brain Magnetic Resonance 
Imaging (MRI) showed slightly thinned corpus callosum (Figure 26). 
The karyotype was normal (46, XX) and search for subtelomeric deletions (22q11 
microdeletions) possibly responsible for the severe neurological impairment was 
negative, as also previously observed in her older daughter. A subsequent examination 
was performed at 2 years and 7 months of age; progressive neuropsychomotor delay 
was evident: she achieved trunk control, but showed pyramidal signs, stereotyped and a-
finalistic movements, poor social interaction, absence of verbal language. 
  
A 
B C 
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Figure 26: Brain MRI of the younger sibling of Family 8 at 8 months of age. The images show 
slight thinning of the corpus callosum in sagittal (A) and coronal (B) view (red arrow). 
 
Microcephaly, growth retardation and diffuse muscular hypotrophy were still present. 
Her intelligence quotient (IQ) measured with the Griffiths Scales of Mental 
Development was 20, indicating severe intellectual disability.  
At present, at 19 and 18 years of age respectively, the two siblings are alive, in very 
similar serious clinical conditions. 
 
5.2.2 Exome sequencing analysis 
WES identified a list of 17, 8 and 7 putative candidate variants in Family 8, 9 and 10, 
respectively. No candidates were shared by all 3 families, which could be partly 
expected based on the heterogeneous geographic and ethnic origin of the patients. We 
addressed more in detail the analysis of the results obtained in the Indian family. 
Among the 17 variants identified, 2 were located in coding regions, 1 was located in an 
intronic region and predicted to impact on the splicing process, while the remaining 
ones were in 3’ or 5’ UTR regions. We selected 5 variants located respectively in the 
SOX11, neuroblastoma-amplified sequence (NBAS), TWIST neighbor (TWISTNB), 
suppressor of cytokine signaling 1 (SOCS1) and solute carrier family 19 (folate 
transporter) member 1 (SLC19A1) genes, on the basis of data in literature on the 
function of these candidates. For example, SOX11 was involved in the regulation of 
embryonic development and in the determination of the cell fate [180]; NBAS was 
suggested to play a role in embryogenesis from studies in zebrafish [181]; TWISTNB 
was located in the microdeletion syndrome 7p21 region, associated with a syndrome 
called Saethre-Chotzen, presenting with craniosynostosis, mild abnormalities of the 
hands and feet and in some cases developmental delay and learning disability [182]; 
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SOCS1 was involved in regulation of cytokine receptor signaling and knock-out mice 
displayed impaired osteoblast differentiation [183]; SLC19A1 had a pattern of 
expression in mouse embryos (in particular, the developing neural tube, craniofacial 
region, limb buds and heart displayed positivity at embryonic day (E) 9-11.5) that could 
support a role for the corresponding protein product in AFFND1 pathogenesis [184].  
First of all, we confirmed the variants identified in these genes by Sanger sequencing in 
the patients and their parents; however, we found 4 out of 5 investigated variants in the 
homozygous state also in a control population of the same geographic origin, 
consequently we considered them neutral polymorphisms common to the Indian 
population, and discarded them. The remaining one was a single nucleotide substitution 
in the NBAS gene (c.6237-3C>G) close to the acceptor splice site. In silico analysis with 
the Human Splicing Finder software predicted a splicing aberration that we verified on a 
cDNA sample produced from PBMCs of the patient. RT-PCR analysis showed aberrant 
splicing; accordingly, by cloning the amplified band we confirmed skipping of exon 48 
and premature termination of transcription, but also a residual amount of wild type 
messenger RNA (mRNA) (Figure 27).  
 
 
 
 
 
 
 
 
 
 
Figure 27: (A) RT-PCR spanning exon 45 and 51 showing aberrant transcripts in the patient as 
compared to the control; GAPDH was used as housekeeping (upper panel). Schematic 
representation of the most abundant aberrant mRNA of NBAS in the proband (lower panel); the 
nucleotide change found in the patient is in bold in the lower line. (B) Chromatogram of 
sequence of the most abundant aberrant transcript found cloning the PCR product spanning ex 
45-51 of the patient’s cDNA. The picture shows skipping of exon 48 and formation of a 
premature stop codon (down in the figure). 
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5.2.3 Functional valuation of mutated NBAS  
We tried to evaluate the effect of this new NBAS mutation (c.6237-3C>G) at the protein 
level using total lysate of the patient’s frozen PBMCs, which was the only cell sample 
available, as well as from frozen PBMCs of a normal donor, as a control. In particular, 
we aimed to assess whether a truncated protein was produced from the mutated cDNA 
of the patient or whether itself underwent nonsense-mediated decay. Unfortunately, 
Western Blot analysis with two different anti-NBAS antibodies failed to detect a protein 
band in both the PBMC samples, while a strong signal was visualized in the lane of SH-
SY5Y cells (which was loaded on the gel as positive control, as indicated by the 
manufacturers’ instructions for the anti-NBAS antibodies, in agreement with data in 
literature). This made us suspect that in PBMCs the NBAS protein was not expressed at 
sufficient levels to be detectable by Western Blot, so this technique was not suitable for 
my purpose. To circumvent this problem, we took advantage of the 
pcDNA3xFLAGhNBAS vector carrying the human full-length NBAS cDNA to 
introduce a modification reproducing the effect of c.6237-3C>G on cDNA. We 
performed site directed mutagenesis to form a stop codon immediately at the end of 
exon 47 and overexpressed the mutant construct in HEK293T cells. Western Blot 
analysis on transfected and non-transfected HEK293T cells using anti-FLAG antibodies 
allowed us to verify that the mutation caused the formation of a truncated NBAS protein 
(Figure 28A).  
Next, we tried to understand if the truncated protein was functional or not. The NBAS 
protein is involved in essential cellular functions, namely the nonsense-mediated decay 
(NMD) pathway, which recognizes and degrades mRNAs containing premature 
termination codons in order to prevent the synthesis of truncated protein products [185]; 
and the retrograde transport from the Golgi to the endoplasmic reticulum for the 
recycling of vesicular components [186]. 
Longman and colleagues previously proposed the hypothesis of a negative loop between 
NBAS and the major components of NMD (in particular the regulator of nonsense 
transcripts 2, UPF2). Another role of NMD is the posttranscriptional regulation of 
selected transcripts. This dual role for NMD raises the possibility that this pathway is 
regulated to prevent the potentially catastrophic alterations in gene expression that 
would contrarily occur if NMD were alterated in response to external signals, such as 
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stress, or to genetic insults. In addition, a negative regulatory loop directly acts on NMD 
factors in order to regulate its response after perturbations. In particular, they 
demonstrated that the new NMD components DHX34 and NBAS carry out a control of 
the NMD homeostasis [187]. Thus, we checked the quantity of UPF2 protein after 
overexpression of NBAS in HEK293T cells. We found a marked reduction of UPF2 in 
the total lysate of HEK293T cells overexpressing wild type NBAS as compared to the 
controls (i.e., HEK293T cells transfected with 3xFLAG empty or treated with 
Lipofectamine only), in agreement with the suggested feedback loop; on the other hand, 
in HEK293T overexpressing mutated NBAS the amount of UPF2 was similar to both 
controls, suggesting partial loss of the regulatory loop (Figure 28B). 
During the secretory pathway, some of the vesicular components are recycled back 
through the retrograde pathway. In mammalian cells, at least 36 soluble N-
ethylmaleimide-sensitive factor attachment protein (SNAP) receptors (SNAREs) are 
localized in membrane compartments and play a role in transport vesicles. Syntaxins are 
a members of this family of proteins and in particular syntaxin 18 is implicated in 
retrograde transport from Golgi to ER. This complex is composed of three SNAREs 
(p31 well-known as USE1, BNIP1 and Sec22) and three peripheral membrane proteins 
(Sly1, ZW10, and RINT-1). Aoki and colleagues demonstrated that NBAS is the protein 
that mediates the interaction between USE1 and ZW10/RINT-1. In particular, NBAS 
was identified as a new component of syntaxin 18 interacting directly with the extreme 
N-terminal region of USE1 [186]. 
Thus, we performed a coimmunoprecipitation for USE1 to check the possible alteration 
of the retrograde transport function. The total lysate of HEK293T cells not transfected, 
or transfected with the empty vector, or with the vector expressing either wild type 
NBAS or mutated NBAS was immunoprecipitated with USE1 antibody and assayed by 
Western blot. We found that the mutated NBAS interacted less with USE1 as compared 
to wild type NBAS (Figure 28C). 
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Figure 28: (A) Western blot analyzed with anti-FLAG antibody and anti-HSP60 as 
housekeeping of proteins extract from HEK293T cells not transfected (lane 1), transfected with 
empty vector (lane 2) and vector carrying wild type (lane 3) or mutated (lane 4) hNBAS. The 
picture shows the production of a truncated NBAS protein at the expected molecular weight. (B) 
Western blot analysis for anti-FLAG, anti-USE1 and anti-HSP60; the loading is as reported in 
A. The expression of UPF2 protein is higher in lane 4 than in lane 3, suggesting reduced 
negative loop in the presence of mutated NBAS. (C) Western blot for anti-FLAG, anti-USE1 and 
anti-HSP60 after co-immunoprecipitation for USE1; the lanes are loaded as in A. The left panel 
represents the total extract before immunoprecipitation showing a comparable starting amount 
of USE1. On the right, the Western blot after immunoprecipitation demonstrate a lower 
interaction of mutated NBAS with USE1 compared to wild type NBAS. Numbers indicate 
relative density determined using the ImageJ software.      
 
5.2.4 Analysis in mouse and zebrafish model  
To assessed the possible involvement of NBAS in development, we used two different 
animal models: mouse and zebrafish model. 
 
 NBAS expression during mouse development 
To support the hypothesis of a possible role of NBAS in the bone tissue and in skeletal 
morphogenesis, we evaluated NBAS expression during murine fetal life starting at 
embryonic day 11.5, since at this stage skeletal elements start to form. We performed 
immunohistochemical analysis for NBAS on fixed embryos from C57BL/6 wild type 
mice. 
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Analyzing the body at E13.5 and E16.5 we found that NBAS expression was widely 
distributed, with higher levels in specific tissues such as liver, spleen, stomach, lung, 
glandular structures and hypertrophic cartilage (Figure 29A).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29: NBAS expression during murine embryonic development. (A) Representative images 
of longitudinal section of the body at E13.5 and E16.5 show widely distribution of NBAS 
expression, specifically in liver, spleen, stomach, lung, glandular structures and hypertrophic 
cartilage. (B) Representative parasagittal section of the total body at E11.5 shows NBAS 
expression in the NT and DRG. NT: neural tube; DRG: dorsal root ganglia. Representative 
images of coronal section of the skull at E13.5 and E16.5 show positive signal in specific 
elements of the head including eyes, dental buds and brain. The inset demonstrates the positivity 
of NBAS in cortical plate (CP), stained with the cortical plate marker Tbr1. Lower panels show 
a representative parasagittal section at PN2 in which NBAS expression is evident in the 
hippocampus and cerebellum.  
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Regarding the central nervous system, at E11.5 stage, high expression of NBAS was 
detected in the neural tube (brain and spinal cord) and neural ganglia. Staining at E13.5 
confirmed high expression in the forebrain: for example the cortical plate, also stained 
on serial sections for TBR1 (a transcriptional regulator involved in brain development 
and considered a marker of cortical plate). The section of the head at E16.5 showed 
positive NBAS staining in the brain and in different elements of the head and face 
including eye and dental buds; furthermore, in the brain at post-natal day 2 (PN2) 
NBAS expression was present in the hippocampus and cerebellum (Figure 29B). 
 
For what specifically pertains to the limbs, the staining for NBAS was quite diffuse at 
E11.5; at a subsequent stage (E13.5) cartilaginous condensations displayed low 
expression, while higher expression was found in the ectoderm and perichondral 
mesoderm. For the E16.5 stage we performed immunostaining on limb serial sections 
with different antibodies specific for COL II, RUNX2, SOX9 and Tenomodulin 
(TNMD) and we confirmed the presence of NBAS in the hypertrophic cartilage, 
periosteum and tendons (Figure 30). 
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Figure 30: NBAS expression during mouse limb embryonic development. Representative image 
of longitudinal section of the limb at E11.5 showing widely diffuse NBAS expression at this 
early stage, while at E13.5 and 16.5 NBAS expression is displayed mainly in the ectoderm and 
perichondral mesoderm. The inset shows longitudinal serial sections of the limb at E16.5 
stained for COLII, RUNX2, TNMD and SOX9 showing that NBAS is specifically expressed in 
hypertrophic cartilage, periosteum and tendons.    
  
Zebrafish experiments 
We took advantage from previous studies in zebrafish, in which, using morpholino 
oligonucleotides (MOs) specifically designed to block z-nbas mRNA translation or to 
alter z-nbas pre-mRNA splicing, showed that the depletion of NBAS protein resulted in 
very severe developmental defects, developmental delay/arrest and reduced embryonic 
viability [181]. These data were consistent with the essential role of core nonsense 
mediated decay factors during zebrafish embryogenesis [188], but the role of zebrafish 
NBAS (z-nbas) during development could not be clearly established due to the severe 
disruption of the morphants’ phenotype. 
In collaboration with Giorgio Merlo’s lab in Turin, we decided to repeat the experiment 
injecting lower doses (1/3 of the original dose) of the same MOs (the translation block 
(TB), the splice site (SS) and the scrambled (scr) oligonucleotides, this latter as control 
containing a 5-bp mismatch) in order to prevent embryo lethality or severe 
developmental anomalies, and to allow embryo development to proceed. Injection of a 
reduced dose of MO was able to deplete the level of endogenous z-nbas mRNA 
approximately by 80%, as detected by RT-PCR on whole injected fish embryos (Figure 
31). 
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Figure 31: Z-nbas expression after MO injection in zebrafish. RT-PCR analysis for z-nbas and 
the housekeeping gene (ef1α) on zebrafish embryos injected with either the translation block 
(TB), or the splice site (SS) or the scrambled (scr) MO and in not-injected control embryos 
shows reduction of z-nbas expression in embryo injected with SS (left panel). The right panel 
shows the quantification of the z-nbas reduction in SS as compared to the controls.  
 
After injections, morphants were allowed to develop for 5 days post fertilization (dpf) in 
a quarantine incubator, a time appropriate for chondrocranium development and 
compatible with the half-life of the MO. This modified protocol did allow staining and 
evaluating the cartilage head skeleton. At 5 dpf, embryos were fixed, and we analyzed 
the chondrocranium, in particular the “splanchno” cranium e.g. that derived from 
Neural Crest Cells (NCC) of the branchial arches. We observed an alteration of the 
angle between the Meckel’s cartilage (Mck) and the palatoquadrate (pq)/ceratohyale 
(ch) cartilages and an alteration of the angle between the right and left ceratohyale 
cartilages (second branchial arch). Based on the examination of the WT (not injected 
embryos) we defined the threshold for the alterated phenotype as an angle > 14 degrees 
between pq and ch and as an angle > 60 degrees between the second branchial arch. 
Using these criteria, we quantified the frequency of injected and not injected embryos in 
terms of increased angle (vs. absence of phenotype) over the total number of surviving 
embryos in each condition. The injection with both SS and TB anti z-nbas MOs brought 
to a significantly higher number of embryos showing the alterated phenotype compare 
to the controls, in agreement with a putative role of z-nbas in morphogenetic processes 
(Figure 32).  
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Figure 32: Representative images of splanchnocranium of embryos fixed in formalin and 
stained with Alcian blue. Fish injected with z-nbas-SS and z-nbas-TB, compared to the control 
scramble, presented a significant enlargement of the angle formed by the left and right 
ceratohyal (ch) cartilages (red arrows in the picture) and a significant widening of the distance 
(red arch in the picture) between the palatoquadrate (pq) and the second branchial arch. Mkc: 
Meckel’s cartilage (upper panel). Quantization of the number of zebrafish showing an altered 
phenotype of the mentioned structural elements. Structural abnormalities were found in a very 
small fraction of wild type (wt) and scramble-injected zebrafish (lower panel). 
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Next generation sequencing was introduced in 2005 as a powerful technology to detect 
genetic variations ranging from single nucleotides to large rearrangements. In particular, 
whole exome sequencing is mainly targeted to exonic regions, since it is known that in 
the 85% of cases of Mendelian disorders the mutation is located in protein coding 
regions. WES is particularly useful in the identification of the causative genes in rare 
genetic disorders, which typically affect a very small number of people (less than 
1:2000). 
The identification of the gene causative for the pathology is essential to define a 
molecular diagnosis for the patients and the carrier status for their relatives, and to 
provide genetic counseling. In addition, it can constitute the starting point to develop 
targeted therapeutic interventions and to better understand the pathophysiological role 
of the protein product [189]. Choosing the correct strategy to filter and prioritize the 
variants identified by WES is crucial; commonly adopted criteria include the mode of 
inheritance, the frequency of the disease and of the variant in the general population, the 
clinical features of the patients, and the severity of the pathology. 
During my PhD project I applied WES to two different rare skeletal diseases: 
osteopetrosis and acrofrontofacionasal dysostosis type 1.  
 
The molecular and clinical heterogeneity of human osteopetrosis is confirmed by the 
results I achieved during my PhD, which describe “classical” ARO and ADO II 
patients, with mutations in already known genes, but also peculiar cases. 
We analyzed by Sanger sequencing 25 osteopetrotic patients and we found the causative 
mutations. These analysis confirmed TCIRG1 as the most frequently mutated gene and 
mutations were found also in the known genes CLCN7, LRP5, SNX10, RANK, OSTM1, 
and CA2. 
In some patients lacking a molecular classification, we performed WES.    
 
The spectrum of clinical features of osteopetrotic patients with mutations in CLCN7 
gene includes infantile malignant recessive and autosomal dominant osteopetrosis. 
These different phenotypes were evident in Families 1 and 2: in fact, in the former the 
patient showed classical ARO with no primary neurological involvement and was a 
heterozygous compound for two different mutations in the CLCN7 gene, whereas in the 
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latter the patients displayed a typical ADO II phenotype and carried a heterozygous 
CLCN7 mutation rather common in this subgroup of patients. So far, no precise 
correlation between the clinical manifestation and the type of CLCN7 mutations has 
been defined.        
The patient of Family 3 carried a homozygous mutation in the OSTM1 gene; 
accordingly, she displayed a severe form of ARO with primary CNS involvement.  
The patient of Family 4 carried a homozygous mutation in the FERMT3 gene, which 
codes for kindlin-3 protein, prevalently expressed in hematopoietic cells and involved in 
integrin inside-out activation. This mechanism is crucial for platelet aggregation, 
leukocyte extravasation and also for osteoclast adhesion and spreading [150]. FERMT3 
mutations cause the LAD-III, a rare pathology characterized by severe bleeding and 
recurrent infections due to alteration in integrin function. In literature, 22 LAD-III 
patients have described and 9 of them also showed osteopetrosis; the disease was cured 
by HSCT in 7 out of 13 transplanted patients [148, 149, 190-193]. At least 10 different 
mutations in the FERMT3 gene have been described, including mainly truncating 
mutations, but also missense mutations, single nucleotide substitutions and deletions. 
The majority affected the C-terminus of the protein, specifically in F3 domain, 
important to bind integrin, with likely loss of interaction and consequent detrimental 
effect. The limited number of reported patients did not allow defining specific 
genotype-phenotype correlations. Interestingly, our patient displayed early-onset bone 
marrow failure and osteoclast-rich osteopetrosis with absence of visual and neurological 
impairment, but did not show recurrent bleeding and infection, which are typically 
present in Kindlin3 mutated patients. This was probably due to the fact that our patient 
was transplanted at a very young age, so possibly before these features could become 
apparent. The curative potential of HSCT for the severe phenotype of kindlin3 
deficiency was confirmed in our patient.     
 
Families 5 and 6 shared the presence of very peculiar mutations, not yet reported in 
osteopetrosis cases: deep intronic mutations in the TCIRG1 gene and synonymous but 
not silent mutations in genes associated with ARO. 
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As already mentioned, intermediated and atypical forms of osteopetrosis are more 
difficult to solve and manage. 
In 2014, a young girl with benign, recessive osteopetrosis carrying an incomplete 
splicing defect in the TCIRG1 gene was reported. At that time it was reasoned that the 
TCIRG1 mutations leading to a mild phenotype were extremely rare because no other 
similar finding was present in literature. Nevertheless, our recent data suggest that this 
is not the case. We identified 4 different mutations in intron 15 of the TCIRG1 gene that 
were predicted to impact on the splicing process. For 2 out of 4 variants, the cDNA 
analysis of the patients carrying these mutations, confirmed aberrant splicing and also 
the production of a small amount of wild-type mRNA. Interestingly, all these mutations 
were located in close proximity in intron 15, probably identifying a hot spot region that 
impact in the splicing process. In particular, mutations were in the middle of TCIRG1 
intron 15, which is composed of 368 nucleotides, so quite far from the canonical splice 
sites, thus explaining why their identification through our standard molecular analysis, 
based on amplification and direct sequencing of exons and exons-introns boundaries, as 
well as by WES failed. Analyzing the sequence of the aberrant transcript we could 
highlight the usage of a cryptic acceptor site in TCIRG1 exon 15 and a cryptic donor 
site in intron 15. In accordance with our results, deep intronic mutations, leading to the 
formation of alternative transcripts through the activation of alternative splice sites, 
have been recently reported in several diseases, such as Lowe Syndrome, Fukuyama 
congenital muscular dystrophy, hypertrophic cardiomyopathy and also in patients with 
bone dysplasias [194-197]. In general, these data clearly highlighted the possible impact 
of noncoding mutations on the onset of human diseases and suggested the need to verify 
the pathogenicity of intronic variants in known disease genes, when obvious mutations 
are not immediately identified.  
In our cohort, the patients carrying these particular mutations displayed a different level 
of disease severity: 2 of them were diagnosed in early life and were treated with HSCT, 
whereas the other 2 presented bone defect at school age and the pathology progression 
was slow and overall benign, examples of typical intermediate cases. The range of 
severity was particularly evident in the two siblings of Family 5: the elder showed 
secondary neurological defects, whereas her younger brother seemed to be less affected. 
Actually, this is common in ADO II, in which a role for SNPs in modifier genes has 
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been suggested but not formally demonstrated. Of note, we found that the siblings of 
Family 5 carried a different set of SNPs in the CLCN7 gene and in particular the 
brother, with the milder phenotype, presented 2 heterozygote SNPs in exon 15 
(rs12926089 and rs12926669) which had already been associated with low bone mineral 
density in different populations [198, 199]. Likewise, it was possible that additional 
variants in other genes could have influenced bone metabolism and modulated clinical 
manifestations. Furthermore, in adolescence and adult life, sexual hormones could have 
impacted on the phenotype. 
 
The analysis of Family 6 identified a synonymous mutation in the homozygous state as 
causative for the disease. Actually, during the workflow of exome sequencing, a 
challenging step is the filtering of the called variants, since the list of variants produced 
for further investigation may change based on the adopted criteria. In particular, 
synonymous variants are usually filtered out because of the common assumption that 
synonymous mutations, which by definition do not cause an amino acid change, do not 
have an impact on the protein structure and function. So, the involvement of 
synonymous mutations in pathogenetic mechanisms has likely been underestimated. 
Our results add to the limited number of reports in literature demonstrating that some 
synonymous changes cause different pathologies [200, 201], including skeletal defects 
[202, 203]. In our work, we found 2 patients that carried synonymous variants in 
TCIRG1 and CLCN7, respectively, leading to an alteration of the splicing process due to 
the creation and activation of a cryptic splice site. This would cause a frameshift with 
consequent no protein production, if the formation of a premature stop codon targets the 
aberrant mRNA to nonsense-mediated RNA decay, and/or lower amount of normal 
protein, if the mutation is hypomorphic.  
Because of the high number of variants obtained by WES, it is clearly not possible to 
perform functional evaluations for all synonymous changes, but it might be considered 
to further investigate those located in genes already associated with the pathology when 
obvious mutations are not found at a first analysis. 
Moreover, the synonymous mutation found in CLCN7 in the second patient, might raise 
the hypothesis that this type of changes contributes to the spectrum of severity of 
CLCN7-dependent osteopetrosis.  
6. DISCUSSION 
95 
 
The patient of Family 7 was affected by osteopetrosis and poikiloderma with 
neutropenia, and carried a homozygous mutation in the C16orf57 (USB1) gene. 
PN is a rare autosomal recessive syndrome, first described by Clericuzio and colleagues 
in 1991 [204], characterized by a skin manifestation and an immunological defect. For 
the skin, a papular erythematous rash typically starts in early infancy on the limbs, then 
spreads towards the trunk and face and becomes a frank poikiloderma with generalized 
hyperkeratosis. In the bone marrow, myelodysplasia with neutrophil maturation defects 
and chronic neutropenia responsive to growth factors, is responsible for recurrent 
infections, particularly affecting the airway tract [205-207]. Thickening of the toenails, 
growth retardation, facial dysmorphism, mild splenomegaly with transient anemia, and 
photosensitivity are present in some patients. The association between OP and PN 
seems to be extremely rare: in literature only one patient has been described so far 
[177], while in the other reported individuals only minor skeletal defects were present. 
The reason for this phenotypic variability is not known. 
PN is caused by mutations in USB1 that encodes a 265-amino acid protein highly 
conserved among vertebrates and broadly expressed, with high levels in myeloid 
lineage cells and moderate in the skin, adipose tissue, kidney, intestine, cerebral cortex, 
smooth muscle, adrenal and thyroid glands. USB1 is involved in the processing of U6 
small nuclear RNA (snRNA), an essential component of the RNA splicing machinery 
[208]. Lymphoblasts from a PN patient bore elongated non-templated oligo(U) tracts 
and oligo(A) tails at the U6 snRNA 3’ end, targeting it to nuclear RNA surveillance and 
degradation, pointing to USB1 role in a quality control pathway  [209]. 
In 2015, a zebrafish model of PN was developed by morpholinos (MOs) injection into 
one-cell-stage embryos, for usb1 gene knock-down [210]. A 60% reduction in Usb1 
transcription was achieved as maximum; usb1-deficient zebrafish displayed severe 
developmental defects: bent tail, reduced body length and a thin yolk extension at 25 
hours post fertilization (hpf), smaller head and eyes and pericardial edema at 50 hpf, 
leading all the morphants to death within a week. MOs injection in zebrafish embryos, 
in which neutrophils expressed GFP, highlighted impaired neutrophil development 
likely due to aberrant transcription of neutrophil-specific genes in the morphants [210, 
211]. 
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Moreover, other possible disease mechanisms could be explored; for example, USB1 
directly interacts with SMAD4 [178], so the possibility that PN development depends 
on the direct or indirect regulation of SMAD4 as well as other as yet unknown partners 
could be considered. For the bone compartment, a defect in the osteoclast lineage could 
be expected, since mature osteoclasts derive from myeloid progenitors and the USB1 
gene is highly expressed in myeloid cells. In addition, SMAD4 is involved in bone 
homeostasis and its conditional deletion in osteoclast precursors reduces osteoclast 
differentiation and activity [212]. Moreover, SMAD4 plays a well-known role in the 
skin as demonstrated by hair follicle collapse and progressive hair loss, and by 
epidermal hyperplasia, increased proliferation of keratinocytes and spontaneous 
development of skin tumors after conditional deletion in mouse keratinocytes [213, 
214]. 
Overall, unraveling the pathogenetic mechanism will be relevant for a better 
understanding of the physiopathology of all the systems involved. 
 
With respect to AFFND1, we did WES in 3 families and completed the analysis in 
Family 8, where we identified a novel homozygous truncating mutation in the NBAS 
gene in the two affected siblings. 
The neuroblastoma amplified sequence/neuroblastoma amplified gene (NBAS/NAG) 
was originally found co-amplified with MYCN in neuroblastoma cell lines and primary 
tumors [215]. The gene is located in chromosome 2, it’s very large and gives rise to two 
different transcripts (4.5 kb and 7.3 kb); the latter is more abundant and encodes for 
2371 amino acid protein. It’s highly expressed in connective tissues, eye, brain and 
spinal cord. The protein product contains two functional domains evolutionarily 
conserved: a quinoprotein aminedehydrogenase β chain like, β propeller domain in the 
N-terminal region and a Sec 39 domain in the central region, which is typical of 
proteins of the secretory pathway [216]. Indeed, NBAS was identified as a member of 
the syntaxin 18 complex, which comprises also p31 (USE1), ZW10 and RINT1 and acts 
in the retrograde transport from the Golgi to the endoplasmic reticulum for the recycling 
of vesicular components [186]. In particular, the N-terminal region of NBAS was 
shown to interact with and stabilize USE1 on the endoplasmic reticulum membrane, 
while the C-terminal with ZW10-RINT1.  
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Another important function assigned to NBAS is a role in the nonsense-mediated decay 
pathway, the complex mechanism by which mRNAs containing premature termination 
codons are recognized and degraded in order to prevent the synthesis of truncated 
protein products [185]. Morpholino-induced depletion of nbas in zebrafish caused 
severe developmental defects and reduced embryonic viability, as is also observed after 
depletion of other NMD core factors, thus suggesting that an active NMD pathway is 
crucial in zebrafish embryogenesis [181]. Moreover, in caenorhabditis elegans, in 
zebrafish and in human HeLa cells NBAS was suggested to be involved in an 
autoregulatory circuit and to contribute to the regulation of a large number of 
endogenous RNA targets, comprising also many genes relevant for the bone tissue, 
being the matrix Gla protein (MGP) and BMP2 genes those with the strongest 
upregulation upon NBAS depletion [187]. NMD factors are required for correct 
embryogenesis in several animal models [217]. In humans, mutations of UPF3B, an 
important component of the NMD surveillance machinery, cause facial dysmorphism 
and intellectual disability [218]. The similarity with the phenotype of AFFND1 patients 
supports the hypothesis that the mutation in the NBAS gene could affect development in 
humans. Unfortunately, we did not have an adequate cell sample available from the 
patients, so we could not directly demonstrated if the mutant NBAS protein was present 
or not. However, our experiments in HEK293T cells demonstrated that the mutation 
caused the formation of a truncated protein that, if produced in the patients, might affect 
the NMD negative loop through partial loss of down regulation of another NMD core 
factor (UPF2). Moreover, the mutated NBAS displayed a reduced interaction with 
USE1 in the syntaxin 18 complex. Overall, these results strongly suggested that the 
NBAS mutation found in these AFFND1 patients altered both functions of this protein. 
The importance of NBAS in skeletal morphogenesis was supported by our experiments 
in two different species, mouse and zebrafish, which are widely exploited as models of 
skeletal development [219, 220].  
In the wild type mouse we focused particularly on limbs and on the craniofacial region 
characterizing the pattern of NBAS expression during embryo development. We found 
NBAS expression in cartilage cells and early tendons of the skeletal system and in 
progenitor cells of the embryonic cortex and cerebellum, supporting a possible role of 
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the NBAS protein in skeletal and brain development, and in general in morphogenetic 
processes. 
In the zebrafish model we found a phenotype specifically associated with z-nbas down 
regulation in early phases of life. In more detail, we injected the z-nbas morpholino 
oligonucleotides (splice site, translation block or scrambled) at the 1-to-4 cell stage and 
performed the analysis at 5 dpf. We found alterations of different structures in the 
chondrocranium upon z-nbas depletion, strengthening the hypothesis that NBAS defects 
could determine phenotypic abnormalities such as those present in our AFFND1 
patients. 
For what pertains human pathologies, mutations in the NBAS gene have been recently 
associated to different diseases: SOPH syndrome, presenting with short stature, facial 
dysmorphisms, optic nerve atrophy and Pelger-Huet anomaly of the neutrophils [221]; 
recurrent acute liver failure (RALF) with onset in infancy [222-224]; a multisystem 
disorder reported in two patients and involving bone, connective tissue, liver, immune 
system and retina [225] and atypical osteogenesis imperfecta (OI) [226].  
The mutations reported in literature are distributed along the NBAS gene with particular 
frequency in the first half part and no clear association between genotype and 
phenotype. Indeed, the most common missense mutation (p.Arg1914His) was reported 
in different disease as SOPH, RALF and OI.  
Very few studies tried to define the exact pathogenetic mechanism underlying these 
diseases; in detail, functional studies were performed in 2016 in fibroblasts of RALF 
patients. This study showed reduced intracellular protein levels of NBAS and USE1, 
thermal instability of mutant NBAS and impaired tethering of vesicles associated with 
endoplasmic reticulum/Golgi [224].  
Very recently, Balasubramanian and colleagues measured circulating MGP in a OI 
patient with mutated NBAS gene and any alteration was found, in contrast with 
previously reported up-regulation of this gene in HeLa cells after its depletion [226]. So 
the influence of NBAS deficiency on MGP in the skeletal phenotype is under debate. 
Interestingly, the presence of short stature and bone alterations, including delayed bone 
age, low bone mineral density and fractures, and various dysmorphic traits, such as 
facial dysmorphism and hypo/hypertelorism, is shared by the majority of patients 
bearing mutations in the NBAS gene, independently from the specific clinical diagnosis 
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(including also AFFND1) suggesting a link between NBAS gene and skeletal formation 
and homeostasis. On the other hand, some clinical features are specific for AFFND1 
patients. 
Different hypothesis could explain this phenotypic heterogeneity: each specific 
mutation might otherwise affect either or both molecular function of the transcript, and 
this might have a different effect depending on the specific cell type; moreover, 
modifier genes might modulate the phenotypic manifestation [227].   
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We exploited WES analysis in two different rare skeletal diseases (osteopetrosis and 
acrofrontofacionasal dysostosis 1). In particular, we confirmed the utility of WES in the 
molecular diagnosis of a genetically heterogeneous disorder and in patients with 
atypical phenotype. Beyond genes already associated with osteopetrosis we also 
identified single patient with mutation in gene rarely (or, even, just once) linked with 
ARO (FERMT3 and USB1, respectively). On the other hand, we demonstrated some 
limitations of the WES approach, specifically for what pertains the identification of two 
classes of mutations, deep intronic and synonymous variants, because of the criteria 
adopted by standard workflow for variants selection. Instead, we validated the 
pathogenetic effect of the deep intronic single-nucleotide changes found in the TCIRG1 
gene and of two synonymous mutations found in TCIRG1 and CLCN7. 
Therefore, we underlined the need to implement strategies to integrate the technological 
power of WES with a better capacity to interpret mutations, identifying the clinically 
relevant ones. Even when data in literature sufficiently support the suspect of a 
detrimental effect of the identified variant, it is important to investigate the pathogenetic 
mechanism. In this respect, based on the results achieved by WES on AFFND1, the 
conservation of intronic nucleotide in mouse species and the confirmation of the 
alteration of splicing by in vitro prediction, we’re in the process to generate a knock-in 
(ki) mouse model bearing the NBAS mutation (c.6237-3 C>G) identified in the Indian 
patients above described. We will characterize the new mouse model: first of all we will 
determine if homozygous ki mice are embryonic lethal, performing timed mating to 
determine the stage of death and genotype litters at different stages of development, 
from E8.5 to E17.5. On the other hand, if homozygous mice are viable, we will look 
whether any dysmorphic sign (including for example abnormal skull shape, micro- or 
macrocephaly, proportionate or disproportionate dwarfism, supernumerary digits or 
absence of any finger or toe) is present in the mutant mice. In addition, we will perform 
Alcian Blue/Alizarin Red preparations for skeleton analysis in order to visualize 
cartilage and bone and to perform measurements of the different skeletal elements. 
Moreover, we will try to define the molecular signature deriving from the mutant NBAS 
by performing a transcriptomic profiling as compared to wild type littermates. In this 
way we will be able to detect differences in the levels of transcripts, but also different 
levels of alternative splicing isoforms with specific functions and the presence of 
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aberrant products resulting from splicing impairment. We will group differentially 
expressed genes into functional classes, thus refining the exact cellular function of 
NBAS protein for further investigations. 
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8.1 Samples 
Samples, including blood and DNA, were collected from patients and their relatives 
after informed consent. This research complies with the World Medical Association 
Declaration of Helsinki–Ethical Principles for Medical Research Involving Human 
Subjects, and with the standards established by the Independent Ethical Committee of 
the Humanitas Clinical and Research Centre, Rozzano (Milan), Italy. 
Peripheral blood mononuclear cells (PBMC) were isolated from blood of patients, 
parents or healthy donor. The blood was diluted with sodium chloride 0.9% (Baxter) 
(ratio 1:1) and subjected to density gradient separation on Lympholyte® Cell Separation 
Media (Cedarlane) and centrifuged for 20 minutes 800 G. After centrifugation the 
PBMC layer was collected and washed twice time with Dulbecco’s phosphate buffer 
saline (PBS) 1X.   
 
8.2 PCR analysis and Sanger Sequencing 
The molecular analysis of genes was performed by polymerase chain reaction (PCR) 
amplification and sequencing of the exons and intron-exon boundaries. The technique 
was well established in our lab. Briefly, the thermocycling conditions were: initial 
denaturation step at 94°C for 3 minutes, followed by 34 cycles of denaturation at 94°C 
for 30 seconds, annealing at temperature between 55°C and 62°C for 40 seconds 
(depending on specific primers), and amplification at 72°C for 50 seconds. The PCR 
products were purified with Wizard® SV Gel and PCR Clean-Up System kit (Promega) 
following manufacturers’ instruction and sequenced by BioFab Research laboratory. 
The chromatogram files were visualized by chromas software (version 2.4.4) and 
aligned with the reference genomic sequence by basic local alignment search tool 
(BLAST https://blast.ncbi.nlm.nih.gov/Blast.cgi).  
 
8.3 Exome sequencing 
For the exome sequencing we used 1.5 μg of high-quality genomic DNA from patients 
and their parents, and the exome capture was performed with the TruSeq Expandend 
Exome Enrichment Kit (Illumina Inc., San Diego, CA, USA). The Agilent DNA 1000 
Kit (Agilent Technologies Inc., Santa Clara, CA, USA) was used to validate the 
8. MATERIALS AND METHODS 
105 
 
enriched library and the clonal clusters was created on the cBot Station (Illumina Inc.) 
loading the library on the flow cell. Sequencing was performed on the Hiseq2000 
Instrument. Reads obtained after sequencing were aligned to the reference genome hg19 
by using BWA-MEM [228] and stored in compressed binary files (BAM). All the 
variants, single nucleotide variations, insertions, and deletions were found calling with 
the Genome Analysis Toolkit (GATK) [229]. The entire analysis was performed using 
the Orione platform [230]. The variants identified were merged in a 
VariantCallingFormat (VCF) file, annotated by KGGSeq [231], prioritized, and filtered 
considering the paternal consanguinity and the incidence of the disease. 
 
8.4 RNA isolation and RT-PCR 
RNA was extracted from PBMCs and from HeLa cells using Trizol reagent (Thermo 
Fisher Scientific, Waltham, MA, USA) and retrotranscribed with the High-capacity 
cDNA Reverse Transcription Kit (Applied Biosystems, Waltham, MA, USA), 
according to the manufacturers' instructions. The RT-PCR analysis was performed on 2 
µl of the cDNA with the primers reported in table 6. 
 
Table 6: primers used for RT-PCR analysis 
Gene Exons Primers 
TCIRG1 14-17 F: GCCTGGCTGCCAACCACTTG 
R: CATCGGAGCTCCAGCCATT 
TCIRG1 7-10 F: GGGGTGAGCAGATCGGACAG 
R: TGTAGGGAGCGGGTTGACC 
CLCN7 11-16 F: TCCTGTTCAGCTTGGAGGAG 
R: TCACCACGCTCTTCTCCG 
CLCN7 16-20 F: GTACAACTCCATGGCTGCG 
R: TGAGTGAGTGTGAGGTGACC 
CLCN7 11-18 F: TCCTGTTCAGCTTGGAGGAG 
R: CAGTGTCATCCGCACAATCC 
NBAS 45-51 F: AGTGAGCAGGAAACACTGCA 
R: TCCTTCACACCCTCTGCAGG 
GAPDH 8-9 F: GGTCTCCTCTGACTTCAACA 
R: AGCCAAATTCGTTGTCATAC 
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8.5 Cloning and vectors 
TA cloning: the PCR product obtained from each experiment was cloned in the TA 
cloning vector (Life Technologies) following the manufacturer’s instructions; about 70 
independent clones were sequenced using the M13F primer. 
 
Minigene vector: the hybrid pTB minigene vector contains the alpha globin promoter 
region with the SV40 enhancer. This promoter is followed by a genomic containing 
exon 1, 2 and 3 of the human alpha globin gene; in particular exon 3 carries a portion of 
the fibronectin gene and presents an unique intronic NdeI restriction site used to clone 
the genomic region of interest. This hybrid vector has been previously demonstrated to 
reproduce the splicing pattern of several gene systems [176, 232]. In this case we 
inserted the TCIRG1 genomic region spanning exon 11 to 13 amplifying with forward 
primer 5’-TTTTCATATGctgtgcctggctgctaagtg-3’ in intron 10 and reverse primer 5’-
CCCCTCGACCATATGcccactcccagctgccttca-3’ in intron 13. Upper case identifies the 
nucleotides added to reproduce the NdeI enzyme restriction site to clone it into 
minigene vector. 
 
pcDNA3xFLAGhNBAS vector: this vector carrying the human full-length NBAS cDNA 
was kindly provided by Prof. Caceres. It contains the FLAG-tag sequence (5’-
GACTACAAAGACCATGACGGTGATTATAAAGATCATGATATCGATTACAAG
GATGACGATGACAA-3’) immediately after the ATG start site and in frame with the 
NBAS cDNA sequence, thus it drives the production of a fusion protein in which the 
FLAG oligopeptide, that is repeated three times 
(DYKDHDGDYKDHDIDYKDDDDK) in front of NBAS protein sequence, allows the 
detection of the whole product by means of the anti-FLAG antibody. The 
pcDNA3xFLAG empty vector, without NBAS gene insert, was obtained using NheI 
restriction enzyme.  
 
Each plasmid was transformed in One Shot™ TOP10 Chemically Competent E. coli 
(Thermo Fisher Scientific Inc.) following manufacturer’s instruction and then DNA was 
obtained with PureYield™ Plasmid Miniprep System (Promega) kit.   
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8.6 Site-directed mutagenesis  
Site-directed mutagenesis was performed in the pcDNA3xFLAGhNBAS vector at 
NBAS level using the QuickChange Site-Directed Mutagenesis Kit (Stratagene) 
following the manufacturer’s instructions. Briefly: the PCR was performed using the 
modified primers forward 5′-GGTGAAACCAGCTCCTACCCCTTGTCCACACTGG-
3′ and reverse 5′-CCAGTGTGGACAAGGGGTAGGAGCTGGTTTCACC-3′ to 
synthesize the mutant strand. The PCR product was digested with DpnI enzyme and 
then the transformation in Supercompetent cells was performed. The mutated inserted 
sequence was verified by DNA sequencing. 
 
8.7 Cell culture 
HeLa (epitheloid cervix carcinoma), HEK293T (human embryonic kidney) and SH-
SY5Y (neuroblastoma from neural tissue) cell lines were purchased from ATCC®. 
HeLa cells and HEK293T cells were cultured in DMEM (Lonza) supplemented with 
10% fetal bovine serum (FBS), 1% penicillin/streptomycin (P/S) (Invitrogen) and 2 mM 
L-glutamine.  
SH-SY5Y cells were expanded in MEM (minimum essential medium eagle, Lonza) 
supplemented with 10% FBS, 1% P/S, 2 mM L-glutamine, 1% non-essential amino 
acids (NEAA) and 1% Sodium Pyruvate.  
Cells were kept in a humidified 5% CO2 incubator at 37°C.  
 
8.8 Cell transfection 
All the transfections were performed using Lipofectamine 2000 (Life Technologies) 
following the manufacturer’s instruction.  
In particular, the HeLa cells were seeded in 6 well plates and at about 80% confluence 
were transfected with 4 µg of minigene vector carrying the WT or mutated TCIRG1 
genomic sequence. RNA was extracted after 48 hours and cDNA obtained as described 
above. PCR was carried out with the forward 2-3α  and reverse B2 primers specific for 
minigene vector [176]. 
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HEK293T cells were seeded in T25 flask and at 80% confluence were transfected with 
6 μg of the WT or mutated pcDNA3xFLAGhNBAS and empty vector was used as 
control. After 48 hours, cells were lysed for protein analysis. 
 
8.9 Western blot analysis 
Total protein extracts, gel electrophoresis, transfer and visualization were performed 
using standard techniques. Briefly, cells were lysed in homemade RIPA buffer (50mM 
tris-HCl pH 7.6, 150mM NaCl, 0,5% deoxycholate, 1% NP-40, 0,1% SDS, 1X protease 
inhibitor). DCTM protein assay kit II (Bio-Rad) was used to quantify protein 
concentration following the manufacturer’s instructions, on a SynergyTM H4 
instrument (BioTek Instruments, Inc.). Thirty micrograms of protein extracts were 
separated on an 8% or 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE), according to the experimental condictions, transferred to a nitrocellulose 
membrane (Biorad) and blocked overnight at 4°C with milk 5% in TBST (tris-buffered 
saline, 0.1% Tween 20). The membrane was then incubated for 4 hours at room 
temperature with different primary antibodies: anti-NBAS antibodies, 1:500 
(Proteintech Group, Inc) and 1:1000 (St John’s Laboratory Ltd); anti-UPF2, 1:200 
(Santa Cruz Biotechnology, Inc); anti-HSP60, 1:10,000, anti-FLAG, 1:1000, and anti-
USE1, 1:200 (all from Sigma-Aldrich). After incubation, the membrane was washed 
three times with TBST and incubated for 1 hour at room temperature with the rabbit 
secondary antibody (for NBAS, USE1 and HSP60), the mouse secondary antibody for 
FLAG and the goat secondary antibody for UPF2 (1:2500, Thermo Fisher Scientific 
Inc.) conjugated with HRP. After three times washing with TBST, the membrane was 
developed using the ImmobilonTM Western kit (Millipore). Images were captured 
using the ChemiDoc™ MP Imaging System equipped with Image Lab™ Software (Bio-
Rad). Quantization of bands was performed with ImageJ software (National Institutes of 
Health, USA, http://imagej.nih.gov/ij).  
 
8.10 Immunoprecipitation 
The total cell lysate was obtained by lysing not-transfected HEK293T cells and cells 
transfected with the pcDNA3xFLAG empty vector or the vector carrying either the wild 
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type (WT) or the mutant NBAS sequence with home-made lysis buffer (50 mM Hepes, 
50 mM NaCl, 1% glycerol, 1% triton X-100, 1.5 mM MgCl2, 5 mM EGTA, 1X 
protease inhibitor). Two hundred-fifty μg of total protein extracts from each condition 
were incubated overnight at 4°C with 60 μl of slurry 50% G sepharose beads (Thermo 
Fisher Scientific Inc.) and 1 μg anti-USE1 antibody (Santa Cruz Biotechnology, Inc). 
The beads were then washed twice with lysis buffer to remove the unbound proteins; 
then, the purified antibody-antigen complexes were eluted with 2X sample buffer  and 
subjected to SDS-PAGE as above described. 
8.11 Histological and immunofluorescence analysis 
Bone biopsy of Family 5 patient was used to perform histological analysis. The bone 
was fixed in 4% paraformaldehyde (PFA), decalcified for 4 hours at 20°C in 5% HCl, 
rinsed in water and then paraffin-embedded. It was sectioned at 6 µm thickness and 
deparaffinized for hematoxylin-eosin staining and for fluorescent antibody detection as 
described [233]. A monoclonal mouse TCIRG1 antibody (Sigma Aldrich Co., St. Louis, 
MO, USA) and a rabbit polyclonal TRAP antibody (Abcam) were used both at 1:100 
dilution. Sections were blocked in PBS with 2% BSA for 2 hours, reacted overnight 
with primary antibodies in PBS 0.01% Tween 20, then labeled for fluorescent analysis 
using Alexa Fluor 488 Donkey Anti-Mouse IgG (H+L) Antibody (green) or Alexa Fluor 
594 Donkey Anti-Rabbit IgG (H+L) Antibody (red) antibodies, at 1:1000 (Life 
Technologies) for 1 hour. For nuclear labeling, Hoechst 33342 blue (Invitrogen) was 
used. A Nikon TE2000 inverted microscope was used for imaging, via 14-bit 
2048x2048 pixel monochrome CCD and RGB filters to reconstruct color (Spot, Sterling 
Heights, MI, USA).  
 
8.12 In silico analysis 
The prediction of the effect of mutations on splicing process was analyzed using two 
different software: Human Splicing Finder, version 3.0 
(http://www.umd.be/HSF3/HSF.html) and Berkeley Drosophila Genome Project 
(http://www.fruitfly.org/seq_tools/splice.html).     
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8.13 Mouse model: immunohistochemical analysis 
All the procedures involving mice were execute in accordance with ethical rules of the 
Institutional Animal Care and Use Committee of Humanitas Clinical and Research 
Institute and with international laws. Wild type C57Bl/6J mouse embryos were 
collected from pregnant females at embryonic day (E) 11.5, 13.5 and 16.5, considering 
E0.5 the day when the vaginal plug was visible. Embryos were fixed in 4% 
paraformaldehyde, embedded in paraffin and 3 μm thick parasagittal sections for total 
body, coronal sections for the head and longitudinal serial sections for the limb, were 
obtained and mounted on glass slides. All the sections were deparaffinized, treated for 
antigens retrieval in citrate-based buffer, incubated with 2% H2O2 for 20 min in the 
dark, washed with PBS 0,05% Tween 20 (PBST) (GIBCO® and Merck Millipore, 
respectively) and blocked with background sniper (from Biocare Medical) for 40 min at 
room temperature (RT). Then, they were incubated with the following primary 
antibodies, diluted in PBST: anti-NBAS, 1:300 (St John’s Laboratory Ltd); anti-COL II, 
1:200, anti-SOX9, 1:200, and anti-RUNX2, 1:2000, anti-TBR1, 1:400 (all Abcam) and 
anti-TNMD, 1:50 (Biorbyt). All but the anti-RUNX2 primary antibody were incubated 
overnight at 4°C whereas anti-RUNX2 was incubated 1 hour at room temperature (RT). 
Sections were then rinsed in PBST and incubated with secondary antibodies Mach 1 
(from Biocare Medical) for 30 min at RT, rinsed in PBST, developed with 3,3'-
diaminobenzidine (DAB) and counterstained with hematoxylin. Images were acquired 
on an Olympus XC50 Microscope. 
 
8.14 Zebrafish model: gene knockdown  
All procedures using zebrafish (Danio rerio) were authorized by the Ethical Committee 
of the University of Turin and the Italian Ministry of Health. Adult fishes (TL-AB 
strain) were maintained and bred according to standard procedures [234], kept under a 
14/10 light/dark photoperiod at a constant temperature of approximately 28°C. Eggs 
were fertilized, collected and embryos were grown in the presence of 0.003% 1-phenyl-
2-thiourea (PTU) to prevent formation of melanin pigment.  
The antisense morpholino oligonucleotides (MO) used to knockdown z-nbas (Ensembl 
gene ID: ENSDARG00000008593) were designed based on a sequence previously 
described [181] and synthesized by GeneTools, LLC. The MOs were: translation block 
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(TB) (5’-ATCACCTGCCATGTTTTCAATGAAC-3’), designed to anneal on the ATG 
start codon; splice site (SS) (5’-GCCAGCCATGCTCCACATACCTGAC-3’), to block 
splicing at the exon 2-intron 2 junction; scrambled (scr, negative control) in which 5 
mismatches were introduced in the TB sequence. Fertilized eggs were collected at one 
cell stage and injected with 4 nl of 100 µM of each MO, under a stereomicroscope, in 
the presence of phenol red for further selection of the injected embryos. They developed 
for 5 days and then processed for Alcian Blue staining. Embryos were fixed in 4% PFA 
at 4°C overnight, washed in PBS and stained with Alcian Blue for the visualization of 
chondrocyte condensations, according to published protocols [235, 236]. Finally, 
stained embryos were either kept floating in PBS or embedded in 4% low melting 
agarose, and examined with a low-magnification stereomicroscope (Leika MZ12), 
equipped with a digital photocamera (Leika IC80 HD). Digital images were contrast 
balanced and color matched using Photoshop 7 (Adobe), cropped, rotated and 
assembled into figures with QuarkXpress software (Pantone Inc.). 
 
8.15 Zebrafish model: gene expression analysis 
Total RNA was extracted from pools of 5-6 zebrafish embryos at the age 3 dpf using the 
Trizol reagent and retrotranscribed as above. RT-PCR analysis to evaluate z-nbas 
expression was conducted using a forward primer in exon 7 (5’-
GTGCTCTGCTGGCATATGCC-3’) and a reverse primer in exon 11 (5’-
CTGGGCATCTTGAAGAATCC-3’) of the transcript; the housekeeping elongation 
factor 1 α (z-ef1α) mRNA was used as a control of the total input mRNA with the 
forward primer 5’- CTGGAGGCCAGCTCAAACAT-3’ and reverse primer 5’- 
ATCAAGAAGAGTAGTACCGCTAGCATTAC-3’. ImageJ software was used to 
perform bands quantifications. 
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ABSTRACT
Autosomal recessive osteopetrosis (ARO) is a rare genetic bone disease with genotypic and phenotypic heterogeneity, sometimes
translating into delayed diagnosis and treatment. In particular, cases of intermediate severity often constitute a diagnostic challenge
and represent good candidates for exome sequencing. Here, we describe the tortuous path to identiﬁcation of the molecular defect
in two siblings, in which osteopetrosis diagnosed in early childhood followed a milder course, allowing them to reach the adult age
in relatively good conditions with no speciﬁc therapy. No clearly pathogenic mutation was identiﬁed either with standard
ampliﬁcation and resequencing protocols or with exome sequencing analysis. While evaluating the possible impact of a 3’UTR
variant on the TCIRG1 expression, we found a novel single nucleotide change buried in the middle of intron 15 of the TCIRG1 gene,
about 150 nucleotides away from the closest canonical splice site. By sequencing a number of independent cDNA clones covering
exons 14 to 17, we demonstrated that this mutation reduced splicing efﬁciency but did not completely abrogate the production of
the normal transcript. Prompted by this ﬁnding, we sequenced the same genomic region in 33 patients from our unresolved ARO
cohort and found three additional novel single nucleotide changes in a similar location and with a predicted disruptive effect on
splicing, further conﬁrmed in one of them at the transcript level. Overall, we identiﬁed an intronic region in TCIRG1 that seems to be
particularly prone to splicingmutations, allowing the production of a small amount of protein sufﬁcient to reduce the severity of the
phenotype usually associated with TCIRG1 defects. On this basis, we would recommend including TCIRG1 not only in the molecular
work-up of severe infantile osteopetrosis but also in intermediate cases and carefully evaluating the possible effects of intronic
changes. © 2015 American Society for Bone and Mineral Research.
KEY WORDS: AUTOSOMAL RECESSIVE OSTEOPETROSIS; TCIRG1; EXOME; HYPOMORPHIC MUTATION; SPLICING DEFECT
Introduction
Human osteopetrosis is a genetic bone disease characterizedby increased bone density owing to failure in bone
resorption by osteoclasts. For a long time, two main forms
have been distinguished: an autosomal recessive form, also
called malignant infantile, because of its early onset and
frequent lethal outcome in the absence of a therapy; and an
autosomal dominant form, also termed benign, because of its
later presentation and milder course. Since 2000, the molecular
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basis of both forms has largely been unraveled, revealing a great
genetic heterogeneity.(1) Subsequently, careful clinical charac-
terization and longer follow-up have identiﬁed patients who do
not ﬁt within either class, documenting a wider variability of
phenotypes, some of which escapedmolecular characterization,
because a responsible mutation could not be identiﬁed. In
particular, it has become clear that, besides the paradigmatic
recessive malignant and dominant benign forms, an intermedi-
ate group exists, in which the defect can be inherited as either a
recessive or a dominant trait. These intermediate cases often
represent a diagnostic challenge but also constitute the
opportunity to learn important lessons on the bone biology.
On this regard, we have recently reported on a young
osteopetrotic patient in which an incomplete splicing defect
in the TCIRG1 gene allowed for the production of the limited
amount of wild-type transcript sufﬁcient to dampen the severity
of the disease to an almost completely normal lifestyle.(2)
However, in that article, we pointed out that a deﬁnitive
conclusion regarding the prognosis of the pathology was not
possible because of the young age of the patient and the
extraordinary nature of the mutation.
Exome sequencing is a powerful, high-throughput technique
that in few years has greatly improved the discovery of the
genetic defect underlying Mendelian disorders.(3) This approach
is fundamentally based on the observation that the vastmajority
of mutations causing inherited diseases are located in coding
regions of the genome and, vice versa, a large fraction of rare
variants altering a protein structure are predicted to impact on
its function. However, current sets of probes for exome capture
target not only coding regions but also 50 and 30 untranslated
regions (5’UTR and 30UTR, respectively) and stretches of intronic
regions, including exon-ﬂanking regions and short introns
contained between targeted exons.
Here, we describe the tortuous and, to some extent,
serendipitous identiﬁcation of the molecular defect in the
middle of intron 15 of the TCIRG1 gene in two siblings affected
by intermediate recessive osteopetrosis and in three additional
patients in which a single mutated allele in the same gene had
previously been found.
Materials and Methods
Samples
Clinical data and specimens, including blood and DNA samples,
were collected from patients and their relatives after informed
consent. This research complies with the standards established
by the Independent Ethical Committee of the Humanitas Clinical
and Research Centre.
Exome analysis
Exome capture was performed on 1.5mg of high-quality
genomic DNA from patients 1A and 1B and their parents, and
the TruSeq Exome Enrichment Kit (Illumina Inc., San Diego, CA,
USA) was used. The enriched library was validated by the Agilent
DNA 1000 Kit (Agilent Technologies Inc., Santa Clara, CA, USA)
and loaded on the cBot Station (Illumina Inc.) to create clonal
clusters on the ﬂow cell. Sequencing was performed on the
Hiseq2000 Instrument. Reads extracted with the Illumina tools
were aligned to the reference genome hg19 by using BWA-
MEM(4) and stored in compressed binary ﬁles (BAM). Single
nucleotide variations, insertions, and deletions were called using
the Genome Analysis Toolkit (GATK).(5) All the analyses were
performed using the Orione platform.(6) The variants identiﬁed
were merged in a VariantCallingFormat (VCF) ﬁle, annotated by
KGGSeq,(7) prioritized, and ﬁltered according to a standard
workﬂow for exome sequencing.
Molecular studies
The molecular analysis of genes known to be responsible for the
different types of the disease (TCIRG1, CLCN7, PLEKHM1, RANKL,
RANK, and SNX10) was performed by ampliﬁcation and direct
sequencing of exons and intron-exon boundaries as previously
described.(8–13) The TCIRG1 intron 15 was ampliﬁed using the
forward primer 10271F 50-TGTTCCTCTTCTCCCACAGC-30 located
in exon 15 and the reverse primer 5R 50-CATCGGAGCTCCAGC-
CATT-30 in exon 17; sequencing was performed using the 10271F
primer. After mRNA isolation fromperipheral bloodmononuclear
cells lysed in Trizol (Invitrogen, Carlsbad, CA, USA) and reverse
transcription using theHighCapacity cDNAReverse Transcription
kit (Life Technologies, Carlsbad, CA, USA) according to the
manufacturers’ instructions, the effect of the intronic variants on
TCIRG1 transcript processing was investigated with the forward
primer9912F50-GCCTGGCTGCCAACCACTTG-30 inexon14andthe
reverseprimer 5R in exon17. For patient (Pt) 1A andPt 1B, the PCR
product was directly cloned in the TOPO TA Cloning plasmid
vector (Life Technologies, Carlsbad, CA, USA), according to the
manufacturer’s instructions, and individual clones were se-
quenced using the 9912F forward primer. For Pt 2, a PCR product
was obtained from the cDNA with the forward primer 5F 50-
CTGGCCCAGCACACGATGCT-30 in exon 13 and the reverse primer
5R in exon 17; this productwas cloned and individual cloneswere
sequenced using primer 5R. For the conﬁrmation of the variant in
the LRP5 gene, the relevant genomic region was ampliﬁed using
primers forward 50-TGGGAGGAAGGAAGGAATGC-30 and reverse
50-TCAGTGGCATGGGGATTAGG-30, whereas primers forward 50-
GGGAGTGAGCACCGTCTATA-30 and reverse 50-CTCCTAGGAC-
TACGCCCAAG-30 were used for conﬁrmation of the variant in
the CHKA gene; in both cases, sequencing was performed using
the forward primer.
For all the PCR reactions above, the thermocycling conditions
were: initial denaturation step at 94°C for 3 minutes, followed by
34 cycles of denaturation at 94°C for 30 seconds, annealing at 62°
C (55°C for the LRP5 variant) for 30 seconds, and ampliﬁcation at
72°C for 30 seconds.
The effect of the mutations identiﬁed in the intron 15 of the
TCIRG1 gene was predicted using the software Human Splicing
Finder, Version 2.4.1 (www.umd.be/HSF).(14) The mutation
nomenclature conforms to HGVS (www.hgvs.org/mutnomen).(15)
Histological analysis
A bone biopsy specimen of Pt 1A was ﬁxed in 4% paraformal-
dehyde (PFA), decalciﬁed for 4 hours at 20 °C in 5% HCl (pH !1),
then rinsed in water, parafﬁn-embedded, and sectioned at 6mm.
Sections were deparafﬁnized for hematoxylin-eosin staining and
for ﬂuorescent antibody labeling as described.(16) For TCIRG1
labeling, a mouse monoclonal (clone 6H3) antibody was used
(Sigma Aldrich Co., St. Louis, MO, USA) at 1:100 dilution. For
TRAP, a rabbit polyclonal antibody, C-terminal (Abcam PLC,
Cambridge, UK) was used at 1:100 dilution. Brieﬂy, sections were
blocked in PBS/2% BSA for 2 hours, reacted overnight with
antibodies at indicated concentrations in PBS with 0.01% Tween
20, then labeled for ﬂuorescent analysis using Alexa Fluor 488
Donkey Anti-Mouse IgG (HþL) Antibody (green) or Alexa Fluor
594 Donkey Anti-Rabbit IgG (HþL) Antibody (red) antibodies, at
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1:1000, both from Life Technologies, for 1 hour. For nuclear
labeling, Hoechst 33342 blue (Invitrogen) was used. A Nikon
TE2000 inverted microscope was used for imaging, via 14-bit
2048# 2048 pixel monochrome CCD and RGB ﬁlters to
reconstruct color (Spot, Sterling Heights, MI, USA). Green
ﬂuorescence (Cy-2) used excitation at 450 to 490 nm, a 510-
nm dichroic mirror, and a 500- to 570-nm emission ﬁlter. Red
ﬂuorescence (Cy3) used excitation at 530 to 560 nm, a 575-nm
dichroic mirror, and a 580- to 650-nm emission ﬁlter.
Results
Clinical evaluation of patients
Patients 1A and 1B (Pt 1A and Pt 1B) were two affected siblings
born from Italian consanguineous parents (third-degree con-
sanguinity). Pt 1A, female, was ﬁrst evaluated at age 6 years
because of visual problems, in particular right amaurosis and
divergent strabismus. A radiological investigation of the skull
revealed increased bone density, and a skeletal survey
conﬁrmed generalized osteopetrosis (Fig. 1A). Computed
tomography (CT) scan showed bilateral optic and acoustic
foramina restriction; analysis of the visual evoked potentials
(VEP) conﬁrmed visual impairment on the right eye, whereas
brainstem evoked response audiometry (BERA) gave normal
results. At that time, her hematological function was normal
despite mild hepatosplenomegaly. On these results, a diagnosis
of osteopetrosis with low progression was made. The presence
of a similar bone phenotype in her younger brother (Pt 1B) at the
age of 2 years (Fig. 1B), together with the absence of
pathological ﬁndings in their parents as well as their
consanguinity, suggested an autosomal recessive pattern of
inheritance. In the following years, the clinical history of both
patients was mainly characterized by recurrent fractures (8 in Pt
1A, 11 in Pt 1B) at different skeletal segments, particularly the
lower limbs (Fig. 1C), and dental problems, with delayed tooth
eruption, congenitally missing teeth and, in the elder sibling,
dental abscesses, requiring intravenous administration of anti-
biotics and a surgical intervention. The visual acuity progres-
sively worsened in Pt 1A andwas completely lost in the right eye
side at the age of 9 years; subsequently, a surgerywas performed
to preserve the vision of the left eye. In addition, she lost hearing
in the left ear starting from age 6 years. Most recent laboratory
investigations, performed concomitantly with an orthopedic
surgery for total hip replacement after removal of a previous
prosthesis, did not show alterations of the evaluated parameters
(Table 1). Histological analysis on a bone specimen from Pt 1A
demonstrated an incomplete osteopetrosis with some areas
displaying mostly retained mineralized cartilage and primary
spongiosa, whereas others showing mostly normal lamellar
bone in well-formed trabecular bone (Fig. 2). Importantly,
several osteoclasts were visualized, thus clearly identifying the
disease in this patient as an osteoclast-rich osteopetrosis (Fig. 2).
At present, both affected siblings do not receive any speciﬁc
therapy. Overall, their clinical picture can be considered benign,
with Pt 1B displaying no sensorial defects and leading an almost
completely normal life at age 32 years.
Patient 2 (Pt 2) was the third child of unrelated, healthy Italian
parents. The symptoms of the disease appeared at age 4 years,
with a generalized increase in bone density (representative,
most recent radiological ﬁndings in Fig. 1D). He reported 7
nontraumatic fractures and suffered from recurrent osteomyeli-
tis of the jaw. He underwent 3 orthopedic surgeries and several
maxilla-facial interventions. No hematological nor sensorial
deﬁcits arose, and the patient is alive and reasonably well at age
24 years.
Patient 3 (Pt 3) has been already described (Pt 6 in Mazzolari
and colleagues(17)). Brieﬂy, the patient presented with a classical
ARO phenotype, with bone defects and secondary hematologi-
cal and neurological deﬁcits at age 6.5 months. She received
hematopoietic stem cell transplantation (HSCT) from a matched
unrelated donor (MUD) at age 20.5 months, achieved full
engraftment, and was alive and well 7.5 years after
transplantation.
Patient 4 (Pt 4) was born from healthy unrelated parents from
Southeastern Asia. He presented with bone defects, blindness,
and hepatosplenomegaly in neonatal life. He received HSCT but
eventually died 4 years after HSCT without engraftment. No
further information is available.
Genetic findings
Based on the suspected recessive pattern of inheritance of the
disease in Pt 1A and Pt 1B, molecular analysis in this family
initially focused on the genes known to cause recessive
osteopetrosis (TCIRG1, CLCN7, PLEKHM1, RANKL, RANK, and
SNX10); the OSTM1 gene was not included in the analysis
because the two affected siblings did not display the primary
neurological defects that are a hallmark of this ARO form.
However, no molecular defect could be identiﬁed; therefore, we
performed exome sequencing on both patients and their
parents. This approach achieved an 80# mean coverage over
the 62 Mb of exomic sequence, with more than 94% of targeted
regions covered. The overall transition to transversion rate (Ti/
Tv) was 2.4, which is in line with what was expected for exome
sequencing. The analysis identiﬁed a total of 191,872 variants
that were ﬁltered with dbSNP138 and 1000 Genome Project and
according to the pattern of inheritance of the disease and to the
parental consanguinity (Table 2).
Among the homozygous variants, we found a single
nucleotide change in exon 22 of the LRP5 gene (Supplementary
Fig. 1A) (NG_015835.1:g.138882C>T; NM_002335:c.4574C>T)
predicted to cause an amino acid substitution (p.Ala1525Val).
Thus far, the so-called “activating mutations” linked with an
increased bone density are clustered in the ﬁrst beta-propeller,
at the extracellular N-terminus of the protein, whereas
mutations causing low bone density appear to be clustered in
the second beta-propeller.(18) Interestingly, the variant
c.4574C>T lies in a completely different region of the protein,
that is the cytoplasmic tail (Supplementary Fig. 1B), known to
interact with axin and FRAT, which are key components in the
Wnt/b-catenin signaling pathway.(19,20)
Sowe conﬁrmed this variant by Sanger sequencing and tested
its activity in a classical luciferase reporter assay; however, the
activation of the Wnt signaling was comparable in the presence
of either the wild-type or the mutant LRP5 construct
(Supplementary Fig. 1C). In addition, in this experiment, no
difference between the wild-type and mutant LRP5 was
observed after cotransfection with sclerostin (Supplementary
Fig. 1C), whereas the “activating mutations” in LRP5 are known
to result in increased Wnt signaling activity owing to reduced
inhibition by sclerostin or dickkopf 1. So, these results did not
support the hypothesis of a causative role for the variant in the
pathogenesis of the disease. Accordingly, at the time when this
article was in preparation, an update of SNP databases included
this change in the LRP5 gene at the homozygous state.
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Therefore, we returned to the list of variants identiﬁed by
exome sequencing. No additional noteworthy variants in coding
regions were present, so we focused our attention on variants in
30 untranslated regions (30UTR) because they are known to
inﬂuence gene expression.(21) A single nucleotide change was
annotated in the 30UTR of the choline kinase alpha (CHKA) gene
(NM_001277; *327T>C), at the homozygous state in patients 1A
and 1B and at the heterozygous state in their parents.
Interestingly, CHKA maps to chromosome 11q13.2 on the
reverse strand and immediately downstream to the TCIRG1
gene. Because of the close proximity of the two genes, we asked
whether the *327T>C variant might affect the expression of the
TCIRG1 gene. Investigation at the cDNA level through semi-
quantitative RT-PCR did not show reduced expression; however,
at least two unexpected bands in the two affected siblings by RT-
PCR spanning exons 14 to 17 were observed (Fig. 3A),
suggesting a splicing aberration. Therefore, we sequenced the
corresponding genomic region, including also the whole of the
three introns, and identiﬁed a single nucleotide change in the
middle of intron 15 (g.10466G>A, c.1884þ146G>A), which was
Fig. 1. Representative X-rays of Pt 1A, Pt 1B, and Pt 2, showing a diffuse increase in bone density, the typical harlequin-mask pattern of the sclerotic skull
base on the AP cranium, the lack of metaphyseal bone remodeling, and the bone deformities resulting from the remodeling defects and the non-perfect
healing and remodeling of fractures. (A) Pt 1A at age 6 years; (B) Pt 1B at age 2 years; (C) Pt 1A at age 35 years; (D) Pt 2 at age 22 years. Overall, the
radiographs testify for a severe form osteopetrosis.
Table 1. Most Recent Laboratory Data in Pt 1A andPt 1B
Pt 1A Pt 1B Ref. range
Age (years) 37 33
Erythrocytes (# 106/mL) 3.79 5.10 4.2–5.4
Hemoglobin (g/dL) 11.2 14.5 12–16
Hematocrit (%) 34.5 43.9 37–47
Serum calcium (mmol/L) 2.38 2.48 2.10–2.60
Serum phosphorus (mmol/L) 1.22 1.40 0.80–1.50
Serum iron (mg/dL) 98 123 50–170
Serum ferritin (ng/mL) 23 288 10–120
Serum alkaline phosphatase (U/L) 44 65 40–150
Serum bone ALP isoenzyme (mg/L) 6.2 10.9 6–26
Serum osteocalcin (ng/mL) 21 18 6.5–42.3
Serum PTH (pg/mL) 37.6 27.1 14.5–87.1
Serum calcitonin (pg/mL) 3.8 4 0–5.5
Serum 25(OH)D3 (ng/mL) 10.4 23.2 8.6–54.8
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not reported in dbSNP andwas present at the homozygous state
in Pt 1A and Pt 1B and at the heterozygous state in their parents
but absent in 100 control chromosomes from a matched
population (Fig. 3B and data not shown). Despite this change
being far from both the donor of exon 15 and the acceptor of
exon 16, in silico analysis suggested a potential detrimental
effect on the splicing process, by altering the strength of
alternative splice sites compared with the wild-type sequence.
As a conﬁrmation of this prediction, when we cloned the cDNA
PCR product spanning exons 14 to 17 and sequenced 73
independent clones, we found that few clones displayed the
wild-type sequence (4/73 clones), whereas at least 8 diverse
aberrant transcripts were produced, the most abundant being
clones retaining 144 nucleotides of intron 15 (22/73 clones) and
clones inwhich the ﬁrst 183 nucleotides of exon 15were skipped
and 144 nucleotides of intron 15 retained (30/73 clones)
(Fig. 3C). These data clearly supported the hypothesis of a
pathogenetic role of the variant.
Prompted by these ﬁndings, we sequenced TCIRG1 intron 15
in 26 osteopetrotic patients not yet assigned to any subgroup
because of the absence of mutations in known genes, as well as
in 7 ARO patients in which we had previously identiﬁed only a
single mutated TCIRG1 allele(17,22) (unpublished data). Although
nomutation was found in the 26 unclassiﬁed patients, in 3 of the
7 patients harboring a single mutated TCIRG1 allele, we found 3
additional, heterozygous single nucleotide changes in intron 15,
Fig. 2. Representative histological sections of a bone specimen from Pt 1A at age 35 years. (A) Visualization in polarized light and hematoxilin-eosin
staining. Scale bar¼ 200mm. The mature cortical bone shows lamellae in polarized light; the defects within the bone are islands of retained mineralized
cartilage. (B) Higher magniﬁcation of hematoxilin-eosin staining showing several multinucleated osteoclasts. Scale bar¼ 100mm. (C) TRAP ﬂuorescent
antibody labeling (red) and phase contrast with the ﬂuorescence image overlaid; nuclei are stained with Hoechst (blue). The inset shows a single
osteoclast at twice the magniﬁcation. Scale bar¼ 100mm; inset¼ 10mm. (D) TCIRG1 ﬂuorescent antibody labeling (green) and phase contrast with the
ﬂuorescence overlaid (right). Scale bar¼ 100mm; inset¼ 10mm.
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close to that carried by Pt 1A and Pt 1B, namely g.10462T>A
(c.1884þ142T>A) in Pt 2 (mutation conﬁrmed at the heterozy-
gous state in Pt 2’s healthy mother and in one unaffected
brother; data not shown), g.10452T>C (c.1884þ132T>C) in Pt 3,
and g.10469C>T (c.1884þ149C>T) in Pt 4 (Fig. 3B and Table 3. In
silico analysis was performed also on these variants, obtaining a
similar prediction of potential disruptive effects on the splicing
process. A cell sample suitable for expression studies was
available only for Pt 2, and we could conﬁrm also in this case by
RT-PCR followed by cloning and sequencing, the presence of a
residual amount of wild-type transcript (5/75 clones, 6.7%) and
the same pattern of aberrant transcripts previously found in Pt
1A and Pt 1B, namely 12/75 clones retaining 143 nucleotides of
intron 15, 20/75 clones skipping the ﬁrst 183 nucleotides of exon
Table 2. Number of Variants/Genes Identiﬁed in Pt 1A and Pt 1B
Through Exome Sequencing
Total variants 191,872
Shared variants after
variant-quality filtering
157,065
Variant with MAF<0.05 19,170
Nonsynonymous/indel/splice
sites/UTR variants
1319/98/506/5149
Homozygous variants 32
Novel variants
(dbSNP138/1000GP queried)
2
Genes with plausible
disease association
1 (LRP5)
Fig. 3. (A) Semi-quantitativeRT-PCRspanningexons14to17 (upperpanel), showingthepresenceofat least twoabnormalbands in thepatients (thenormal
band seen in Pt 2 is from the other mutated allele), or exons 7 to 10 (middle panel), showing only the presence of the expected band in all the samples. (B)
Schematic representationof the relevant regionof theTCIRG1gene, highlighting thepositionof themutations identiﬁed in intron15; thenucleotide change
found ineachpatient is inbold in the lower line. (C) Structureof themost frequentaberrant transcripts found inPt1A,Pt1BandPt2: i) clones inwhichonly the
last 31 nucleotides of exon 15 are retained, followed by 143 nucleotides of intron 15, and ii) clones retaining 143 nucleotides of intron 15. The nucleotide
change found in each patient is in bold in the lower line, as in panel B.
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15 and retaining 143 nucleotides of intron 15, 20/75 clones
skipping the ﬁrst 183 nucleotides of exon 15 and retaining 141
nucleotides of intron 15, plus other less frequent species.
Sequence analysis of individual clones showed that loss of large
part of exon 15 was due to the usage of an internal, cryptic
acceptor site, while retention of 143 nucleotides of intron 15was
due to the usage of an intronic, cryptic donor site (Supplemen-
tary Fig. 2).
Discussion
Fifteen years of genetic dissection of human osteopetrosis have
greatly extended our understanding of the physiopathology of
this disease and, more in general, of the bone tissue. At present,
an exact classiﬁcation is obtained in most cases of the extreme
phenotypes: on one hand, autosomal recessive forms with a very
severe and early presentation; on the other, adult, benign forms
mildly impacting on the patients’ life. This allows the identiﬁca-
tion of the most appropriate therapy. On the contrary,
intermediate, atypical forms are more difﬁcult to solve and
manage; therefore, these are often addressed by next-generation
sequencing technologies or require an adaptation of commonly
used protocols.
We recently reported the identiﬁcation of an incomplete
splicing defect in the TCIRG1 gene leading to benign, recessive
osteopetrosis in a young girl.(2)At that time, we thought that this
kind of phenotype owing to the TCIRG1 gene was extremely rare
because no other similar ﬁndingwas present in either our cohort
of more than 300 patients or in the literature, to the best of our
knowledge. However, our present data suggest that this is not
the case; in fact, we report here the identiﬁcation of 4 different
single nucleotide changes in intron 15 predicted to impact on
the splicing process of the neighboring exons. For 2 of 4 novel
mutations, the effect was demonstrated at the cDNA, showing
that these genetic defects were hypomorphic and allowed for
the production of a small amount of wild-type transcript. In
addition, bone histology in Pt 1A allowed us to clearly document
osteoclast-rich osteopetrosis, in the presence of areas of well-
formed, mature trabecular bone. Interestingly, the mutations
herein described are located in close proximity to one another
and probably identify a hot spot region for mutation within
intron 15. Moreover, they are found in the middle of a 368-
nucleotide-long intron, quite far from the canonical splice sites,
so our standard molecular analysis of the TCIRG1 gene initially
failed to identify them. Due to their localization, we were not
able to exactly deﬁne the pathogenic mechanism; however, a
careful sequence analysis of the alternative transcripts revealed
the usage of cryptic splicing sites, namely an acceptor in exon 15
and a donor in intron 15. Deep intronic mutations, leading to the
formation of cryptic splice sites which compete with the
canonical ones during RNA processing, have been recently
reported also in different diseases, such as Stargardt disease,
Gorlin syndrome, optic atrophy, Marfan syndrome and
others.(23–26) In the ﬁeld of skeletal diseases, a deep intronic
mutation in the TMEM165 gene has been reported to cause the
congenital disorder of glycosylation type II with bone dyspla-
sia.(27) At present this type of defects is likely underestimated,
since the genetic tests are still mainly focused on coding
genomic sequences and transcript analysis is rarely performed;
however, these data clearly highlight the importance of the
noncoding genome and the need to assess the functional
impact of remote intronic variants in potential disease-genes.
The patients described in the present study displayed a
different level of severity of the disease. Whereas in Pt 3 and Pt 4
the diagnosis was made in early life and their osteopetrosis was
treated with HSCT, in Pt 1A and Pt 2 the bone defects became
apparent at school age and the disease progressionwas slow and
overall benign, thus representing typical intermediate cases.
Moreover, Pt 1B was diagnosed at an asymptomatic early stage
because of the previous identiﬁcation of his elder affected sister,
Pt 1A. In this regard, the difference between these two siblings is
interesting; whereas the elder showed important secondary
neurological deﬁcits, these were completely absent in her
younger brother, who seemed to be more mildly affected. This
is reminiscent of what is commonly observed in autosomal
dominant osteopetrosis, in which phenotypic variations can be
observed in the presence of the very same genetic defect, even
within the same family. A role for variants in modiﬁer genes has
been often suggested. Intriguingly, we noticed that Pt 1A and Pt
1B carried an almost completely different set of single-nucleotide
polymorphisms (SNPs) in the CLCN7 gene (only 2 shared SNPs out
of 30genotyped, datanot shown). Among these, Pt 1B, but not his
sister, bore 2 SNPswithin exon15 (rs12926089 and rs12926669) at
the heterozygous state, which have been associated with low
bone mineral density in different populations.(28,29) Similarly, it
could be hypothesized that additional variants in other genes
inﬂuencing bone metabolism are present in one or the other
affected sibling and modulated their phenotype. Moreover, in
adolescence and adult life, sexual hormones might have further
impacted on the disease manifestation.
In conclusion, our results depict an even wider spectrum of
mutations and phenotypes in TCIRG1-dependent osteopetrosis
and suggest the analysis of this gene is appropriate not only in
Table 3. Molecular Findings
Patient Genomic changea Location cDNA changeb Effect
1A and 1B
g.10466G>A Intron 15 c.1887+146G>A Putative aberrant splicing
g.10466G>A Intron 15 c.1887+146G>A Putative aberrant splicing
2
g.9909G>A Exon 14 c.1559G>A p.Trp520X
g.10462T>A Intron 15 c.1887+142T>A Putative aberrant splicing
3
g.11622T>C Exon 19 c.2345T>C p.Met782Thr
g.10452T>C Intron 15 c.1887+132T>C Putative aberrant splicing
4
g.8600T>C Intron 11 c.1305þ2T>C Putative aberrant splicing
g.10469C>T Intron 15 c.1887+149C>T Putative aberrant splicing
aAccession number genomic sequence of the TCIRG1 gene: AF033033.
bAccession number of the TCIRG1variant1 cDNA: NM_006019; the numbering used starts with nucleotideþ1 for the A of the ATG-translation initiation
codon.
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the molecular work-up of severe patients but also of
intermediate cases. Based on these ﬁndings, standard protocols
for gene ampliﬁcation and sequencing, focused on exons and
exon-intron boundaries, are likely to be revised. In particular,
intron 15 should be included in the routine sequencing of the
TCIRG1 gene; more in general, intronic changes in genes
associated with osteopetrosis, even deeply embedded in
introns, should be considered and their effect carefully
evaluated.
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ABSTRACT
Autosomal recessive osteopetroses (AROs) are rare, genetically heterogeneous skeletal diseases with increased bone density that are
often lethal if left untreated. A precise molecular classiﬁcation is relevant for the patient’s management, because in some subgroups
hematopoietic stem cell transplantation (HSCT), which is the only curative therapy, is contraindicated. In two unrelated AROpatients,
the molecular analysis revealed the presence of a synonymous variant in known ARO genes, namely in the TCIRG1 gene in one
patient and in the CLCN7 in the other patient, predicted to impact on the splicing process. In the latter case, sequencing of the
transcript conﬁrmed the splicing defect, whereas in the former, for whom an RNA sample was not available, the defect was
reconstructed in vitro by theminigene technology. These results strongly suggest that these synonymous changes were responsible
for the disease in our patients. Our ﬁndings are novel with respect to ARO and add to the few reports in literature dealing with
different diseases, underlining the importance of cDNA analysis for the correct assessment of exonic changes, even when exome
sequencing is performed. In particular, we highlight the possibility that at least in some cases ARO is due to synonymous changes,
erroneously considered clinically silent, in the genes already described in literature, and suggest carefully reevaluating the
sequencing results of these genes when mutations are not found at a ﬁrst analysis. In addition, with respect to the CLCN7 gene, we
suggest that synonymous variants might also contribute to the large spectrum of severity typical of CLCN7-dependent osteopetrosis
through more subtle, but not negligible, effects on protein availability and functionality. © 2016 American Society for Bone and
Mineral Research.
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Introduction
Autosomal recessive osteopetroses (AROs) are rare inheritedskeletal diseases characterized by increased bone density
due to failure in bone resorption by the osteoclasts and
secondary hematological and neurological defects.(1) ARO is
genetically heterogeneous; mutations in the TCIRG1 gene
encoding the osteoclast speciﬁc a3 subunit of the vacuolar
proton pump, responsible for the acidiﬁcation of the resorption
lacuna, account for more than 50% of ARO cases.(2,3) About 100
different mutations in this gene have been reported in the
literature, comprising missense and nonsense mutations,
splicing defects, and small insertions or deletions(2–4) (http://
structure.bmc.lu.se/idbase/).(5)Moreover, our group has recently
identiﬁed four different deep intronic mutations affecting the
splicing process of TCIRG1, thus highlighting the possibility that
nucleotide changes in intronic regions far from those with a
well-recognized function can also be responsible for the
disease.(6)
The second most frequently affected gene in human ARO
(about 13% of cases) is CLCN7,(7) encoding a 2Cl–/1Hþ antiporter
involved in the acidiﬁcation process. A great variety ofmutations
have been reported for this gene too, in association with a range
of severities of the disease.(8,9)
To the best of our knowledge, no synonymousmutation in the
TCIRG1 and CLCN7 genes (or in the other ARO genes) has been
attributed a causative role in human osteopetrosis.
Synonymous mutations are nucleotide changes in the coding
region of a gene that do not lead to a modiﬁcation in the amino
acid sequence of the encoded protein because of the
degeneracy of the genetic code. These mutations have long
been considered silent, that is with no functional effects,
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because of the assumption that the structure, and hence the
function, of a protein is dictated by the amino acid sequence
which is identical to the wild type in the presence of a
synonymous change.(10) This paradigm became a matter of
discussion in recent years because of evidence from disease
genes suggesting that even translationally silent mutations
could be able to impact on gene functionality.(11) Indeed,
accumulating data in literature pointed to a non-neutral effect of
at least some synonymous changes through different mecha-
nisms, including alterations of the splicing process, of the RNA
structure, of transcription factor binding, or rate of translation
due to different codon usage.(12) This means that synonymous
mutations may actually be involved in human health and
disease.
In the present work we report for the ﬁrst time synonymous
mutations in the TCIRG1 and CLCN7 genes responsible for the
disease in two ARO patients.
Patients and Methods
Patients and samples
Samples were collected from the patients and their parents after
informed consent. This research complies with the World
Medical Association Declaration of Helsinki–Ethical Principles for
Medical Research Involving Human Subjects, and with the
standards established by the Independent Ethical Committee of
the Humanitas Clinical and Research Centre.
The clinical description of patient 1 (Pt1 in this work, carrying
the synonymous variant in the TCIRG1 gene) has been already
published (as Pt14 in Mazzolari and colleagues(13)). Brieﬂy, the
patient was diagnosed at 2 months of age and presented a
severe osteopetrotic phenotype; in the absence of a matched
donor, hematopoietic stem cell transplantation (HSCT) was not
performed and the patient died because of septic shock at
18 months of age.
Patient 2 (Pt2, carrying the synonymous variant in the CLCN7
gene) is reported here for the ﬁrst time. He was born from an
Italian mother and a Moroccan father, through Caesarean
section at week 39 of gestation because of bradycardia. The
amniotic ﬂuid was stained by meconium, but the clinical
general condition was good (Apgar score 9/9; birth weight
2900 g). On the third day of life he developed a bacterial
sepsis treated with antibiotics. The newborn was discharged
after 3 weeks with mild thrombocytopenia (platelet count
70! 109/L) ascribed to bone marrow late toxicity. At 2 months
of age the infant was referred to the Pediatric Hematology Unit
for splenomegaly (splenic edge 1 cm below the umbilical line);
he also displayed anemia (hemoglobin 7.7 g/dL) and throm-
bocytopenia (platelet count 30! 109/L) and was transfused.
Bone marrow (BM) aspiration revealed reduced cellularity
without abnormal cells. In the workup for differential
diagnosis, Juvenile myelomonocytic leukemia, familial hemo-
phagocytic lymphohistiocytosis, and Gaucher disease were
ruled out by the appropriate assays.(14–16) Chest radiograph
performed before insertion of a central vein catheter, showed
increased bone intensity and aftereffects of fractures in both
humeri. Total body radiographs revealed the typical diffuse
bone sclerosis (Fig. 1A). In addition, light reﬂex was absent and
CT scan showed narrow optical foramina and optical
nerve atrophy. All these ﬁndings led to the diagnosis of
osteopetrosis. No speciﬁc biochemical evaluations, such as
tartrate resistant acid phosphatase and creatine kinase brain
isoenzyme serum levels,(17) were performed nor was a bone
biopsy taken from the patient.
At 7 months of age he received BM transplantation from a
fully matched unrelated donor, according to the guidelines of
the European Society for Immunodeﬁciencies (ESID) and the
European Society for Blood and Marrow Transportation (EBMT)
Working Party (WP) on Inborn Errors. He achieved full
engraftment, and 3 months after transplantation hemoglobin
and platelet levels were in the normal range. One year after
transplantation, the bone defect was completely corrected
(Fig. 1B). The patient is alive andwell at 5.6 years; impaired vision
persists, but light reﬂex is present and the child can follow
objects nearby.
Fig. 1. Representative radiographs of Pt2 showing: (A) diffuse increase
in bone density and aftereffects of humeral fracture, and (B) complete
restoration of bone phenotype and marrow cavity after transplantation.
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Sanger sequencing
PCR ampliﬁcation and direct Sanger sequencing of the TCIRG1,
CLCN7, RANKL, RANK, and SNX10 genes was performed as
described(4,8,18–20) in Pt1, whereas OSTM1, CAII, and PLEKHM1
were not directly analyzed because the clinical signs in this
patient were not in accordance to the typical presentation of
OSTM1-dependent ARO, CAII deﬁciency, or PLEKHM1-dependent
ARO. In Pt2 only TCIRG1 and CLCN7geneswere analyzed, because
the evaluations at the transcript level of the twomutations found
in the CLCN7 gene strongly supported the hypothesis regarding
their pathogenicity, so further genetic investigations were not
deemed necessary.
The effect of the identiﬁedmutations was predicted using the
following software: Berkeley Drosophila Genome Project (http://
www.fruitﬂy.org/seq_tools/splice.html) and Human Splicing
Finder, Version 3.0 (http://www.umd.be/HSF3/HSF.html).
The mutation nomenclature conforms to the Human Genome
Variation Society (HGVS; http://varnomen.hgvs.org/).(21)
Exome analysis
Exome capture, sequencing, and analysis was performed on a
DNA sample of Pt1 and his parents, according to a previously
reported protocol.(6)
Minigene construct for splicing analysis in Pt1
The pTB hybrid minigene vector used here to investigate the
putative splicing defect in the TCIRG1 gene of Pt1 has been
described.(22) The TCIRG1 genomic region spanning exons 11 to
13 was ampliﬁed from the paternal DNA using forward primer
50-TTTTCATATGctgtgcctggctgctaagtg-30 in intron 10 and reverse
primer 50-CCCCTCGACCATATGcccactcccagctgccttca-30 in intron
13; upper case indicates the nucleotides added to obtain the
NdeI enzyme restriction site; thermocycling conditions are
available upon request.
The PCR product was cloned in the TA cloning vector (Life
Technologies, Carlsbad, CA, USA), according to the manufac-
turer’s instructions. Independent clones carrying either the wild-
type or the mutated variant were identiﬁed by direct Sanger
sequencing using the M13R primer, digested with the NdeI
enzyme (New England Biolabs, Ipswich, MA, USA) and inserted
into the pTB minigene vector. HeLa cells were transfected with
4 mg of each construct DNA using Lipofectamine 2000 (Life
Technologies). RNAwas extracted after 48 hours using the TRIzol
reagent (Thermo Fisher Scientiﬁc, Waltham, MA, USA) and
retrotranscribed with the High-capacity cDNA Reverse Tran-
scription Kit (Applied Biosystems, Waltham, MA, USA). Finally,
PCR was carried out as described with primers 2-3a (forward)
and B2 (reverse) speciﬁc for the pTB vector.(23)
Transcript cloning and sequencing in Pt2
RNA was extracted from peripheral blood mononuclear cells
(PBMCs) using the TRIzol reagent and retrotranscribed as
described in the previous section. Primers and conditions for
all the RT-PCR described in the text are available upon request.
Each PCR product was separately cloned in the TA cloning
vector, according to the manufacturer’s instructions; about 50
independent clones for each cloning reaction were sequenced
using the M13R primer.
In addition, for the ampliﬁcation of the CLCN7 cDNA region
containing both the paternally and the maternally inherited
mutations, a forward primer in exon 11 and a reverse primer in
exon 18, were speciﬁcally designed. The PCR product was cloned
as described in the previous section; 62 independent clones
were tested for the length of the cDNA amplicon and nine of
them were sequenced, including the only three clones with
apparently normal size.
Results
In Pt1, molecular analysis through Sanger sequencing of the
known ARO genes did not identify obvious mutations in the
investigated regions, nor did exome sequencing detect evident
candidate variants for further conﬁrmation after application of
common ﬁlters to exclude low-quality, common, and synony-
mous variants. However, a number of occurrences on the
synonymous variant c.1371C>A, p. (Thr457¼) found in the
patient in the exon 12 of the TCIRG1 gene attracted our
attention: the nucleotide variant was present at the homozy-
gous state in the proband and at the heterozygous state in his
parents, as expected based on parental consanguinity, whereas
it was not found in SNP databases nor in our in-house database
or in the TCIRG1-dependent patients of our cohort. The
threonine residue in that position was highly conserved
throughout evolution, but interestingly the adenosine nucleo-
tide in the third position of the corresponding codon was never
present (Fig. 2A). In addition, in silico prediction with different
software suggested a pathogenetic role. In the absence of an
RNA sample from the patient or his parents, we tested this
prediction using the minigene technology, as we have already
done in the past for other mutations suspected to affect the
splicing process.(22) The minigene assay is a functional splicing
assay based on hybrid constructs that, when transfected into
eukaryotic cell lines, are able to reproduce the splicing pattern
of a speciﬁc genomic sequence inserted therein.(23) For the
present purpose, we cloned the wild-type and mutant TCIRG1
genomic region spanning exons 11 to 13 into the pTBminigene
vector (Fig. 2B), and analyzed the pattern of transcripts
produced from the obtained hybrid after transfection in
HeLa cells. By this means we conﬁrmed that the variant
c.1371C>A caused aberrant splicing, namely loss of 67
nucleotides (D67nt) of exon 12, due to the usage of the
internal acceptor site created by the variant (Fig. 2C, D).
Because of the inherent artiﬁcial nature of this system, it is
expected that a variety of transcripts is also generated in the
clones carrying the wild-type sequence; however, the keynote
is the complete absence of the splicing aberration D67nt in
these wild-type clones (Fig. 2C). At the protein level this
nucleotide loss was predicted to result in frameshift and
premature termination (p.Ile436AlafsX70).
A similar ﬁnding occurred in Pt2, who was found to be a
compound heterozygote for two different changes in the CLCN7
gene: the paternally-inherited allele carried a transition
(c.1098G>A) at the last nucleotide of exon 12, constituting a
synonymous substitution p. (Glu366¼), not previously reported
in any database to the best of our knowledge; on the maternal
allele a deletion of two nucleotides in intron 17 (c.1617þ
6_1617þ7delTG), close to the canonical acceptor splice site, was
present. In this case we could directly verify the effect of each
mutation on the cDNA of the patient and conﬁrm that both
changes led to splicing aberration (Fig. 3A). In fact, we ampliﬁed
the two relevant cDNA regions separately, spanning exons 11 to
16 and 16 to 20, respectively, cloned the RT-PCR product, and
sequenced about 50 independent clones; in this way, we found
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that the c.1098G>A transition caused in-frame skipping of exon
12, thus demonstrating a non-neutral effect (Fig. 3B, left panel).
On the other allele, the deletion of two nucleotides in intron 17
gave rise to at least three aberrant transcripts, respectively
showing retention of 230 nucleotides of intron 17 or complete
skipping of exon 17, both predicted to cause frameshift, or
deletion of 93 nucleotides of exon 17, predicted to cause in-
frame loss of 31 amino acids (Fig. 3B, right panel). Then, using ad
hoc–deﬁned PCR conditions and primer pair, we also obtained a
larger CLCN7 cDNA product spanning exons 11 to 18, thus
containing both mutations. Also in this case, we cloned the RT-
PCR product and sequenced independent clones, and we never
found the wild-type transcript (Fig. 3C). In fact, even the band
that migrated as expected for the normal transcript, once
sequenced, turned out to lack 13 nucleotides as compared to
the wild-type. Overall these data strongly suggested that both
mutations were completely disruptive and did not allow any
residual normal splicing.
Discussion
A precise molecular diagnosis has become an essential part of a
patient’s management, strongly inﬂuencing therapeutic deci-
sions in many inherited disorders. In recent years, an important
contribution has been provided by next-generation sequencing
approaches(24); in particular, exome sequencing, investigating
the coding fraction of the genome where the large majority
of mutations responsible for inherited disease are found,
has become widely used because it has lower costs and
Fig. 2. (A) Sequence alignment of the TCIRG1 gene and protein in the relevant region in different species, showing absence of the adenosine residue
(A1371) in the last position of codon 457 (only numbering of the human sequence is reported) and evolutionary conservation of the Threonine residue.
(B) Schematic representation of the minigene constructs; the sequences relevant for the assay are the alpha-globin promoter region with the SV40
enhancer, a genomic region spanning exons 1 to 3 of the human alpha-globin gene, a portion of the ﬁbronectin gene inserted into exon 3 of the previous
gene, and an NdeI cloning site used to insert either the normal or mutated TCIRG1 genomic sequence spanning exons 11 to 13. (C) Analysis of the
processed transcripts derived from the minigene constructs carrying the normal or the mutant TCIRG1 sequence; the composition of the corresponding
bands (determined by sequence analysis) is represented respectively on the left and on the right. (D) Sequence of the TCIRG1 gene spanning exons 11 to
13; upper case indicates exonic regions, lower case intronic ones. The creation of a new acceptor site in exon 12, possibly used instead of the canonical
one, is highlighted.
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produces a more manageable amount of data as compared to
whole-genome sequencing.(25) Independent of the approach,
the most challenging step is the ﬁltering of the called variants
and the functional validation of those possibly damaging based
on software prediction and suspected to be disease-causing. In
this process synonymous variants are actuallymost often ﬁltered
out, based on the common assumption that they do not have an
impact on the protein product; on the other hand, this is
probably the case for many, but not all of them.
Our results strongly suggest the causative role of deleterious
synonymous mutations in the pathogenesis of human ARO. In
fact the patients herein reported carried synonymous sub-
stitutions in the TCIRG1 and CLCN7 genes, respectively, leading
to the production of aberrant transcripts with a causative role in
the pathogenesis of their disease. Protein sequencing, per-
formed for example through mass spectrometry, would
strengthen the results obtained at the cDNA level and conﬁrm
in silico predictions; on the other hand, this is not a routine
procedure. In addition, when the synonymous mutation causes
a splicing defect with frameshift, it is likely that no protein or a
lower amount of the normal protein is produced due to
nonsense-mediated RNA decay, thus limiting the utility of
protein sequencing.
Similar ﬁndings have been reported in other disorders,(26–32)
also including skeletal defects(33–35); nonetheless, the contribu-
tion of synonymous mutations to human pathologies is likely
highly underestimated at present. Although performing func-
tional evaluations of all the synonymous changes in an
individual exome is not cost-effective, it might be worth
assessing the effect of those located in genes already known to
be associated with diseases.
With particular respect to humanARO, seven genes have been
involved in the pathogenesis of this disease, and the presence of
mutations in additional genes is likely in the non-classiﬁed
patients, who represent about 20% of cases. The data reported
in the present work support the hypothesis that at least in some
cases ARO is due to synonymous changes erroneously regarded
as silent, in the genes already described in the literature.
Therefore, based on our experience, we would suggest carefully
reevaluating the sequencing results of the known ARO genes,
Fig. 3. (A) RT-PCR of the CLCN7 gene in Pt2. (B) Schematic representation of the relevant region of the aberrant CLCN7 transcript produced in Pt2 from
the paternal allele, showing skipping of exon 12 (on the left), and from the maternal allele, showing at least 3 different sequences (on the right). (C) RT-
PCR spanning exons 11 to 18 of the CLCN7 gene on the Pt2 cDNA (on the left) and PCR ampliﬁcation of 6 independent clones of this product (on the right).
The asterisk indicates the apparently normal transcript lacking 13 nucleotides as compared to the wild type. HD¼healthy donor; CTRL–¼negative
control.
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whenmutations are not found at a ﬁrst analysis. In addition, with
particular respect to the CLCN7 gene, our result can raise the
hypothesis that synonymous but not silent changes may
contribute to the spectrum of severity typical of CLCN7-
dependent osteopetrosis. Speciﬁcally pertaining to the Pt2
described herein, no wild-type transcript from both mutated
alleles was produced, which could be in agreement with the
severe presentation, requiring HSCT in early life. On the other
hand, by eliciting different effects on transcription and transla-
tion, synonymous variants might also constitute at least one of
the long-sought, elusive elements responsible for phenotypic
differences reported in different individuals carrying the same
mutations, if they only mildly impact CLCN7 protein function.
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Case Report
Hematopoietic stem cell transplantation corrects osteopetrosis in a child
carrying a novel homozygous mutation in the FERMT3 gene
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Osteopetrosis (OPT) is a rare skeletal disorder with phenotypic and genotypic heterogeneity: a variety of clinical
features besides the bony defect may be present, and at least ten different genes are known to be involved in the
disease pathogenesis. In the framework of this heterogeneity, we report the clinical description of a neonate, ﬁrst
child of consanguineous parents, who had osteoclast-rich osteopetrosis and bonemarrow failure in early life, but
no other usual classical features of infantile malignant OPT, such as visual or hearing impairments. Because of the
severe presentation at birth, the patient receivedHematopoietic StemCell Transplantation (HSCT) at 2months of
age with successful outcome. Post-HSCT genetic investigation by means of exome sequencing identiﬁed a novel
homozygous mutation in the Fermitin Family Member 3 (FERMT3) gene, which was predicted to disrupt the
functionality of its protein product kindlin 3. Our report provides information relevant to physicians for recogniz-
ing patients with one of the rarest forms of infantile malignant OPT, and clearly demonstrates that HSCT cures
kindlin 3 deﬁciency with severe phenotype.
© 2017 Elsevier Inc. All rights reserved.
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1. Introduction
Osteopetrosis refers to a group of genetically heterogeneous, rare
skeletal diseases characterized by increased bone density due to failure
in bone resorption and a variety of associated clinical phenotypes [1].
Hematological (bone marrow failure, hepatosplenomegaly) and neuro-
logical defects (cranial nerves compression, blindness, deafness, devel-
opmental delay, hydrocephalus) are frequent, particularly in the
severe end of the spectrum of infantile malignant osteopetrosis [1].
Some features are mainly present in association with mutations in spe-
ciﬁc genes (e.g. renal tubular acidosis and cerebral calciﬁcations with
carbonic anhydrase 2 deﬁciency, skin manifestations with NEMO or
SLC29A3mutations, and spontaneous bleeding with kindlin 3 deﬁcien-
cy) [2–5]. Others, such as primary hypothyroidism, structural brain ab-
normalities, poikiloderma and neutropenia, juvenile xantogranuloma,
congenital aural atresia, are sporadic and due to as yet undeﬁnedmolec-
ular defects [6–10], thus at present it is not known whether they are
incidental ﬁndings due to the co-occurrence of different diseases in
the same patient [11], or whether they are caused by mutations in spe-
ciﬁc genes responsible for both the skeletal defect and the extraskeletal
manifestation. In most cases Hematopoietic Stem Cell Transplantation
(HSCT) is the only curative treatment option and should be performed
early to prevent progressive visual and hearing impairment, bone mar-
row failure and growth retardation.
2. Materials and methods
Clinical data and specimens (peripheral-blood for DNA isolation)
were collected from the patient and her parents after informed consent.
This research complies with the standards established by the Indepen-
dent Ethical Committee of the Humanitas Clinical and Research Centre,
Rozzano (Milan), Italy.
Based on the clinical data and presence of osteoclasts in the bone
marrow trephine biopsy, only genes known to cause the different
types of osteoclast-rich OPT (TCIRG1, CLCN7, OSTM1 and SNX10) were
initially analyzed by ampliﬁcation and direct Sanger sequencing of
exons and intron-exon boundaries as previously described [12–15].
Based on our recent report [16], the CTSK gene was as well included in
the analysis. Since no mutation was found in the above mentioned
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genes, for a more comprehensivemolecular analysis we decided to pro-
ceed with exome sequencing.
Exome capture, sequencing and data analysis of DNA collected from
the patient and her parentswas performed as previously described [17].
3. Results
3.1. Patient
A female newborn, the only child of Pakistani consanguineous par-
ents (ﬁrst degree consanguinity), presented at birth with widespread
purpuric/petechial rash, hepatomegaly (+3 cm), limited bleeding of
the scalp (where electrodes were placed), severe anemia (hemoglobin
5.5 g/dL, normal range 10.5–13.5), thrombocytopenia (platelet count
33 × 109/L, normal range 150-450 × 109/L), and leucocytosis (white
cell count 30.7 × 109/L, normal range 6.0–17.5 × 109/L) with
leucoerythroblastic picture on peripheral blood smear, and normal
blood clotting tests. Although initially these features were suggestive
for neonatal leukemia, themorphology and immunophenotyping of pe-
ripheral blood, and bonemarrow aspirate showed no features of malig-
nant cells. The borderline and clinically asymptomatic hypocalcaemia
and hypophosphatemia (serum calcium 1.8 mmol/L, normal range
2.2–2.6 mmol/L; phosphate 1.06 mmol/L, normal range
1.4–2.5 mmol/L), pale optic discs and very dense bones noted on initial
abdominal radiography (Fig. 1A) suggested infantile malignant
osteopetrosis. This was conﬁrmed by subsequent iliac crest bone mar-
row trephine biopsy showing strikingly abnormal architecture with
profuse overgrowth of bone around cartilage in an expanded network
encroaching on themarrow space, strikingly increased large osteoclasts,
and reduced residual hematopoiesis, the appearances typical of
osteoclast-rich osteopetrosis (Fig. 1B). There were no signs of pulmo-
nary hypertension; brain MRI and electroencephalography showed no
abnormalities, CT scan of the skull base showed no obstruction of
optic or auricular canals, and functional assessment of hearing and vi-
sion (evoked potentials, electroretinography), revealed nomajor abnor-
malities suggestive of the exceptionally severe forms of infantile
malignant OP with progressive neurodegeneration [18].
Despite somewhat surprising absence of visual or hearing impair-
ments usually present in infantile malignant osteopetrosis, our patient's
clinical presentation was deemed particularly severe already at birth,
suggesting in utero onset. At 2 months of age she underwent allogeneic
HSCT from a matched unrelated umbilical cord (HLA 10/10)
(0.9 × 106/kg CD34+ stem cell dose) donor after conditioning with
ﬂudarabine (150 mg/m2), treosulfan (36 mg/m2), thiotepa (5 mg/kg)
and rabbit anti T cell globulin (ATG) (6 mg/kg, dose reduced due to
cytomegalovirus viremia), with cyclosporine andmycophenolatemofe-
til for graft versus host disease (GvHD) prophylaxis. The early post-
transplant period was complicated by prolonged but transient acute
GvHD of skin (grade 3) and liver, cytomegalovirus (CMV) reactivation,
candida pneumonitis, and hypertrophic cardiomyopathy, which all re-
solved. She was discharged to home after 6 months hospital stay with
full and stable engraftment (100% donor chimerism in myeloid, T and
B cells) since 2 months post-HSCT, and good immune reconstitution
with normal peripheral blood lymphocyte markers, serum immuno-
globulin levels and speciﬁc vaccine antibody responses.
Two and a half years post-HSCT an irregular osteolytic lesion of un-
known etiology with sclerotic borders within the proximal metaphysis
of the left ﬁbula (Fig. 1C) was found on knee radiography performed
during investigation of the cause of limping and mild ﬂexion contrac-
ture of the left knee; however, gait was improved by physiotherapy.
Three years post-HSCT she developed Grave's thyrotoxicosis (TSH 0.07
mIU/L, normal range 0.3–4.7; free thyroxine 47.6 pmol/L, normal
range 9.5–21.5; free T3 19.5 pmol/L, normal range 3.5–6.5; thyroid per-
oxidase antibodies 30 IU/mL, normal value b35, but increased thyrotro-
pin receptor antibodies 16.6 U/L, normal value b1.8), for which she
remains on carbimazole treatment [19].
At the last follow-up at 5.5 year of age she was well, in school full
time, with no visual, hearing or developmental problems, growing nice-
ly with weight on the 75th and height on the 9th centile for age, under
dentist follow up because of secondary dentition formation problems,
which are a common complication of OPT even after successful HSCT
[1].
3.2. Molecular studies
The analysis of the genomic sequence of the TCIRG1, CLCN7, OSTM1,
SNX10 and CTSK gene revealed no mutations, indicating the involve-
ment of a different gene in the pathogenesis of the disease in this family.
Therefore, trio-based exome sequencing was performed at CRS4 (Sci-
ence and Technology Park Polaris, Pula, Italy) and achieved an 80×
mean coverage over the 62 Mb of exomic sequence, with N94% of
targeted regions covered. The analysis identiﬁed a total of 10,166 vari-
ants with a minor allele frequency lower than 0.05 (MAF b0.05);
among them, there were 7815 variants in untranslated regions
(UTRs), 2137 nonsynonymous, 180 indel and 34 splice site variants.
They were further ﬁltered based on known parental consanguinity,
yielding 316 homozygous variants, comprising 68 novel ones. In this
group, we found a novel single nucleotide deletion in the Fermitin Fam-
ily Member 3 (FERMT3) gene (c.1802delA). Themutation, conﬁrmed by
Sanger sequencing to be present at the homozygous state in the affected
Fig. 1. (A) Representative radiographies demonstrating osteopetrotic phenotype before HSCT (B) Iliac crest bone marrow trephine biopsy, parafﬁn-embedded sections stained with
hematoxylin-eosin showing abnormal bone architecture (light blue) with cartilage remnants (bright pink), numerous large multinucleated osteoclasts (indicated by arrows) and
limited residual hematopoiesis. Magniﬁcation: 10× (C) Radiography (left knee) performed at the time of limping, showing restoration of normal bone density 2.5 years after HSCT.
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child and at the heterozygous state in her parents, was predicted to
cause a frameshift (p.Asn603Thrfs*?) affecting the F3 domain, which
is involved in integrin binding [20]. Unfortunately, it was not possible
to evaluate the presence or absence of a mutant protein by Western
blot; however, based on its position the mutation could be predicted
to severely impact on the protein function and was considered as re-
sponsible of the disease in the patient.
4. Discussion
The FERMT3 gene is mainly expressed in hematopoietic cells and
codes for kindlin-3 protein, which plays a crucial role in integrin
inside-out activation, a mechanism required for platelet aggregation,
leukocyte adhesion and extravasation and osteoclast adhesion and
spreading, as demonstrated in the kindlin3−/−mousemodel [21].Muta-
tions in the FERMT3 gene impair integrin activation and cause a rare dis-
ease named leukocyte adhesion deﬁciency type III (LAD III),
characterized by severe bleeding, recurrent infections and (in some pa-
tients) osteopetrosis [5,22,23]. To the best of our knowledge, so far 22
patients (of Turkish, Maltese and Middle-Eastern origin, and more re-
cently an Afro-American and a Thai patient), have been described in lit-
erature carrying loss of function mutations in the FERMT3 gene [5,
22–28]. Recurrent infections and bleeding were common features,
whilst osteopetrosis was clearly apparent in only 9 out of 22 patients
[5,22,25,28]; in additional 9 it was deﬁned as not a prominent feature
[22]. HSCT was reported to cure the disease in 7 out of 13 transplanted
patients [5,22,23,25–27].
Ten different mutations have been identiﬁed in this small cohort of
patients, including mainly truncating mutations (p.Arg509Ter, which
is the most frequent; p.Trp229Ter; p.Arg513Ter, p.Gln533Ter,
p.Arg573Ter; and p.Trp16Ter, the latter suggested to allow for the pro-
duction of a shorter protein product starting from a downstream tran-
scription start site at codon 181), a single nucleotide substitution
(c.1683-2A N G) causing aberrant splicing, a single nucleotide deletion
(c.1287delT) predicted to lead to frame shift and premature termination
of the protein product (p.Glu430ArgfsTer3) and two missense muta-
tions (p.Gly308Arg and p.Gln595Pro). As reported above with respect
to our newly identiﬁedmutation, themajority of those reported in liter-
ature affect the C-terminus of the protein, namely the F3 domain, sug-
gesting loss of integrin binding as likely pathogenetic mechanism; in
addition, in some patients complete absence of the protein product
has been demonstrated by Western blot analysis [23,25,26]. On the
other hand, a few mutations lie in domains with no speciﬁc function
recognized thus far, so in these cases the exact pathological mechanism
still has to be clariﬁed. So far, no correlation between the speciﬁc
FERMT3 mutation and clinical presentation has been deﬁned, in part
due to the limited number of reported patients, and interestingly our
patient did not have recurrent bleeding and infections, possibly due to
very early presentation and HSCT.
Allogeneic HSCT is curative for most forms of infantile malignant
osteoclast-rich osteopetrosis, except for those associated with progres-
sive neurodegeneration [1]. Whilst knowing the genetic mutation is
helpful when making the decision about HSCT (mutations in OSTM1
are always ‘a contraindication’), the ultimate decision is almost always
based on clinical grounds for twomain reasons: ﬁrst, there is phenotype
heterogeneity (some patients do presentwithmore severe neurological
features questioning the indication for HSCT), and second, obtaining re-
sults of genetic mutation analysis usually (still) takes too long as infan-
tile malignant OPT is a progressive disease HSCT should be undertaken
as an emergency procedure [1].
Our report of a patient bearing a homozygous novel mutation in the
FERMT3 genewidens the clinical andmolecular features of this rare dis-
ease. Early-onset bonemarrow failure and osteoclast-rich osteopetrosis,
in spite of absence of visual impairment otherwise expected in infantile
malignant osteopetrosis, and of severe neurological impairment sugges-
tive of progressive neurodegenerative form of the disease, inﬂuenced
the decision to perform HSCT even before reaching a deﬁned molecular
diagnosis which was subsequently identiﬁed as homozygous FERMT3
gene mutation. Finally, we conﬁrm the curative outcome of HSCT for
the severe phenotype of kindlin3 deﬁciency.
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